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Abstract 
Background 
Huge successes have been seen in the prevention of mother-to-child transmission of 
HIV (PMTCT) towards its elimination. Now amidst a landscape of universal 
antiretroviral therapy (ART), focus has been placed on different models of care to 
support and retain mother-infant pairs in the vulnerable postpartum phase.  
Methods 
The aim was to establish economic evidence for scaling-up approaches and models of 
care for PMTCT particularly during the postpartum period in Southern Africa. The 
economic data were collected during three studies, Safe Generations (Eswatini), MCH-
ART and PACER (South Africa), using mixed bottom-up and top-down methodology. 
Outcomes of these studies were used to estimate the cost-effectiveness using an 
incremental cost effectiveness ratio (ICER, calculated by the difference in cost divided 
by the difference in effects) of lifelong ART in comparison to Option A (the standard of 
care at the time) in Eswatini; and to estimate the annual costs, cost-effectiveness and 
budget impact of three models of care (Model I: Routine Care - mothers in general ART 
and infants in well-baby clinics; Model II: Integrated Care - mothers-infant pairs in 
integrated care in midwife obstetric unit; and Model III: Community Care - mothers in 
community adherence clubs and infants in well-baby clinics) in South Africa, from the 
provider and patient’s perspectives. Costs are presented in 2019 United States Dollars 
(US $). 
Results 
Lifelong ART can be considered cost-effective in Eswatini with an ICER of US $984 per 
mother retained in care to six months postpartum. In Cape Town, South Africa, Routine 
Care cost US $226 per mother-infant pair per annum; Integrated Care cost US $341; and 
Community Care cost US $254. Annual patient costs (direct and indirect costs) for 
Models I-III, were US $30-55, US $23-45 and US $76 per mother-infant pair respectively. 
Comparatively Community Care was the most cost-effective model with an ICER of US 
$97 per mother-infant pair retained and mother virally suppressed. Scaling-up 
Community Care nationally in South Africa would require US $5 720 096 more than 
Routine Care, 0.2% of the total health budget for 2020/21.  
Conclusions 
This work has generated novel empirical data in the form of new cost estimates and 
cost comparisons across different models of care. It has also provided a unique 
comparison of the different models of care using a cost-effectiveness analysis; and 
further a novel budget impact analysis of different approaches to rolling these strategies 
out. This data has helped to fill the gap in the evidence base for instance lifelong ART 
was implemented in Eswatini as a direct result of the Safe Generations study findings. 
Community Care was found to be cost-effective and if scaled up nationally in South 
3 
Africa would only require a small increment of the total health budget. However, we 
recommend a mixture of models of care to cater for the needs and preferences of 
patients. Decision makers can use the empirical findings to help set realistic budgets in 
Southern Africa and explore ideal model implementation to support mother-infant pairs 
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1 Chapter One: Introduction and overview 
1.1 Structure of the thesis 
This first section of this thesis is an introduction and overview which contains a brief 
background and rationale for the thesis, establishes its aims and objectives, and 
provides an outline of the contents. This includes a summary of the methodology used 
to address the aim and objectives of the thesis. This is followed by a comprehensive 
literature review (Chapter Two), then the four results chapters (Chapters Three-Six), 
and a discussion and conclusion (Chapter Seven) to bring together the contents of the 
four results chapters summarizing the key messages for policy makers. A reference 
section and appendices are also included at the end of the dissertation. 
1.2 Overall aim 
The aim of the proposed research was to evaluate the cost and cost-effectiveness of 
different models of prevention of mother-to-child transmission of human 
immunodeficiency virus (HIV) (PMTCT) for women living with HIV (WLH) and their 
infants, in order to estimate the national budget for large scale implementation in South 
Africa and Southern Africa generally, taking into consideration the change to the lifelong 
antiretroviral therapy (ART) (Option B+) approach. 
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1.3 Specific objectives 
 
1. To compare the costs and effects of the Option B+ approach to the Option A 
approach to prevention of mother-to-child transmission of HIV (PMTCT) from a 
provider’s perspective in a cost-effectiveness analysis 
 
2. To estimate the costs of three models of care for mother-infant pairs during the 
postpartum phase (at 12 months postpartum) from a provider and patient’s 
perspective and b.) to estimate the costs of the pregnancy phase for mothers 
from a provider’s perspective 
 
3.  To compare the costs and effects of three models of care for mother-infant pairs 
during the postpartum phase (12 months postpartum) from a provider and 
patient’s perspective in a cost-effectiveness analysis 
 
4. To estimate the budget impact of nationally scaling-up models of care for the 
postpartum period  
 
1.4 Situating this dissertation  
 
Table 1 displays the relationship between four specific objectives the analytic methods 
and the main outcomes. The conceptual framework for the dissertation can be visually 
seen in Figure 1 which shows how the objectives build on each other to fulfil the study 
aim.  
 
As South Africa had already changed over to lifelong ART for pregnant women, for this 
dissertation the Option B+ approach (lifelong ART) was evaluated and compared to the 
Option A approach, in Eswatini. This was done during the Implementation Science Study 
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called Situkulwane Lesiphephile - Safe Generations (SG) for which Professor Elaine 
Abrams was the Principle Investigator.  The SG study was funded by the United States 
Agency for International Development (USAID), through the United States President’s 
Emergency Plan for AIDS Relief (PEPFAR), USAID Award Number: AID-OAA-A-12-00020. 
In April 2018, the King of Swaziland, King Mswati III, changed the name of Swaziland to 
Eswatini (the ‘Kingdom of eSwatini’), however as this work was published prior to this 
official name change, Swaziland will be used in Chapter Three of the dissertation (1). 
 
Further to the work done to assess the cost-effectiveness of lifelong ART, it was necessary 
to assess which of the evolving models of care during the postpartum period are best 
suited to the context under the Option B+ approach. Three postpartum models were 
evaluated in a high HIV burden peri-urban context in South Africa with the intention to 
provide evidence to aid policy decision-making around the costs and cost-effectiveness 
of these models. Data generated through a budget impact analysis provides information 
on the financial requirement for the potential national scale-up of these models in South 
Africa.  This work was accomplished during the Strategies to Optimize ART Services for 
Maternal and Child Health (MCH-ART) study for which Professors Elaine Abrams and 
Landon Myer were the principal investigators and later the supplement study 
Postpartum Adherence Clubs to Enhance Support (PACER). Funding was provided by 
PEPFAR through the National Institute of Child Health and Human Development 
(NICHD), Grant Number 1R01HD074558 for MCH-ART and PACER. We recommend that, 
if possible, the reader first read each primary outcome paper (2-5) 
 
This Doctor of Philosophy (PhD) study is situated within an economic evaluation 
framework, as it aimed to value costs and outcomes and to maximise the health effects 
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of PMTCT models of care given the costs and available resources. It intended to assist 
decisions on where scare resources for PMTCT and postpartum care should be 
positioned for applicable scale-up in South Africa and Southern Africa generally. 
 
1.5 Ethical considerations   
 
This research in this doctorate did not pose any risks for the participants. Information 
provided for use in this study, such as salary data, remained confidential and anonymity 
was maintained.  
 
The Faculty of Health Science’s Human Research Ethics Committee (HREC) at the 
University of Cape Town reviewed the PhD proposal and granted ethical approval HREC 
number 461/2016 (see Appendix 1 for the letter of approval and subsequent renewal 
approval). 
 
Proposals for SG, MCH-ART (trial number NCT01933477, April 2013-December 2016) 
and PACER (trial number NCT02417675 February 2015-October 2016) studies were 
reviewed and approved by HREC at the University of Cape Town and Columbia 
University Institutional Review Board (see Appendices 2-4), and there was individual 
written informed consent. 
 
1.6 Summary of the methodology used  
 
Here we briefly outline the methodology utilised to address the aim and objectives of 
the thesis. For Chapter Three, the empirical cost data for the cost-effectiveness analysis 
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was collected during the Implementation Science Study SG. The PhD candidate traveled 
to Eswatini to liaise with research staff, meet Ministry of Health Officials, collect costs 
using an ingredients-based approach, presented a capacity building workshop and 
research presentation at an Eswatini national conference and fed back results to 
stakeholders in a workshop once the work was complete. Data collection in Eswatini 
also entailed observing in clinics, helping staff fill in timesheets and going through HIV 
registers. The effectiveness measure of retention of mothers at six months postpartum, 
was utilised for the cost-effectiveness analysis. Data analysis took place in a custom-
built tool within Microsoft Excel by the PhD candidate. 
Empirical cost data were collected for this cost analysis from a provider and patient’s 
perspective as presented in Chapter Four. This was done during the MCH-ART study 
and later the supplement study, PACER. We compared three models of postpartum care 
for mother-infant pairs, namely Model I - Routine Care, Model II – Integrated Care and 
Model III – Community Care. Patient costs were collected through time-in-motion 
studies conducted by the PhD candidate as well as through a questionnaire as part of 
the larger MCH-ART and PACER studies. Postpartum care activities in the midwife 
obstetric unit (MOU) (and antenatal care activities), general ART clinics and community 
adherence clubs were observed, informal interviews were undertaken with staff, space 
was measured, inventory was taken, and registers were assessed. Additional 
information was sourced from Provincial Department of Health, the City of Cape Town 
and others. A short section on the pregnancy phase costs for mothers in the MOU from a 
provider’s perspective, which has not been published, is also included in the PhD at the 
end of Chapter Four. Data analysis was performed by the PhD candidate, utilising a 
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custom-built tool within Microsoft Excel as well as in the interface RStudio, using R 
Programming. 
In Chapter Five, costs which were collected (as described under Chapter Four) were 
inflated to 2019 United States Dollars using the consumer price index. These inflated 
costs were then combined with the MCH-ART and PACER overall study outcomes to 
produce a cost-effectiveness analysis assessing the cost per mother-infant pair retained 
and virally suppressed at 12 months postpartum. Viral suppression was defined as HIV 
ribonucleic acid (RNA) <50 copies/mL. Data analysis took place in a custom-built tool 
within Microsoft Excel as well as in the interface RStudio, using R Programming by the 
PhD candidate. 
For Chapter Six, data analysis took place in an adapted National Institute for Health and 
Care Excellence (NICE) Budget Impact Template in Microsoft Excel. Epidemiological 
data for these calculations were obtained from publicly available datasets. This budget 
impact analysis assessed the financial requirement of scaling-up the most cost-effect 
model of care, Model III (from Chapters Four and Five) to cater for all postpartum WLH 
in South Africa. Further to this we explored different scenarios of scale-up, with a 
mixture of the three models of care, as a slightly increased budgetary requirement may 
produce a suite of care that will both cater to mother-infant pair preferences and better 
assist with retention in care leading to improved outcomes.
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Table 1: Relationship of analytic methods to specific objectives 
Specific objective Study  Analytic method Main outcome 
1. To compare the costs and effects
of the Option B+ approach to the
Option A approach to PMTCT
from a provider’s perspective in a
cost-effectiveness analysis
Safe Generations in Eswatini Provider costs: estimation of total and unit 
costs based on collection of capital and 
recurrent costs  
Cost-effectiveness: linking the costs and 
outcomes to establish the cost-effectiveness of 
the two approaches to PMTCT 
• Cost-effectiveness analysis
• ICER: the cost per mother retained at 6
months postpartum
• Total and unit costs of treatment under
the Option A and Option B+ approaches
• Cost-effectiveness information to support
decision making for both Eswatini and
Southern Africa generally 
2. To estimate the costs of three
models of care for mother-infant
pairs during the postpartum
phase (at 12 months postpartum)
from a provider and patient’s
perspective and
b.) to estimate the costs of the
pregnancy phase for mothers
from a provider’s perspective
MCH-ART (Models I – Routine 
and II – Integrated Care) and 
PACER (Models I - Routine 
and III - Community Care). in 
Cape Town, South Africa 
Provider costs: estimation of total and unit 
costs based on collection of capital and 
recurrent costs  
Patient costs: using time motion tools to 
evaluate the loss of productive time by patients 
as well as use of questionnaires to assess the 
direct and indirect travel costs  
• Total and unit costs of providing
postpartum ART care for mother-infant
pairs in three different models of care
• Total and unit costs of the pregnancy
phase of care to support budgeting in
South Africa and Southern Africa
generally 
3. To compare the costs and effects
of three models of care for
mother-infant pairs during the
postpartum phase (at 12 months
postpartum) from provider and
patient’s perspective in a cost-
effectiveness analysis
MCH-ART (Models I – Routine 
and II – Integrated Care) and 
PACER (Models I - Routine 
and III - Community Care). in 
Cape Town, South Africa 
Cost-effectiveness: linking the costs and 
outcomes to establish the cost-effectiveness of 
the three models of care 
• Cost-effectiveness analysis of the three
postpartum models of care
• Ranking the models in terms of cost-
effectiveness
• ICER: the cost per mother-infant pair
retained and virally suppressed in care
12 months postpartum
• Information generated to support
decision making in South Africa and
Southern Africa generally 
4. To estimate the budget impact of
nationally scaling-up models of
care for the postpartum period
MCH-ART (Models I – Routine 
and II – Integrated Care) and 
PACER (Models I - Routine 
and III - Community Care). in 
Cape Town, South Africa 
Budget impact analysis: ranking the models of 
care in terms of cost-effectiveness (Objective 
3). Estimate the budget impact of scaling up-
the model nationally by using national data  
• Budget impact analysis
• To assist resource allocation and decision
making around the PMTCT programme in
South Africa in terms of nationally









Objective 1: To compare the costs and effects of the Option B+ approach to the 
Option A approach to PMTCT from a provider’s perspective in Eswatini 
Most cost-effective approach 
(umbrella for models of care)
Objective 4: To estimate the budget impact of nationally scaling-
up models of care for the postpartum period in South Africa 
Objective 3: To compare the costs and effects of three models of care for mother-
infant pairs during the postpartum phase (at 12 months postpartum) from provider 
and patient’s perspective in a cost-effectiveness analysis (in South Africa)
Objective 2: a.) To estimate the costs of three models of care for mother-infant 
pairs during the postpartum phase (at 12 months postpartum) from a provider and 
patient’s perspective and b.) to estimate the costs of the pregnancy phase for 
mothers from a provider’s perspective in South Africa
Cost analysis
Rank models according to ICERS
Inform policy on 
roll out and 






2 Chapter Two: Literature review 
 
We find ourselves in the general context of there being a worldwide movement towards 
universal health coverage outlined in the Sustainable Development Goals (specifically 
under SDG 3.8), which should include financial risk protection as well as quality, safe 
and efficacious essential services that are accessible in terms of affordability (7). The 
crucial part of Universal Health Coverage relating to health economics is the financial 
risk protection, to prevent catastrophic spending on health care (8) while still 
incorporating factors such accessibility and services of high quality.  
 
Mothers who acquire HIV prior to pregnancy or during pregnancy are at risk of vertical 
transmission of HIV to their babies. Perinatal modes of transmission are during 
pregnancy (in utero), during birth and delivery (intrapartum) and postpartum during 
the breastfeeding period (9). It is also possible for infants to obtain HIV through 
horizontal transmission linked to blood products, needles or other equipment, or 
breastmilk (either expressed or delivered through surrogate breastfeeding) which is 
contaminated with HIV and sexual abuse (10, 11). It is unclear how much these modes 
of transmission contribute to the paediatric HIV burden overall, one study suggests 
11.5%(11), however, there have been several studies which report on the issue of 
horizontal transmission in children (10, 12-14). The United Nations four pronged 
approach to PMTCT was established in 2002, and consists of: Prong I) prevention of HIV 
in women of reproductive age; Prong II) preventing unintended pregnancies in women 
living with HIV; Prong III) preventing transmission of HIV from mother-to-child; and 
Prong IV) the treatment and care including support of both women living with HIV and 
their infants (and families) (15, 16). In South Africa we are privileged to have three 
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iterations of National Strategic Plans for HIV, Tuberculosis (TB) and Sexually 
Transmitted Infections (STIs). The most recent version published in 2019 are fully 
costed and include budgets for HIV (17). 
The overall aim of the dissertation was to evaluate the cost and cost-effectiveness of 
different models of PMTCT for WLH and their infants, taking into consideration the 
change to the lifelong ART (Option B+) approach to inform decision making, in order to 
estimate the national budget for large scale implementation. Given this, the aim of this 
literature review is to provide context and background for the reader, surrounding 
PMTCT in low- and middle-income countries (LMICs) such as those found in Sub-
Saharan Africa and the previous economic evidence generated. 
This literature review will situate the reader, with a summation of the literature 
surrounding the topics of antiretroviral therapy (ART), the impact of Coronavirus 
Disease 2019 (COVID-19), HIV preventions specifically for the prevention of mother-to-
child transmission of HIV (PMTCT), models of care, health economics specifically 
economic evaluation and budget impact analysis (BIA). It will also provide an overview 
of where we were with relevant literature when the parent studies, Situkulwane 
Lesiphephile - Safe Generations (SG), Strategies to Optimize ART Services for Maternal 
and Child Health (MCH-ART) and Postpartum Adherence Clubs to Enhance Support 
(PACER) were conceived and initiated. And flow into more up to date data on where we 
are now in terms of HIV prevention programmes, specifically for postpartum period and 




The human immunodeficiency virus/acquired immunodeficiency syndrome 
(HIV/AIDS), which attacks and weakens people’s immune systems has infiltrated many 
different communities worldwide since the epidemic began (18).  Incidence of HIV has 
declined over time from 2.8 million cases in 2000 to 1.7 million in 2018, and deaths 
from 1.4 million to 770 000 in the same time period (19). Globally, it has been estimated 
that 3 million lives had been lost to the virus, while there were around 38 million people 
living with HIV and AIDS (PLWHA) at the end of 2019 (18). 
Diagnosis of HIV/AIDS through a simple blood test identifies the presence of antibodies 
to the virus (18). Voluntary testing for HIV should include counselling and be linked to 
prevention, treatment and care services (18, 20). As there is no cure for HIV infection, 
prevention is necessary and, for instance, this can take the form of barrier contraception 
methods (18, 20). Prevention of HIV infection will be discussed in more detail below. 
2.1.1 ART 
With the advent of ART, PLWHA are able to live longer than without treatment and 
continue to have productive lives (21). In 2012, there were a reported 9.7 million 
people on ART in LMICs which was a remarkable scale up from 300 000 people in 2002 
(22). The 2016 World Health Organization (WHO) recommendations for starting 
lifelong ART were a cluster of differentiation 4 (CD4) cell count of below 500 cells per 
microliter (cells/μl), or starting regardless of CD4 count for certain population groups, 
such as those with active TB (23) and pregnant women. Advances were then made such 
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as the development of fixed dose combination ART that is taken once daily in adults, 
which has been a major improvement in HIV treatment (24). This simplifies 
administering treatment and eases supply chain management (24).  Same day initiation 
of ART (on the day of HIV testing) has been recommended since 2017 in South Africa 
and coverage of this practice has increased over time (25).  
 
The Joint United Nations Programme on HIV/AIDS (UNAIDS) had set the ambitious 
target of making sure that by 2020 90% of PLWHA know their HIV status; 90% of those 
with a confirmed HIV infection receive sustained ART; and that 90% of those 
individuals receiving ART are virally suppressed (26). Further to this is the goal to 
completely eliminate the AIDS epidemic by 2030 (27). Eswatini (formerly Swaziland) is 
one of the seven African countries that has now reached and surpassed this target with 
98%, 98% and 97% for each of the three categories respectively (PLWHA know their 
status, receive ART and are virally suppressed). South Africa is moving in the right 
direction particularly in the first and third category with 92%, 75% and 92%, for 2019. 
The second category has yet to be met despite South Africa being known as having the 
world’s largest ART programme, with 5.2 million individuals on treatment in 2019 (28). 
 
A large randomised control trial (which was run for 16 months before being ceased so 
that the control group could join the intervention group) determined that taking ART 
continuously reduces the risks of opportunistic infections and death in comparison to 
intermittent use of ART (29). Study results by Lundgren et al. (30) added to evidence on 
ART initiation, supporting the early start of ART for adults with CD4 counts above 500 
cells/μl (30).  If started early it was shown that PLWHA will benefit from a 50% reduced 
 20 
risk in becoming ill or dying in comparison to those who had delayed treatment (only 
starting treatment once their CD4 count was below 350 cells/μl) (30).   
 
ART guidance now promotes universal treatment which is for both clinical as well as 
public health benefit whereas the emphasis previously was on treatment of PLWHA 
who were the most clinically unwell (19). The treatment cascade in the era of universal 
ART, sees the patient moving from testing to linkage to care, initiating ART and then 
being retained on ART in both the short and long term (31). Globally the effect of 
universal ART has been that both the incidence as well as the number of deaths from 
HIV/AIDS have declined over time (19). Other positive effects such as the reduction of 
incident TB cases by a staggering 75%, has been noted in Ethiopia since the shift to 
universal treatment (32). At the end of 2019, 25.4 million PLWHA had accessed ART 
globally (18, 33).  
 
However, when evaluating outcomes in South Africa before and after universal 
treatment was implemented, Hirasen and colleagues (34) found that under universal 
treatment there was more loss to follow up, which in part they ascribed to PLWHA 
starting ART when clinically well, which may inhibit attributing benefits to taking 
medication as no improvement may be noted (34).  
 
2.1.2 The impact of COVID-19  
 
At the time of writing in 2020, an emergent virus ‘Severe Acute Respiratory Syndrome 
Coronavirus 2’ (SARS-CoV-2) which causes COVID-19, had led to a global pandemic 
which is expected to have far reaching impact on the progress that is being made on the 
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90, 90, 90 goals set by UNAIDS (35). Efforts to model the effects of COVID-19 on HIV 
have indicated that the deaths for those with HIV could increase by 10% in high burden 
settings such as South Africa over the next five years (36). In a bold statement by the 
Lancet HIV, it is stated “Given advances in prevention, testing, and treatment, every HIV 
infection and death in 2020 is preventable” however they go on to say that COVID-19 is 
threatening the progress that has being made by disrupting services (35). There is 
advocacy for patients to be served outside of healthcare facilities for instance in 
community adherence clubs (CACs) and to be given extended refills of their ART in 
order to facilitate less frequent engagement with large groups and individuals seeking 
care with  COVID-19 infection (37). 
 
2.1.3 Investment in prevention  
 
HIV prevention encompasses education; mobilising resources; empowering females; 
supplying condoms; pre-exposure prophylaxis (PrEP), voluntary medical male 
circumcision (VMMC) and targeting key at risk and vulnerable populations such as 
pregnant women (38). 
 
The estimated amount that will need to be invested in HIV care in order to reach the 
SDG for HIV/AIDS elimination (among other infectious diseases) by 2030 (SDG 3.3) is 
US $32 billion in 2020. The goal being to reduce the number of incident infections to 
lower than 500 000 (by 2020). UNAIDS has put forward the concept that a quarter of 
this budgeted investment should be directed at HIV prevention (38). 
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2.1.4 PMTCT  
 
Mother-to-child transmission of HIV (MTCT) is responsible for almost all new HIV 
infections in children around the world (39). Mothers who find out about their HIV 
status when accessing antenatal care at clinics are faced with the challenge of ensuring 
that their infants are born HIV negative, through the use of PMTCT programmes (23). It 
is important to note that, even with the reduction of MTCT, children will continue to be 
exposed to HIV (24) and be infected with HIV.  There is a global effort to eliminate 
paediatric HIV as well as ensure maternal health and longevity (39) and maintain health 
of HIV exposed uninfected infants primarily through safe breastfeeding. This is 
particularly in light of the huge reduction seen in high-income countries where 
transmission rates were as low as 1% in 2013 (24) now countries such as Cuba (2015), 
Armenia and Thailand (2016), Malaysia (2018), Sri Lanka and the Maldives (2019) have 
succeeded in the elimination of MTCT (eMTCT) as validated by WHO (40). The global 
performance indicator for the complete elimination of incident cases of paediatric HIV 
as well as ensuring maternal health and sustained well-being by 2021 laid out by 
UNAIDS (27) is on track for two of the outcomes for the output titled “Access and 
quality of comprehensive eMTCT services improved” . These outcomes are lifelong ART 
being offered to pregnant women living with HIV (92% in 2018) and offering HIV 
testing to their partners (82% in 2018). The outcomes that are still ‘in progress’ relate 
to offering repeat testing to those pregnant and breastfeeding women not living with 
HIV (49% in 2018), and the engagement of women in the eMTCT strategy improvement 
and realisation (68% in 2018) (27).   
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There are now more than 80% of pregnant and breastfeeding women living with HIV 
accessing ART worldwide with the proportion as high as 93% in Eastern and Southern 
Africa (27). However accessing care is only a part of the picture of PMTCT as the global 
MTCT rates are unexpectedly high at 13%, suggesting that poor retention in care and 
late timing of ART initiation among other factors are playing roles continued MTCT 
(27).  
 
There has been a shift to a more universal approach to PMTCT over time. The use of 
antenatal care as an access point to testing and treating women with HIV is successful 
and advantageous, as has been found after success in PMTCT programmes (24). 
However decreased levels of MTCT rely on early and robust antenatal care with good 
coverage and patients following the PMTCT cascade (24). Loss to follow up is high for 
women who are pregnant and HIV positive. Approximately 49% of women who are HIV 
positive are lost to follow up between antenatal care initiation and delivery of their 
child globally  (41).   
 
PMTCT is the poster child for prevention in that eMTCT in infants is an imminent and 
attainable goal (38). In a systematic review PMTCT was also found to have the lowest 
median incremental cost effectiveness ratio of US $1 144/HIV infection averted and US 
$191/DALY (disability adjusted life year) averted when compared to other HIV 
prevention interventions of VMMC, PrEP, treatment as prevention (TasP), other 
biomedical interventions, behaviour change, and structural interventions (42). 
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2.1.5 The history of PMTCT 
 
In the early 1980s, it was discovered that paediatric HIV infections were due to MTCT 
(24). However, at this time if a woman was HIV positive the only option to ensure HIV 
was not transmitted to the infant was to avoid pregnancy, as no preventative 
interventions had been established (24). Now mothers protect their infants from 
infection through taking prophylactic ART during pregnancy and breastfeeding and 
giving post exposure prophylaxis to their infants. 
 
In the first decade of the 2000’s, the WHO guidelines for PMTCT changed four times, 
which emphasises the dynamic nature of PMTCT programmes (24). LMICs made their 
best attempt at adopting each recommendation in turn, sometimes with the result that 
implementation challenges have hampered their success and have created confusion 
(24).  Botswana was the first African country to have a PMTCT programme in the late 
1990s, which comprised a short course of zidovudine (AZT) and a single dose of 
nevirapine (24). In countries such as Kenya and Eswatini there has been a drive to 
integrate sexual and reproductive health services and HIV services, with the idea that 
this would benefit patients, improve service delivery and result in cost savings (43). 
 
Previously the Option A approach to PMTCT was utilised, for instance in countries like 
Eswatini and South Africa. The Option A approach separated pregnant mothers into two 
categories, either eligible or ineligible for lifelong treatment based on their CD4 count 
(this CD4 count threshold was 200 then 250, then 350, and then 500 cells/μl). Those 
ineligible mothers were only given prophylactic monotherapy treatment during their 
pregnancy period (which differed from the triple ART given to eligible women). The 
 25 
WHO also identified another approach to PMTCT called the Option B approach. The 
Option B approach uses treatment as prophylaxis for all but differentiates between 
those above and below the threshold of a CD4 count of 350 cells/μl. Initially women all 
start the same triple ART, however those women with a CD4 count below 350 cells/μl 
are started at diagnosis and continue for life, whereas those with a CD4 count above 350 
cells/μl start ART from around 14 weeks gestation and cease treatment one week after 
stopping breastfeeding (44). 
 
There has been a global move to the Option B+ approach, which places all pregnant 
mothers who are HIV positive on lifelong ART regardless of their CD4 count (23). This 
approach was first suggested in Malawi as a public health approach to PMTCT, in 
response to an identified need to start treatment prior to receiving, often delayed, CD4 
count results (45). Option B+ is now referred to as lifelong ART. 
 
The value of lifelong ART is the potential reduction in both vertical (MTCT) and 
horizontal (between sero-discordant couples) transmission of HIV and reducing 
maternal morbidity and mortality (44). As well as individual benefits in starting ART 
early for those women who start lifelong treatment under the PMTCT programme, such 
as reduced risk of TB due to early initiation (46). There is growing evidence of 
individual benefit with very early ART, but concerns have been raised about retention 
in care with this approach. Lifelong ART automatically provides PMTCT for subsequent 
pregnancies (if women are adherent), which along with reduced horizontal 
transmission, may be a significant public health benefit. 
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The Option B+ approach was in line with evidence for starting treatment earlier on, as it 
allowed pregnant women to start ART regardless of their CD4 count, which reduced 
harm from treatment interruption and had public health, PMTCT and individual 
benefits from treatment for all. Additionally, the study by Lundgren et al. (30) called for 
progress within the health system to improve HIV diagnosis and linkage to care, which 
the Option B+ approach aimed to do.  
 
PMTCT has been a large public health achievement as it has globally prevented the 
infection of hundreds of thousands of children with HIV (24). Despite the improvements 
of the PMTCT programmes, the access and movement of pregnant women through the 
treatment cascade is still crucial to the success of the programme (24). Hence, if women 
do not access antenatal care, they may not be initiated on treatment during pregnancy 
(24). For those who do access antenatal care, the loss to follow up of HIV positive 
pregnant women in Sub-Saharan Africa countries between first antenatal care 
registration and delivery was found to be around 49% by a systematic review (41). This 
may be especially relevant where delivery is not in a health facility.  
 
2.1.6 PMTCT Implementation influences and challenges 
 
Challenges for PMTCT still centre on retention and adherence of patients (44) as well as 
on late presentation for antenatal care. In addition, the way to refer mothers into HIV 
treatment and care programmes remains a concern (44). The Safe Generations study in 
Eswatini found an overall retention of 39% of mother-infant pairs from first antenatal 
care visit until six months postpartum, and 53% when only assessing universal ART (5).  
WLH in rural Uganda and urban South Africa were compared and found to have 90% 
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ART adherence during the postpartum period and 40% respectively , whereas this was 
91% and 74% during the pregnancy phase (47). Emotional support has been 
recommended as an aid to retain WLH, especially in the postpartum period (47). For 
example emotional support can be in the form of encouragement or reminders about 
ART, from a peer or treatment buddy or family member (48).  
 
In Zimbabwe, a study was conducted to assess the implementation of a rural PMTCT 
programme between 2001 and 2003. The authors found that following up the mothers 
(loss to follow up) as well as collection of test results were the largest challenges (49). 
This could be partly due to the mobility of the population studied as well as monitoring 
of follow up only taking place in hospitals and not in clinics, posing limitations such as 
patient transport  (49). The training health care workers receive in counselling services 
also has influence on the care provided and should be an aspect that is focused on (49). 
 
Lack of follow up was also highlighted in another South African study, with the 
additional concern that PMTCT services were not well integrated into routine care. For 
instance, there was a lack of clarity around the roles of staff in well baby services as to 
who should be doing testing for HIV exposed infants as well as poor recording of 
essential PMTCT information in files (50). In a further South African study, pregnant 
women had concerns that the ‘rules’ that governed how they received care and the 
timing of treatment were not made explicit (51). The authors of the study raised the 
suggestion that women should be empowered in the ANC setting and perhaps this 
would help overcome this challenge (51). 
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2.1.7 PMTCT in Sub-Saharan Africa 
 
It is in Sub-Saharan Africa that the burden of HIV is most heavy. It has been estimated 
that 2 million HIV infant infections have been prevented, as a result of ART during the 
pregnancy and postpartum phases for mothers (52). Of 160 000 incident cases in 
children (0-14 years of age) in 2018 worldwide, approximately 139 200 were in Sub-
Saharan Africa.  There has been a decrease in the number of incident HIV cases in Sub-
Saharan Africa for those aged between 15-49 years of age by 37% between 2010 and 
2017 (2.14 per 1000 uninfected in 2017) (53). Mukose and colleagues (54) in Uganda 
costed lifelong ART (Option B+) in four facilities and found the largest driver of costs to 
be the ART itself, with the unit cost for the mother-infant pair being US $442 (in 2014 
US $) over a two year period. Another study in Ethiopia, had similar findings of ART 
being the cost driver for PMTCT services for mother-infant pairs, with a per person year 
cost range of US $319-1099 (also in 2014 US $) among the 12 facilities that they studied 
(55). Sarkar et al. (42) in their systematic review found that the median cost-
effectiveness for PMTCT interventions and services in 17 studies in the Sub-Saharan 
African context was US $1 144 per HIV infection averted and US $191 per DALY averted 
(in 2018 US $) (42). There are of course elements of the literature included in the 
review by Sarkar et al. (42), which makes comparability difficult such as the divergent 
settings and different timing of the studies such as before or after the introduction of 
lifelong ART. Malawi, Zambia and South Africa were the most highly represented 
countries in their systematic review each accounting for four estimates between 2009 
and 2016 (42). The authors caution that focus should shift to vulnerable and under 




2.1.8 PMTCT in South Africa 
 
The HIV pandemic began in South Africa around 1990 and has been on the increase 
since (56).  South Africa has made good headway with reducing new paediatric HIV 
infections, since the PMTCT programme was established in 2002 (56). Prior to this a 
pilot PMTCT programme was initiated in 1998 in the Western Cape at two midwife 
obstetric units (MOUs) in Khayelitsha by the Provincial Department of Health (56). 
After the formal initiation of the PMTCT programme, the government extended the 
PMTCT programme, in 2003, to all pregnant mothers and their children, and those 
pregnant women with CD4 counts of less than 200 cells/μl were deemed eligible for 
highly active antiretroviral therapy (HAART) (56) as was anyone with CD4 count less 
than 200.  
 
The national PMTCT accelerated plan was launched in 2008 by the Minister of Health, 
which had the ambition to decrease MTCT from 12% to less than 5% between 2008 and 
2011 (56). Between 2009 and 2012, there was a 46% decrease in new HIV infections in 
children in South Africa, with a 7% MTCT rate in 2012, which had decreased from a 
13% MTCT rate in 2009 (39). Coverage of ART for pregnant WLH in PMTCT 
programmes in South Africa was in excess of 95% in 2019 and 302 936 WLH had 
received ART (28). 
 
The Minister of Health endorsed the idea of exclusive breastfeeding in 2011, with the 
rationale to improve child health, which had the implication that freely provided 
formula milk distribution should be ceased (56). In 2012, in South Africa, the coverage 
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of ART was 83% in pregnant women and the number of newly infected women had 
decreased by 28%, which contributed to lower HIV transmission rates and a decreased 
number of HIV infected infants (39). South Africa moved from the Option A approach, 
which was implemented in 2010 (56), to Option B in 2013 (in all but name), and then to 
the Option B+ approach of immediate initiation of ART being recommended for all 
pregnant and breastfeeding women at the beginning of 2015 (57).  
 
One study found that in the peri-urban setting of Gugulethu in South Africa, 58% of 
pregnant women enrolled in antenatal care had found out about their HIV status during 
pregnancy (58).  However in South Africa there is a tendency to present late for the first 
antenatal visit and only around 40% of pregnant women attend prior to 20 weeks (56) 
and early initiation generally leads to better outcomes.  With this in mind the adoption 
of lifelong ART was prudent, especially for the coverage of subsequent births. 
 
2.2 Infant HIV testing 
 
There is some discussion around the best timing of infant HIV testing using HIV 
polymerase chain reaction (PCR) testing, as ART is taken by both mother and infant in 
the PMTCT programme and may impact on the results of the HIV PCR test (59, 60). In 
South Africa, a large proportion of women attend a health facility for delivery, which 
could allow for high levels of coverage of testing at birth but may require point of care 
testing to be successful (59, 60) and will not detect intrapartum transmissions. PMTCT 
reduces the proportion of intrapartum transmissions more than the in-utero 
transmissions especially due to late antenatal care bookings and therefore a PCR done 
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at birth detects more infections than a delayed PCR. The in-utero transmissions are at 
extremely high risk of rapid progression if not treated early. 
 
2.3 Postpartum HIV care 
 
Transition to postpartum HIV care (which is part of Prong III and IV of PMTCT) from 
receiving as ART during the antenatal period through PMTCT programmes is a crucial 
step in the treatment cascade and presents a vulnerability where mother-infant pairs 
may be lost to follow up.  Where integration has taken place and mother-infant pairs are 
continue in care within PMTCT such as part of the Strategies to Optimize ART Services 
for Maternal and Child Health (MCH-ART) study, it may be that women are protected 
during the particularly vulnerable stage of shifting from antenatal to postpartum care 
by delaying movement to general ART services (61). In Nigeria, the use of an integrated 
PMTCT intervention resulted in 85% of mother-infant pairs being retained at 6 weeks 
postpartum and 75% at 12 weeks which is close to a staggering ten times higher than in 
the control arm of the study, where 9% and 7% of and mother-infant pairs at the same 
time points (62).  Qualitative work which has investigated the ways in which mothers 
personally navigate the health care system provide value insight into the barriers and 
facilitators to postpartum care for women living with HIV (WLH) (61).  For instance, it 
seems that stigma in areas of Cape Town, South Africa still remains an obstacle around 
which women negotiate their health care, seeking care where they will not be 
recognised and keeping their folders out of sight (61). Two factors which seem to be 
important in remaining in care are improved understanding and knowledge of the 
rationale for receiving care as well as social support, such as being able to openly 
 32 
discuss treatment with families, a partner or friend. Both of these factors may enhance 
the motivation of WLH and empower them to take their treatment seriously (61).   
 
2.4 Models of care/ differentiated care 
 
Two aspects that have been focused on in the WHO Consolidated Guidelines are 
decentralised HIV treatment and care, as well as task shifting for this care (20). With 
this in mind several models, including community-based care, have been suggested and 
implemented. World Vision has identified 20 countries, including South Africa, Eswatini, 
Mozambique and Lesotho, that could potentially implement further community-based 
PMTCT programmes (63).  
 
Other models have been used for HIV care, for instance the Médecins Sans Frontières 
(MSF) community ART group approach in Mozambique, where groups of six individuals 
collect medication in a rotation, so that only one individual travels to the clinic in a 
given month (64, 65). This approach has been used for PLWHA generally and not 
specifically for pregnant HIV positive mothers.  
 
Limited experience in the utilisation of the Option B+ approach necessitated research 
into the implementation of the approach, as well as recommendations regarding its 
cost-effectiveness in the Southern African setting. Previous work has been done around 
modelling the two PMTCT approaches (Option A and B+), and this work indicates that 
the cost-effectiveness of Option A and Option B+ are comparable, or that Option B+ has 
a potential to be more cost-effective than Option A (66).   
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In order to improve retention and adherence under the lifelong ART, innovative 
strategies need to be implemented which can simplify the treatment and enhance 
adherence (67).  For instance increasing peer support, and decreasing the time spent 
waiting at clinics, as well as the number of clinic visits, in an attempt to strengthen 
adherence (67). And so, the evolution on lifelong ART is the idea of different models of 
care or differentiated care or differentiated service delivery, which can unburden 
facilities, simplify care, enhance adherence and improve the experience of patients as 
recommended by the WHO (20).  We are reminded that the focus of differentiated care 
should be on the patients’ needs, hence the term ‘client-centred approach’ (68) 
 
A lot of work has been done to create frameworks for differentiated care that enable 
countries to develop context specific models of care tailored to the needs of their 
population. Breastfeeding WLH in the postpartum phase are one of the specific 
populations that has been highlighted as needing to benefit from differentiated care 
(69).  
 
Integrating ART delivery and care with other health services is another part of 
differentiated care that has been endorsed by WHO (20). Integrating PMTCT into 
primary health care was a step on its own in South Africa given the history of political 
‘AIDS denialism’ (70). There are of course arguments for integrating care with other 
diseases such as cervical cancer which was found to be cost-effective in one site in 
Kenya (71) and tuberculosis. Nugent et al. (72) wisely add the need to consider how HIV 
positive and HIV negative individuals’ chronic healthcare needs can be managed in an 
integrated, sustainable and affordable way. However, Nugent et al. (72) and Golovaty et 
 34 
al. (73) caution that more economic work is required on the integration of HIV and non-
communicable diseases prior to uptake.  
  
In Tanzania, a PMTCT programme being integrated into maternal and child health 
services was costed and revealed an average annual cost of US $160 for the 12 included 
facilities per patient on ART for 2017 (74). This value ranged from US $ 101-812 
depending on the type of facility which was mostly related to the cost of personnel in 
differing facility levels.  A crucial point that the authors make is that as we see 
improvement in the coverage and health of PLWHA in particular WLH in the antenatal 
period, it will most likely become more costly to detect a case of HIV. However, if 
services are integrated (as they were in Tanzania and as part of the MCH-ART study (2, 
74)) with maternal and child health services then it is likely that the costs of detecting 
HIV in WLH will be absorbed more easily alongside the provision of routine antenatal 
services as the costs at the facility level will be shared for instance the personnel costs 
(74). The benefit of integrated care is further advantageous when one considers the 
inverse relationship that was observed between the number of tests performed and the 
cost per test.  The average yield of positive tests from the total number of women 
testing for HIV found in the study was a low 1.1% (74). 
 
Coincidently, Zegeye et al. (55), also costed PMTCT services in 12 facilities in Ethiopia 
(55). However, their costing was of PMTCT services as a whole as opposed to integrated 
care. A marked difference was found between facilities in rural and urban settings, with 
costs being above three times higher in urban settings (US $1 099 compared to US $319 
annually per mother-infant pair in rural settings in 2014) despite higher volumes of 
patients (i.e. diseconomies of scale) (55).  
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Enhancement of models can be assisted through means such as peer support and the 
involvement of technology (75). Three studies in South Africa showed differences from 
the status quo. These studies included providing point of care CD4 testing and 
counselling (rapidly provided in one case) in two instances and accompanied transport 
from home to the facility among other interventions in the third (76-78). When point of 
care CD4 testing was provided with counselling in mobile clinics, linkage to care was 
improved in comparison to the standard of care, although still surprisingly low at the 
three month post-test stage (moving from 29% of individuals amongst those in 
standard of care to 38% in the point of care CD4 and counselling intervention arm). 
Shamu et al. (78) ultimately recommend that a mix of offerings work best to aid linkage 
to care, such as accompanied transport (particularly for children), triage in queues to 
fast-track patients, and team work, however the strategies they suggest have not yet 
been costed. 
 
2.5 Health care prioritisation  
 
In assessing different models of care, one needs to look at priority setting. Health care 
prioritisation intends to direct resources towards the areas of highest need and where 
impact will be achieved leading to equity (79, 80) . Lack of prioritisation can lead to 
research uptake, which is based on convenience and not necessarily on the most 
pressing health concerns (79). For quite some time there has been a clear promotion of 
cost-effectiveness as a tool to help with priority setting (81) and there are institutions 
such as the United Kingdom National Institute for Clinical Excellence (NICE), which 
regulates adoption of technologies through the use of cost-effectiveness analyses (81). 
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Currently, there is not a body such as NICE in South Africa. Importantly, the adoption of 
new practices or technologies is not always required, as the tools to tackle ill health can 
be found in existing interventions (79). Cost-effectiveness is often the first question 
posed while the second question of affordability is also crucial to examine (72).  
 
The resources available for health research in LMICs remain low despite the large 
burden of disease in those countries (79, 80). In LMICs, the expectancy is that research 
should be in line with the health needs of the community and hence be prioritised 
accordingly (79) but this is not always the case. Some of the identified challenges in 
priority setting in LMICs relate to participation with stakeholders, availability of data 
and capacity limitations (79). 
 
2.6 Economic evidence for PMTCT  
 
The economic problem we face in healthcare is based on the basic definition of economics, 
unlimited wants due to the variety and demand of illnesses (choice) and healthcare needs 
and limited resources to address these needs (constraints). Resources in terms money for 
paying for technology and healthcare providers salaries; but also healthcare providers 
time and capacity; infrastructure, for instance provision of quality space; limited funds 
for diagnostic tests, medication (new and existing) and consumables needed to provide 
quality services among others (82, 83). 
 
Inefficiency in spending on healthcare has an impact on the healthcare sector in that the 
value we could have gained is lost, referred to as an opportunity cost.  However, the 
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impact ripples further than the healthcare sector as the opportunity cost can also be felt 
in the education sector, housing sector and social services (82).  
 
Economic evaluation recognises that looking at the effectiveness of a programme is 
necessary but not sufficient for decision-making and therefore one should also 
incorporate the costs of the programme (84). Therefore, economic evaluation looks at 
both the costs and consequences of different competing and comparable options (83, 
85, 86). An economic evaluation can be seen as a useful tool in deciding where scarce 
resources should be placed (85). 
 
2.6.1 Cost-effectiveness analysis  
 
A cost-effectiveness analysis is a type of economic evaluation where in essence we are 
looking to maximise the health benefits, taking into consideration the cost and available 
resources (85).  The first step is to estimate the cost and effectiveness measures of the 
comparable health interventions for a population. In the form of a ratio one then looks 
at the incremental cost effectiveness ratio (ICER), which is a difference in costs divided 
by a difference in effectiveness (84). Therefore in a cost-effectiveness analysis we are 
looking at a measure of the incremental cost per unit of additional effect (85).  
 
The Second Panel on Cost-Effectiveness in Health and Medicine was formed to align 
efforts in cost-effectiveness analysis, in an attempt to make the estimates more precise 
and informative. One of their recommendations is to use an “Impact Inventory” to better 
illustrate where and how costs were collected (82).  Another aim which is echoed by the 
International Decision Support Initiative Reference Case for Economic Evaluation and 
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the Reference Case for Global Health Costing is that of quality and comparability (87-
89). A reference case’s role is to provide a set of methodological standards that one 
aspires to - in this case when performing a costing or cost-effectiveness analysis. Cost-
effectiveness analysis has the ability to inform investments in new programmes (aiding 
decisions in incorporating new technology or not) as well as advising disinvestments in 
programmes, technology and interventions that are not cost-effective (82).  
 
A cost-effectiveness analysis is a tool that can be used to aid decision making. However, 
it does not make the decision for us, deliberation is still needed, for instance in thinking 
about the context and affordability of introducing a new cost-effective technology. It 
would be impossible to implement all the interventions that are found to be cost-
effective to the health benefit of all, unless we had unlimited resources (82) in which 
case we would not need to care about cost effectiveness.. 
 
2.6.2 Cost and cost-effectiveness analyses investigating HIV/AIDS and PMTCT 
 
Importantly, one can see that costs fall after the first year of treatment which is credited 
to decreased hospital costs, but on the other hand costs rose if a patient passed away 
before the second year of treatment (90).  When assessing the outpatient cost of 
initiating ART (for general adult ART services) in four different sites in South Africa, it 
was found that on average the cost was US $928 for the first year of treatment of a 
patient, with the inputs comprising 47% for medication, 19% for laboratory testing, 
16% for the outpatient visits and 19% for the infrastructure and other fixed costs  (91). 
However, for a patient to be reported as in care and responding to treatment, the cost 
increased by 55% on average (to US $1 438) (91). Another study estimated the average 
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costs for ART care in South Africa to be US $404 per patient for the first month of 
treatment, US $2 502 (per patient year of observation) in the first year and US $1 372 
(per patient year of observation) in the second year (90). It has been established that 
HAART is cost-effective and can be cost saving, for instance when locally manufactured 
drugs are used (92).  
 
For patients who were considered stable on their ART medication, the cost of down 
referring from a doctor-led, hospital based ART clinic to a nurse-led, primary health 
care facility (in Johannesburg) saw a reduction in costs by 11% from US $551 to US 
$492 over a year’s duration (93). This strategy was found to be more cost effective than 
the hospital based, doctor-led approach (93).  
 
When assessing the expansion of ART services based on CD4 counts, escalating to all 
CD4 count levels (i.e. universal coverage) was estimated to decrease the number of HIV 
infections in South Africa by 3.3 million, a reduction of 45% (94). The estimated cost 
reduction would be US $10 billion over 40 years, with the breakeven point at 2023 (94). 
In 2004 and 2005, the total budget for the South African National PMTCT Programme 
was approximately US $11 594 265, of which the Western Cape received 6.8% (95). 
This was a huge increase from the piloting PMTCT support provided in 2001 and 2002 
of approximately US $1 511 567 (95).  
 
Unit costs per patient for providing PMTCT services in the Western Cape in 2002 were 
calculated for a hospital (Paarl Hospital) and clinic (Phola Park Clinic) (95). The 
researchers found that for counselling and testing the unit cost was US $5, whereas the 
unit cost for delivery was US $21 and the unit cost for follow up care was US $26 (95).  
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A QALY is an effectiveness measure that uses the multi-dimensional aspects of quality 
and quantity of life years gained. In order to inform the quality of life years gained on a 
scale from zero to one, individuals are asked to evaluate their health using a measure 
such as the EQ-5D which is a tool is used to measure health across different diseases/ 
health states which uses five dimensions of health (83, 88, 89). In a study that assessed 
the cost effectiveness of accelerating the initiation of ART among pregnant women in 
Cape Town, South Africa (96), the authors found that the accelerated plan cost US $880 
per women for one year as opposed to the standard of care services which cost US $220. 
The ICER was US $1 160 per QALY (quality adjusted life year) saved, meaning that the 
expedited programme was highly cost effective in South Africa when using the WHO 
national gross domestic product (GDP) per capita standard (96). Importantly this work 
also underlines the potential for South Africa to swiftly initiate pregnant women onto 
ART in antenatal care clinics (96). However, the use of multiples of the GDP as a 
threshold indicator is no longer recommended (indeed it may have been 
misrepresented for quite some time) (97). What is now recommended is the use of a full 
evaluation of the ‘benefits package’ for the particular area of interest such as HIV where 
all cost-effective items are included as far as the budget allows, with the final additional 
item is deemed non-cost-effective or above the ‘threshold’. 
 
Another study in Zimbabwe looked at a model comparison between single dose 
nevirapine, Option A, Option B and Option B+ (98). The authors found that by replacing 
single dose nevirapine (lifetime cost of US $5 760 for the mother-infant pair) with either 
Option A (lifetime cost of US $5 710) or B (lifetime cost of US $5 630), improved the 
outcomes for the mother and infant and was cost saving. Option B+ further improved 
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outcomes for the mother and had a lifetime cost of US $6 620. The ICER for Option B+ 
was US $1 370 per life year saved when compared with Option B, which is comparable 
to other ART related interventions in LMIC settings, although not cost-effective when 
using the WHO GDP standard for Zimbabwe (98).  
 
Similarly, it was found that Option B+ would avert a greater number of both vertical and 
horizontal transmissions in comparison to Option A or B, with a reduced cost in South 
Africa, Kenya, Zambia and Vietnam (99). 
 
In comparison to self-administered ART, a cost utility analysis found that directly 
administered antiretroviral therapy not to be cost-effective in the Sub-Saharan African 
setting (100).  
 
2.7 Scaling up 
 
Scaling up refers to ‘expanding the coverage of health interventions’ (101) with the aim 
to improve health outcomes, benefit more individuals, and support policy and 
programme development at large or national scale, which requires increased resources 
(101). With the change to lifelong ART there will be very high numbers of clinically well 
patients, who are stable on ART and who do not need to be regularly monitored by a 
doctor. 
 
In eight African countries the scale up of PMTCT programmes was supported by 
strengthening the policy environment, ensuring consistent unifying national plans and 
then leveraging funds for the programmes both nationally and internationally (102).  
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One way to scale up PMTCT is to task shift to health care workers at a lower cadre such 
as community health care workers (101). The context within the country is significant, 
and so involving innovative practices that have been locally driven or implemented can 
be beneficial (101, 103). An important part of ensuring scale up is through the 
presentation of alternative health interventions with demonstrated effectiveness, which 
is also important when trying to gain local budget commitment (104). By ensuring 
strong management practices one can allow some flexibility in implementation of a new 
programme, which can decrease the resistance to the inclusion of new treatment 
practices (104). One must also allow sufficient time for scale up to occur (104), as well 
as ensuring that the programme is equitable in terms of providing for the deprived and 
vulnerable sections of society (101). Increasing coverage should be weighed up against 
upholding quality care (101). 
 
The constraints of scaling up models of care could be linked to the health system, the 
staff involved, available or unavailable resources (such as supply shortages), the 
management context within the facility or setting, and the organisational culture and 
leadership (105). Through the understanding of the circumstances and setting that the 
intervention will be scaled up under, one can hope to overcome some of the constraints 
faced (105). WHO suggests three important ways to help overcome constraints: 
identifying and understanding the environmental factors at play; identifying opportune 
timing and opportunities; and, as the scale up evolves, assessing any changes in the 
environment and adapting to these changes (105). 
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In Ghana, the successes of community-based PMTCT scale up was assessed, where 
nurses were sent into the community and the local leaders where engaged in the 
process of PMTCT and it’s scale up. It was suggested that using staff from the area eased 
cultural understanding, continuous review by management allowed for evolution of the 
programme and a common vision by the management aided scale up (106). For scale up 
to be successful, it is also important to anticipate unintended outcomes and to engage 
key actors (107). 
 
In Gugulethu, in Cape Town, South Africa, one of the constraints to scale up of the 
community based HIV treatment programme has been the lack of physical space, 
leading to the relocation of services several times (108).  A success in the scale up has 
been the linking of an available low cadre staff member to each client who helps with 
adherence and retention (108). Adherence and retention are particularly important in 
the context of scaling up, especially when other staff members may not be able to 
provide the focused support that would be possible in a smaller scale programme. 
 
Uganda was one of the countries to roll out differentiated care at a national level, and a 
qualitative study has provided insight into some of the challenges at an individual, 
community and health system level (109). Stigma was found to be a concern in Uganda, 
which was the case in other settings too (35, 109).  
 
2.8 Budget impact analysis 
 
In order to inform scale up, a budget impact analysis can provide a component of a 
comprehensive economic evaluation that takes the point of view of the health care 
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decision maker (110, 111). Information is needed around the costs of scaling up health 
care interventions, such as improving maternal and child health and combating 
HIV/AIDS (103). It is important to assess the current treatment provided and the new 
treatment that may be incorporated, so that resource requirements can be estimated. 
Sullivan et al. (110) provide a framework for budget impact analysis allowing for 
transparency and easy replication. If possible, a budget impact analysis should be done 
alongside a cost-effectiveness analysis. Although one can estimate the increased 
finances that will be necessary to scale up an intervention, it may be that the health 
system constraints mean that the capability does not exist to deliver the intervention 
(101, 112). A projection for programmatic change from Option A to Option B+ within 
Cameroon, found that over a five-year period, the cost would be US $28.9 million more 
than would be spent on Option A (113). However, the price somewhat plateaus once 
women experience a future pregnancy. A large portion of the increased cost results 
from women who were not previously on ART, although they were eligible, due to low 
coverage rates (113).  
 
The budgeted funds for Eastern and Southern Africa for 2020/2021 is 283 million in 
total (including core global, non-core funds and country envelopes) which is 27% of the 
global budget (27) towards the ultimate goal of ending the AIDS epidemic by 2030. The 
national budget for healthcare in South Africa for 2020/21 is US $3.2 billion, while the 
Medium Term Expenditure Framework for the HIV and AIDS Component of the ‘HIV, TB, 
Malaria and Community Outreach Grant’ for the same financial year is US $1.3 billion 
(114-116). In total the National Strategic Plan details that the anticipated budget for 
HIV, TB and STI is R37.5 billion or US $2.1 billion for the 2020/21 period which includes 
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funding from the South African Government, PEPFAR and USAID, Global Fund and 
estimated private sector ART funding (17).    
 
2.9 Conclusion and unanswered questions 
 
Given the above structured literature review the following research gaps in the 
evidence-base on the optimal approaches and models of care for PMTCT, especially 
during the postpartum period for WLH and their infants, the empirical costs of the 
models and the costs to the patient, outcomes in terms of maternal retention and viral 
suppression and the ideal combination of models and financial implications of scale-up 
emerge: 
 
• Further research into ways of retaining mothers in care and ensuring adherence 
is necessary in the southern African context 
• There is limited cost-effectiveness evidence from novel models of care for ART 
provision particularly for postpartum WLH and their infants, but also for 
pregnant WLH 
• Innovative models need further exploration and development to aid the aim of 
eliminating paediatric HIV 
• Evidence on the cost-effectiveness as well as the costs to the patient of different 
models of PMTCT care is lacking 
• There is little economic information, regarding scale up of innovative models of 
care under the lifelong ART (Option B+) approach to PMTCT, especially on the 
costs of different models of care at scale, the best combination of models and 
where capacity will be surpassed leading to system failure 
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• There is a need to look at the roll of task shifting to community health care 
workers for PMTCT 
• Current cost information for PMTCT services would be valuable for budget 
making purposes 
• At the time that this work started pragmatic information was needed 
surrounding starting individuals on ART regardless of CD4 count, such as the 
feasibility and capability of the health system to absorb the additional workload. 
And more empirical, rather than modelled evidence is needed regarding the 
Option B+ approach in Southern Africa 
 
On the basis of these knowledge gaps, the broad objective of this study is to evaluate 
whether improved approaches and models of care which cater to the preferences of 
mother-infant pairs can result in better maternal outcomes (retention and viral 
suppression), lower or similar costs from the provider and patient’s perspective, and 
implementation of these approaches and models based on cost-effectiveness evidence 
and financial guidance from budget impact analysis.   
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3 Chapter Three: Cost and cost-effectiveness of transitioning to 
universal initiation of lifelong antiretroviral therapy for all HIV-
positive pregnant and breastfeeding women in Swaziland 
 
This manuscript was published in Tropical Medicine and International Health in 2018 
and was completed to fulfil Objective 1.) To compare the costs and effects of the Option 
B+ approach to the Option A approach to PMTCT from a provider’s perspective in a 
cost-effectiveness analysis. Formal permission was obtained by the publisher John 
Wiley and sons (license number: 4914720577301). Lucy Cunnama was the first author 
with input from all co-authors, in particular Edina Sinanovic, Elaine Abrams and Landon 
Myer. The citation is as follows (117):  
 
Cunnama L, Abrams EJ, Myer L, Gachuhi A, Dlamini N, Hlophe T, Kikuvi J, Langwenya 
N, Mthethwa S, Mudonhi D, Nhlabatsi B, Nuwagaba-Biribonwoha H, Okello V, Sahabo 
R, Zerbe A, Sinanovic E. Cost and cost-effectiveness of transitioning to universal 
initiation of lifelong antiretroviral therapy for all HIV-positive pregnant and 






To assess the costs and cost-effectiveness of transitioning from antiretroviral therapy 
(ART) initiation based on CD4 cell count and WHO clinical staging (‘Option A’) to 





We measured the total costs of prevention of mother-to-child HIV transmission 
(PMTCT) service delivery at public sector facilities with empirical cost data collected at 
three points in time: once under Option A and again twice after transition to the Option 
B+ approach. The cost per woman treated per month includes recurrent costs 
(personnel, overheads, medication and diagnostic tests) and capital costs (buildings, 
furniture, start-up costs and training). Cost-effectiveness was estimated from the health 
services perspective as the cost per woman retained in care through 6 months 
postpartum. This analysis is nested within a larger stepped-wedge evaluation, which 
demonstrated a 26% increase in maternal retention after the transition to Option B+. 
 
Results  
Across the five sites, the total cost for PMTCT during the study period (from August 
2013 to October 2015, in 2015 US $) was US $868,426 for Option B+ and US $680 508 
for Option A. The cost per woman treated per month was US $183 for a woman on ART 
under Option B+, and US $127 and US $118 for a woman on ART and zidovudine (AZT), 
respectively, under Option A. The weighted average cost per woman treated on Option 
B+ was US $826 compared to US $525 under Option A. The main cost drivers were the 
start-up costs, additional training provided and staff time spent on PMTCT tasks for 
Option B+. The incremental cost-effectiveness ratio was estimated at US $912 for every 
additional mother retained in care through six months postpartum. 
 
Conclusions 
The cost and cost-effectiveness outcomes from this study indicate that there is a robust 
economic case for pursuing the Option B+ approach in Swaziland and similar settings 
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such as South Africa. Furthermore, these costs can be used to aid decision making and 




Option B+, which provides lifelong antiretroviral treatment (ART) for all HIV-positive 
pregnant and breastfeeding women, was by WHO in 2013 and has been adopted by the 
majority of Sub-Saharan African countries (118, 119). Experience with implementation 
of Option B+ is evolving as most countries have only just transitioned or are 
transitioning from Option A. Option A provides differentiated treatment based on CD4 
cell count and WHO stage; those with a CD4 count ≤350 (≤500 in some countries) 
receive lifelong ART, while women with >350 receive zidovudine (AZT) prophylaxis 
while pregnant, single- dose nevirapine (NVP) and 7 days of AZT or tenofovir (TDF) and 
lamivudine (3TC) at delivery and NVP for infants while breastfeeding (44). Option B+ 
provides ART (efavirenz (EFV)+3TC or emtricitabine (FTC)+TDF) with 6 weeks of daily 
NVP for infants. 
 
Evaluation of the cost-effectiveness of Option B+ is insufficient. To date, most research 
on the cost-effective- ness of the Option B+ approach has been assessed through 
economic modelling (120, 121). In a review of published literature measuring outcomes 
relating to infant and maternal outcomes (122), varied cost-effectiveness results were 
noted in the data from African countries, with models running from 10 years to a 
lifetime span, which would incorporate future pregnancies. Due to differences in 
assumptions, input costs and effects within models the conclusion on cost-effectiveness 
was not consistent. The most comprehensive of the studies found Option B+ to be cost-
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effective in terms of infant and partner infections averted (99). However, there may 
have been partiality towards Option B+, and there is a clear need for ongoing cost- and 
cost-effectiveness data on universal ART strategies, including Option B+, in low- to 
middle-income countries (LMICs). 
 
Limited experience in the utilisation of Option B+ at the time necessitated research into 
implementation of the approach, as well as recommendations regarding its cost- 
effectiveness. Empirical information on the costs of PMTCT services is important to 
better utilise resources, for future modelling and to assess the impact of alternative 
approaches (123). The aim of this research was to estimate and compare the costs and 




The Safe Generations (SG) Study (ClinicalTrials.gov identifier: NCT01891799) was an 
implementation science research study, designed to evaluate the Option B+ approach to 
PMTCT. The Swaziland Ministry of Health (MoH) supported the SG Study because 
among others, cost and cost-effectiveness data were critical in informing Option B+ roll-
out costing and planning. The primary outcome for the evaluation was maternal 
retention in care, defined as the proportion of women with any clinic attendance 
documented within 56 days of delivery or estimated due date (antenatal retention) and 
clinic attendance documented within 84 days of 6-months postpartum (postnatal 
retention). These definitions were based on 1 month after the longest possible ART-
dispensing interval during the antenatal and postnatal periods (1 and 2 months, 
respectively). One of the secondary objectives was to compare the cost-effectiveness of 
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Option A and B+. Other outcomes included the proportion of women initiating 
antiretroviral medications during pregnancy, time from first antenatal care visit (ANC) 
to ART initiation, and the proportions of infants testing HIV- positive. The step wedge 
design allowed comparison between Option A (the standard of care when the study 
started) and B+, as transition occurred. There was 1 month of transition between 
Option A and B+ for each clinic. A 26% increase in maternal retention was 
demonstrated after the transition to Option B+. During the study, 54% of infants were 
traced and 53% received a Polymerase Chain Reaction (PCR) test. We therefore decided 
to focus cost-effectiveness analyses on maternal retention and exclude effectiveness 
outcomes for infants as they may not be representative of the entire study cohort (5). 
 
3.2.1 Study design 
 
The economic evaluation was retrospectively undertaken from a health services 
perspective. The cost estimates include both the financial and economic costs. The eco- 
nomic costs differ from the financial costs, as they include training and training 
materials that were provided through the main study. A full rather than an incremental 
costing was undertaken. 
 
3.2.2 Study facilities 
 
Five clinics providing PMTCT, HIV care and ART and baby wellness services (among 
others) were purposively chosen to encompass various factors, which could describe 
variation in characteristics between health facilities (see Appendix S1). The clinics were 
visited by a health economist to observe clinic process, measure clinic space, inventory 
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equipment and furniture and assist staff in completing time sheets at three points in 
time; once while still under Option A, and twice after transition to Option B+. This 
method was used to assess changes in resource use and staff time, and to familiarise the 




Using an ingredients-based approach, the overall clinic costs and the total costs of 
providing PMTCT services under Option A and B+ were assessed from August 2013 to 
October 2015. All costs are presented in 2015 United States Dollars (US $). Costs 
collected in other years were inflated to 2015 US $ using the consumer price index (124, 
125). Costs that were collected in Swazi Lilangeni (SZL) have been converted to US $ 
using the average exchange rate over the period January 2015 to December 2015 of 
12.77 SZL for 1 US $ (126). The cost per woman receiving prophylaxis per month 
includes capital costs and recurrent costs. 
 
3.2.4 Capital costs 
 
Equipment and furniture were audited and costed based on current replacement value 
sourced through medical, hospital equipment and furniture suppliers in South Africa. 
Building space was costed using current replacement value sourced from Council for 
Scientific and Industrial Research (CSIR) in South Africa. For logistical and resource 
reasons we used South African prices. 
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Start-up costs comprised study-specific training for Option B+ per clinic and toolkits for 
each clinic. The toolkit is a desktop flipchart, which aids the staff when educating the 
patients about how to take their medication correctly. Initial costs for training at the 
clinics are presented separately from the start-up costs. Study records provided the cost 
of developing, updating and printing the toolkit. Study-specific and initial training 
included the cost of the venue used, catering, the facilitators’ time and any transport 
provided. Data on initial training on PMTCT under Option A was collected through 
discussion with the staff providing PMTCT services. 
 
These capital costs were annualised using a discount rate of 3%, with the assumption 
that the useful lifespan will be 30 years for buildings, 10 years for equipment and 
furniture, and 5 years each for the toolkit, initial and study-specific training. 
 
3.2.5 Recurrent costs 
 
Salaries of staff at the clinics were obtained from human resources and finance 
departments in the MoH, non-government organisation (NGO) and a faith-based 
organisation (FBO) that run the respective clinics. The overhead costs of running and 
maintaining the clinics were estimated using the expenditure reports from the same 
finance departments. 
 
The prices of medication were collected from Central Medical Stores Swaziland. The 
cost per month of medication was calculated by multiplying the price of one pill of the 
respective medication (taken daily) for ART and cotrimoxazole (CTX) and the price of 
two pills of AZT (taken daily) by 30 days. All women were given daily CTX (under 
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Option A and B+). If a woman made a visit to the clinic it was assumed that she had 
received 1 month’s worth of medication. 
 
The prices of diagnostic tests (CD4, point of care PIMA CD4, haemoglobin, alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), creatinine and rapid HIV 
tests) were obtained from the National Health Laboratory Services South Africa. The 
cost of receiving the tests at first visit, 6 and 12 months later, was distributed over the 
time in care, 15 months (the gestation period (9 months) plus 6 months postpartum) to 
give a per-month diagnostic test cost (per guideline). 
 
3.2.6 Cost allocation 
 
Two unit costs were estimated, a ‘cost per visit’ and a ‘cost per woman treated per 
month’. The total cost of providing Option A and B+ services was divided by the number 
of PMTCT visits made in the same period to get the unit ‘cost per visit’, which does not 
include diagnostic tests or medication costs. 
 
A ‘cost per woman treated per month’ was calculated separately for those on AZT and 
ART under Option A and Option B+, respectively. This was performed by adding the 
‘cost per visit’ to the monthly medication cost and the monthly diagnostic tests cost 
(which were the same for Option A and B+). 
 
The weighted average cost per woman treated was estimated by multiplying the ‘cost 
per woman treated per month’ by the average number of visits made under the two 
different approaches, respectively, until 6 months postpartum (4.34 for Option A and 
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4.52 for B+). For Option A and B+, the proportion of those on ART in the study, (36% in 
Option A and 94% in Option B+) and AZT (64% in Option A and 6% of women who did 
not initiate ART under the B+ and received AZT) was used to weight the costs, 
respectively. In addition, the total costs were estimated by multiplying the total number 
of women enrolled in the study under Option A and B+, respectively, by the weighted 




Using the weighted average cost per woman treated for each approach, and the 
effectiveness data from the trial – the maternal loss to follow-up at 6 months 
postpartum – the incremental cost-effectiveness between the two approaches was 
estimated. The incremental cost-effective- ness ratios estimated reflect ‘the additional 
cost per mother retained at 6 months postpartum’. These estimates are based on 
incremental costs and effects from Option A to B+, where Option A is the baseline.  
 
3.2.8 Sensitivity analysis 
 
To assess the uncertainty in the analysis, five univariate sensitivity analyses were 
performed. Firstly, as Swaziland was rolling out routine viral load monitoring in the 
post- study period, the cost of viral load testing was obtained from Swaziland Health 
Laboratory Services and was added to the primary analysis costs to assess the cost 
impact of adding viral load testing, to the Option B+ approach, as a monitoring test after 
6 months and twelve months on treatment, respectively. 
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Secondly, TDF + FTC + EFV was donated to the study at a cost to the donor (Merck & 
Co). The cost of donated TDF + FTC + EFV was collected through study records and was 
used to assess the cost impact of using this medication on the ICER, rather than the less 
expensive generic medication (TDF + 3TC + EFV) under the Option B+ approach. 
 
Thirdly, the effectiveness measure of maternal retention was varied by 15% above and 
below the proportion used in the primary analysis to consider the effect on the ICER. 
Fourthly, as Option B+ reduces the need for diagnostic testing, the impact of removing 
all diagnostic tests from the Option B+ approach was assessed. 
 
Lastly, as less intensive training for transition to Option B+ may be provided in the 
future, the training cost under the primary analysis was reduced to one-third in the 
sensitivity analysis. This reduction was based on an interview with MoH around 
training they performed for transition. 
 
3.2.9 Ethical considerations 
 
Ethical clearance was provided by the National Scientific and Ethics Committee of the 
Ministry of Health in Swaziland (MH/599C/FWA 000 15267); the University of Cape 
Town (HREC REF: 418/2013); and Columbia University Medical Centre (IRB-
AAAL0661). Throughout the study, anonymity of the women has been maintained using 
unique identifying numbers. Clinic sites have not been mentioned by name. The clinic 
personnel who filled in timesheets consented verbally, and remain anonymous. Study 
data were stored on password-protected computers. There were no direct benefits to 
those participants taking part in the study; however, their participation may positively 
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Using medical record review, under Option A 1296 women (55%) were observed, while 
1051 women (45%) were observed under Option B+. Of those, 353 (27%) were 
retained under Option A and 559 women (53%) were retained under Option B+ (see 
Table 3). A total of 3495 visits (ranging from 364 to 1218) were made under Option A 
and 2670 visits (ranging between 89 and 1518) were made under Option B+ for the five 
facilities. 
 
The average cost per clinic visit under Option A was US $113.46 and US $169.65 under 
Option B+ (see Figure 2). The cost of medication per month was US $2.26 if a woman 
was on AZT (US $2.03) and CTX (US $0.23) and US $11.54 if a woman was taking TDF + 
3TC + EFV (US $11.31) and CTX (US $0.23) (Table 2). The per guideline diagnostic test 
cost was US $2.06 under both Option A and B+ (Table 2). The cost per woman treated 
per month, which includes recurrent and capital costs was US $118 for a woman on AZT 





Figure 2: Average clinic visit cost for Option A and Option B+ in 2015 US $ 
 
 
The weighted average cost per woman treated under Option A was US $525 compared 
to US $826 under Option B+. The main cost drivers were the start-up costs (study 
specific training for Option B+ per clinic and toolkits for each clinic), increased training 
and staff time spent on PMTCT tasks under Option B+ (Figure 2). Staff time relates to 
the MoH, NGO and FBO time staff spent on PMTCT tasks under Option A and B+ 
(separately), with time apportioned through timesheets as described above, which has 




Table 2: Cost per woman in care per month for Option A and Option B+ in 2015 US $ 
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For the five sites, the total cost for PMTCT during the study period was US $868,426 
under Option B+ and US $680 508 under Option A. The difference in cost between the 
two approaches was US $187 918 (Table 3). Considering the 26% difference in maternal 
retention between the two approaches in favour of Option B+, the incremental cost-
effectiveness ratio was estimated at US $912 (see Table 3). 
 
3.2.11 Sensitivity analysis 
 
Findings were sensitive to viral load testing, removing all tests, reduced training, 
medications and retention rates. Introducing viral load testing at 6 and 12 months after 
initial visits, using more expensive medication or decreasing the maternal retention 
under Option B+ increased the ICER, thereby reducing the approach’s cost-
effectiveness. Removing all diagnostic testing, increasing maternal retention and 
reducing the intensity of training under Option B+ decreased the ICER and made Option 




The cost and cost-effectiveness outcomes from this study indicate that there is a robust 
economic case for pursuing the Option B+ approach in Swaziland and similar settings 
such as South Africa. This is one of the first studies to present an empirical economic 
evaluation using primary patient level data as opposed to modelled data as has been 








Option B+ is a costlier, but also a more effective approach in terms of maternal 
retention. The incremental cost-effectiveness ratio was US $912. This means that, under 
the Option B+ approach, it costs US $912 for every additional mother retained to 6 
months postpartum. This is well below Swaziland’s 2015 per capita gross domestic 
profit (GDP) of US $3 068 (132), and falls within the cost-effective range for the country 
(US $288- US $1 559) (133), which suggests that Option B+ is highly cost-effective in 
this setting. 
 
In this study, personnel costs were the key cost driver, which is similar to other studies 
(123, 134), and can be attributed to the increased staff time spent on PMTCT tasks 
under Option B+. Start-up costs and increased training provided under Option B+ also 
impacted on the cost of the Option B+ programme. 
 
Consistent cost results were found in this study to that of Zulliger et al. (96), who 
explored the cost-effectiveness of accelerating the initiation of ART among pregnant 
women, finding it cost US $880 per women for 1 year, compared to standard of care, 
which cost US $220. This is similar to the weighted average cost per woman treated 
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under Option B+ in this study of US $826, and may be comparable as the settings are 
alike and the costs were empirically collected. 
 
Divergent results were found between this study, where weighted average cost per 
woman treated under the Option A approach was US $525 (and US $826 under Option 
B+), and the higher estimates in empirical work by Bautista-Arredondo et al. (123). 
They estimated the costs per woman under the Option A approach receiving medication 
in Kenya, South Africa and Zambia as ranging from US $704 to US $1 385 (in 2013 US $), 
while in Rwanda the cost of Option B+ was estimated to be US $2 214 per woman (123). 
 
Table 4: The impact of alternative assumptions for diagnostic testing, medication, 




Results from Malawi (127), Rwanda (135) and Cameroon (136) differ from our study 
findings as they modelled estimates, are from settings other than Swaziland and have 
differing time horizons. In the five papers reviewed by Karnon and Orji, cost inputs in 
the models for Option A ranged from US $16 to 76, while costs for Option B+ varied 
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from US $114 to 470 per year (122), which are lower than our estimates. In this study, 
the total cost for PMTCT in the five sites during the study period was US $680 508 
under Option A and US $868 426 under Option B+. In comparison, the total programme 
costs for Option B+ as simulated by Tweya et al., (127) in Malawi were US $431 910 for 
a first pregnancy and US $662 074 for a woman’s second pregnancy. 
 
The intermediate outcome of retention in care is an important aspect in the continuum 
of HIV care as being diagnosed and starting ART are vulnerable areas of the HIV 
programme (137). Retention in care is an important precursor to a final outcome of 
prevention of mother-to- child transmission of HIV, as retention increases the potential 
time of patients being in care and on treatment. Improved retention could also be linked 
to increased staff training, improved staff skills and the increased patient- provider 
time. Hence providing additional staff training on PMTCT may result in higher retention 
rates. Attention needs to be paid to continuing the support and training of healthcare 
workers so that retention can be maintained and improved (138). In Cameroon (Option 
B+), retention rates of 88% were noted at 6 months, with decreases in retention over 
time (136) which are much higher than the retention rates found in this study. 
 
Under the Option B+ approach, more women were placed on ART, requiring more 
follow-up and more time with providers. However, no major changes in infrastructure 
or staffing structure were needed to implement Option B+. This could speak to an 
increase in efficiency, and use of spare capacity, which may not be available in all 
settings. Once Option B+ is established and with scale, we may find that costs stabilise 
and plateau at a level that is lower than those found in this study (139). 
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There is a shift towards universal lifelong access to ART for all individuals with HIV (a 
test and treat strategy, not just pregnant women) regardless of their CD4 count (Joint 
United Nations Programme on HIV/AIDS (UNAIDS), (20, 140). Assessing the impact of 
Option B+ for pregnant women with HIV will help policymakers highlight areas that 
need to be addressed as general access to ART improves and more individuals are 
placed on ART. Even with the introduction of Option B+, the rate of retention was still 
suboptimal, which emphasises that focus needs to be placed on improving and 
maintaining retention. Better retention rates may put additional stress on the health 
system as there would be more women on ART. The unit costs in this study could be 
used to inform a budget for universal lifelong access to ART for all individuals with HIV, 
taking into consideration that there may be slight differences in the population group. A 
transition to universal lifelong treatment would impact on the budget due to scale up of 
services, as there would not be a differentiation by CD4 count and treatment would be 
maintained throughout the life of the individual. In addition, other strategies such as 
community-based approaches may be helpful in supporting those on universal lifelong 




There are several study limitations. The cost of running the Option B+ approach over a 
longer period was not estimated. Personnel may behave differently due to the nature of 
being involved in a study, which may impact on both the resources used (i.e. costs) and 
the effective- ness of the intervention (i.e. retention). 
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Difficulties in infant tracing meant that mother-to-child transmission of HIV was not 
included as an effectiveness measure and cost-effectiveness outcome. Future studies 
should be aware of the challenges of tracing these infants, ensuring that medical file 
numbers and other linkages are maintained. In this analysis, we have not considered 
how the presumed health benefits of mothers being on ART and the loss to follow-up of 
patients may impact on the overall estimation of the cost-effectiveness. Due to the 
nature of the step wedge design, health economic researchers did not collect data at the 
same post-transition time points for all clinics. This may mean some variability in the 
information collected in timesheets over time. There is currently no willingness to pay 
(WTP) threshold for Swaziland and therefore GDP per capita and the cost- effective 
range for Swaziland were used as thresholds. This limits comparability with studies in 
countries with WTP thresholds. In addition, dolutegravir-based regimens are expected 
to be introduced more widely and updated estimates of cost and cost-effectiveness will 
be needed. Finally, there is a limit to the generalisability of the results as the data was 
collected specifically in the context of Swaziland transitioning from Option A to Option 
B+. However, in settings such as South Africa, where there is no empirical evidence 




Overall, findings from this economic evaluation suggest that there is a strong economic 
case for pursuing the Option B+ approach in Swaziland. Increased staff time and 
providing additional staff training as was the case in this study, may result in higher 
retention rates in other settings, which in turn may positively impact on the health of 
women in such programmes. As universal HIV treatment programmes are implemented, 
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providing Option B+ for women who are pregnant and HIV-positive is a good platform 
for initiating this expansion. Cost findings from this study could inform budgeting for 
countries moving to the test and treat strategy for all individuals living with HIV. Based 
on this study, there may be optimistic implications in terms of retention to care as all 




4 Chapter Four: Provider- and patient-level costs associated with 
providing antiretroviral therapy during the postpartum phase to 
women living with HIV in South Africa: A cost comparison of three 
postpartum models of care 
 
This manuscript has been accepted in Tropical Medicine and International Health in 
2020 and was completed to fulfil Objective 2) To estimate the costs of three models of 
care for mother-infant pairs during the postpartum phase (at 12 months postpartum) 
from a provider and patient’s perspective.  Formal permission was obtained by the 
publisher John Wiley and sons (license number: 4927670170025). An unpublished 
section on the costs of the pregnancy phase costs follows after which fulfils Objective 
2b.) to estimate the costs of the pregnancy phase for mothers from a provider’s 
perspective.  Lucy Cunnama was the first author with input from all co-authors, in 
particular Edina Sinanovic, Caitlin Dugdale, Elaine Abrams and Landon Myer. The 
citation is as follows (143):  
 
Cunnama L, Abrams EJ, Myer L, Phillips TK, Dugdale CM, Ciaranello AL, Zerbe 
A, Iyun V, MacQuilkan K, Daries V, Sinanovic E. Provider- and patient-level 
costs associated with providing antiretroviral therapy to women living with 





Innovative models of care to deliver antiretroviral therapy (ART) during the 
postpartum period may aid engagement in care among women living with HIV (WLH), 




We conducted two studies implementing three novel models of postpartum ART care 
for WLH: (I) - local standard of care with women in general ART services and infants at 
well-baby clinics; (II) - women and infants continue to receive care through an 
integrated maternal and child care approach during the postpartum breastfeeding 
period; and (III) - referral of women directly to community adherence clubs with their 
infants receiving care at well-baby clinics. We aimed to compare the unit and total costs 
of these three models of care for mother-infant pairs during the postpartum phase from 
provider and patient’s perspectives. The effects found in the MCH-ART study were that 
Model I had 56% of mother-infant pairs retained and virally suppressed (which was 
defined as HIV ribonucleic acid (RNA) <50 copies/mL) at 12 months postpartum; Model 
II had a 77% proportion; and Model III as part of the PACER study, was the most 
effective in terms of these measures, with 84% of mother-infant pairs retained and 
virally suppressed (in comparison to Model I). 
 
Methods 
Capital and recurrent cost data (relating to buildings, furniture, equipment, personnel, 
overheads, maintenance, medication, diagnostic tests and immunisations) were 
collected from a provider’s perspective at six sites in Cape Town, South Africa. Patient 
time, collected via time-and-motion observation and questionnaires, was used to 
estimate patient perspective costs, and are comprised of lost productivity time, time 




The cost of postpartum ART visits under Models I, II and III were US $13, US $10 and US 
$7 per visit for a mother-infant pair, respectively, in 2018 US $. The annual costs for the 
mother-infant pair utilising the average visit frequencies (a mean of 4.5, 6.9 and 6.7 
visits postpartum for Models I, II and III respectively) including costs for infant 
immunisations, visits, medication and diagnostic tests for both mothers and infants 
were: I- US $222, II- US $335 and III- US $249. Sensitivity analysis to assess the impact 
of visit frequency on visit cost showed that Model I annual costs would be most costly if 
visit frequency was equalised. 
 
Conclusions 
This comparative analysis of three models of care provides novel data on unit costs and 
insight into the costs to provide ART and care to mother-infant pairs during the delicate 
postpartum phase. These costs may be used to help make decisions around integrated 
services models and differentiated service delivery for postpartum WLH and their 
children.  
 
4.1 Introduction  
 
The last 20 years have witnessed substantial increases in the coverage of antiretroviral 
therapy (ART) among women living with HIV (WLH) who are pregnant and 
breastfeeding, with consequent declines in mother-to-child-transmission (MTCT) of HIV 
(144). However there are widespread concerns about the ability of existing health 
services to retain postpartum WLH in care and maintain the high levels of treatment 




There is a need for innovative models of care to address these challenges.  Since 2016 
the WHO has suggested the use of alternative models to deliver ART (‘differentiated 
care’) to cater for patient’s needs, promote retention, unload clinics and promote 
accessibility for patients such as stable postpartum mothers (68, 146, 147). The 
International AIDS (acquired immunodeficiency syndrome) Society categorises ART 
service delivery into four main types: ‘facility-based individual models’; ‘out-of-facility 
individual models’; ‘healthcare worker-managed groups’; and ‘client-managed groups’ 
(69, 148). Some examples of specific ART delivery models within these four broad 
categories are: fast track systems for ART collection within clinics such as in Malawi; 
community pharmacy collection in Nigeria; pick up points outside of healthcare 
facilities in the Democratic Republic of the Congo; collection by family members in 
Zimbabwe; teen ART clubs in Malawi and Eswatini; community adherence clubs in 
South Africa; and ART care integrated with other healthcare services such as for 
depression as is being studied in Malawi and Zimbabwe (148-155).  The World Health 
Organization (WHO) and United Nations Children's Fund (UNICEF) particularly 
recommend supporting the adherence of mothers during the postpartum period as part 
of the third and fourth part, of four component strategic approach to the prevention of 
mother to-child-transmission of HIV (PMTCT) (16, 20). Explicitly these components of 
the strategic approach are to prevent: “HIV transmission from a woman living with HIV 
to her infant” and to provide “appropriate treatment, care and support to mothers living 
with HIV and their children and families” (16). 
 
Multiple limiting and enabling factors have been found to assist successful delivery of 
ART. Identified enablers from a qualitative study in South Africa include care being 
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focused on the patient, as well as clear support and guidance from the National 
Department of Health which has been found to aid the adoption of context specific 
models of care which in turn facilitate flexibility for patients (149). Barriers include 
stigma and discrimination, as well as a lack of resources (such as physical space and 
personnel capacity due to their high workload and staff turnover) (70, 149). 
 
Although several models have been put forward, including the approaches used in this 
paper; the costs of these different approaches have received little attention. Two trials 
were conducted in the same population to examine the impact of models of care on 
retention and viral suppression and collect associated cost data for each model from the 
provider and patient’s perspectives. The three models in the postpartum period were 
the local standard of care of referral of women to general ART services and infants to 
well-baby clinics (Model I - Routine Care); women and infants continue to receive care 
through an integrated maternal and child care approach during the postpartum 
breastfeeding period (Model II - Integrated Care); and referral of women directly to a 
community-based adherence club (CAC) and infants to well-baby clinics (Model III - 
Community Care). The effectiveness of these three models of care are reported in detail 
elsewhere (2, 4, 156, 157). Furthermore the costs from this study were utilised to 
update the Cost-Effectiveness of Preventing AIDS Complications (CEPAC)-International 
and CEPAC-Pediatrics Models and inform the cost-effectiveness analysis that was 
undertaken and published (158). Briefly Model III was found to be the most effective in 
terms of retention of mother-infant pairs and maternal viral suppression (which was 
defined as HIV ribonucleic acid (RNA) <50 copies/mL) at 12 months postpartum with 
84% of mother-infant pairs meeting this criteria (2, 4, 156, 157). Model I had a 56% and 
Model II had a 77% proportion of mother-infant pairs retained and virally suppressed 
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at the 12 month mark (2, 156, 157).  Dugdale et al. 2019, found Model II to be cost-
effective in comparison to Model I with an ICER of US $599 per year of life saved with 
the threshold being an ICER below US $903 per year of life saved (158). Our detailed 
cost analysis fed into the study by Dugdale et al. 2019 and will lead into two separate 
upcoming papers (159, 160) and for these reasons as well as the valuable content of this 
analysis we felt this work necessitated a separate manuscript. 
 
In this work we aimed to compare the unit and total costs of three models of care for 





Throughout the methodology section both the Methods for the Economic Evaluation of 
Health Care Programmes textbook and the Reference Case for Estimating the Costs of 
Global Health Services and Interventions have been extensively consulted (83, 87). 
 
4.2.1 Parent studies 
 
Three locally developed and policy relevant postpartum models of care, were compared 
through two studies in South Africa: 1- Strategies to Optimize ART Services for Maternal 
and Child Health (MCH-ART) study (NCT01933477; April 2013-December 2016) and 2- 
Postpartum CACs to Enhance Support (PACER) study (NCT02417675; February 2015-
October 2016) (156, 157). All institutions approved protocols and there was individual 
written informed consent.  
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The MCH-ART study was a randomised controlled trial conducted in a subdistrict of 
Cape Town that evaluated two approaches to postpartum care for WLH who initiated 
ART antenatally and their breastfed children (2). The trial enrolled women from an 
observational cohort (where all WLH seeking antenatal care services who were at least 
18 years of age and eligible for ART initiation, were studied from their second antenatal 
care visit at Site A, located in a community with a high prevalence of HIV, until their first 
postpartum clinic visit further details in the supplementary appendix and cited papers) 
who were less than 6 weeks postpartum (median of 5 days postpartum) and who had 
started ART during their recently completed pregnancy (2, 156, 161). In order to be 
eligible for trial enrolment, women had to be breastfeeding their infants at the time of 
screening. Mother-infant pairs (n=471) enrolled in the trial were randomised to one of 
two arms. The control arm (n=238), referred to here as Model I, consisted of immediate 
postnatal referral to local ART services after delivery, as per standard of care and 
paediatric care for infants at well-baby clinics (where they would receive routine 
immunizations and growth monitoring as well as HIV services including early infant 
diagnosis using polymerase chain reaction (PCR) testing and infant antiretroviral 
prophylaxis with nevirapine). In the intervention arm, referred to here as Model II 
(n=233), women and infants continued to receive care in co-located 
maternal/paediatric care integrated in Maternal and Child Health (MCH) services 
through the postpartum breastfeeding period at Site A. The infants in Model II received 
the same care at Site A that they would in the well-baby clinic. Once breastfeeding 
ceased, women and infants were referred to local clinics for routine care (as per Model 
I). We selected five referral clinics nearest to Site A, where the majority of women were 
referred due to proximity to their homes, for cost data collection. Guidance on preferred 
 74 
ART regimens and routine monitoring was equivalent for Models I and II. The primary 
objective of the MCH-ART study was to evaluate the composite endpoint of maternal 
retention in ART services and viral suppression at 12 months postpartum by trial arm 
(2). These women were followed for 12 months postpartum with study measurements 
at 6 weeks and then at 3, 6, 9 and 12 months postpartum (2).  
 
The PACER study enrolled 129 postpartum breastfeeding WLH who initiated ART 
during their recently completed pregnancy, who met local criteria for CAC membership 
(4, 157, 162). Eligible women were offered a choice for postpartum ART care: Model I 
(as described above) or Model III - referral directly to a CAC with their infants receiving 
care at well-baby clinics. These women were followed for 12 months postpartum with 
study measurement visits that paralleled the MCH-ART study methods. As in the MCH-
ART study, the primary objective of the PACER study was to assess the composite 
endpoint of maternal retention in ART services and viral suppression at 12 months 
postpartum. The work presented here is a detailed costing study using bottom-up 
methodology performed alongside the MCH-ART and PACER studies. See Table 5 for a 
comparison of the three models of care. 
 
4.2.2 Study setting  
 
All study activities took place in a low-income area in Cape Town with high levels of 
poverty and HIV prevalence (163, 164). All women received antenatal care at the same 
large primary care antenatal clinic (Site A). Women referred out from Site A attended 
sites including Sites B-F. Women in Model III (n=84) who chose to be referred to CACs 
received their care at a nearby Community Centre (Site G).  Facility level cost data were 
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collected at Sites A-F and site level costs at Site G (Table 6). We purposively selected the 





Data regarding the mean number of visits was drawn from the study data, through 
medical record abstraction at the facilities. All women were seen in Site A in the 
postpartum phase before forming part of the Model I, II or III cohorts. Those under 
Model II were transferred out to general ART services at the end of breastfeeding or at 
12 months (if breastfeeding was continued for longer than a year) for routine care (as 
per Model I).  
 
4.2.4 Cost analysis 
4.2.4.1 Cost data 
 
When referring to costs in this paper we are referring to the economic costs collected 
through the quantification of the items (for instance the amount of time spent on a task) 
and assigning a value (price) to these items (87). Economic costs differ from financial 
costs in that they include goods that may have been donated or services that have been 
volunteered (83). A unit cost refers here to the average cost of a service i.e. the ‘cost per 
visit per mother-infant pair’, is the average cost of a single visit for postnatal care for 
both the mother-infant pair (87). We have costed the entire postpartum healthcare 
service, rather than using an incremental costing approach, using both a provider and a 
patient perspective (83, 87). A mixture of top-down (i.e. gross costing, allocative 
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method for overheads and maintenance) and bottom-up (i.e. micro-costing, ingredients 
based methods for buildings, furniture, equipment, personnel, medication, diagnostic 
tests and immunisations) costing methodology was utilised (87, 165).   
 
Provider costs comprised an estimation of total and unit costs based on collection of 
capital and recurrent costs for postpartum WLH and their infants (Table 7). Direct non-
medical patient cost data was collected in questionnaire form to assess the travel costs 
(transport time and out of pocket payment for transport) for Models I-III from Sites A 
(Model I), B (Model II) and G (Model III). All of the seven sites (see Table 6) are near Site 
A and so travel time collected for Sites A (Model I), B (Model II) and G (Model III) were 
representative. Time-and-motion studies were performed to evaluate the indirect 
patient costs in terms of loss of productive time by patients at all 7 sites (Sites A to G, for 
Models I-III see Table 6). Time-and-motion studies refer to a researcher observing 
workflow and keeping track of the time that the patients spent in the facility including 
the waiting time (166). This was done through the use of small sheets of paper attached 
to the patient file on which the researcher recorded the time that the patient arrived at 
the facility (through asking the patient), the time the folder was drawn (observed) and 
the time of exiting the facility (when the folder was returned by the patient on leaving 
the facility). Costs are presented in 2018 United States dollars (US $) and were inflated 
where necessary using the South African Consumer Price Index (167). The exchange 
rate of 1:13.24 United States dollars to South African Rands was used for 2018 (the 
average exchange rate for the 2018 year). Capital costs were annuitized using a 
standard discount rate of 3% (83, 87) and an expected number of years of useful life of 
30 years for buildings and 10 years for equipment (168).  
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Table 5: Comparison of key features of the three models of care (2, 162, 169, 170) 
 
Category Model I - Routine Care Model II - Integrated Care Model III - Community Care 
Setting 
 
Clinic-based general ART services at Primary 
Care Clinics (PHC) and well-baby clinics 
Clinic-based services at Midwife Obstetric Unit 
(MOU)  
Community Adherence Club (CAC) and infants 
at well-baby clinics 
Sites B, C, D, E, F  A (Clinic-based) G (Community-based [clinic-based for 
infants]) 
Units of care Individual patient Mother-infant pairs Groups of 25–30 patients 
Patient profile 
 
Mother-infant pairs seen together in Sites C, 




Infants Infants seen separately in well-baby clinics 
for mothers attending services in Site B 
 Infants seen separately in at well-baby clinics 
for mothers attending the CAC 
Key personnel 
 
Professional nurse/staff nurse (Site F only)/ 
counsellors 
Professional nurse who is trained as a midwife 
as well as in PMTCT, HIV and paediatrics/ 
counsellors 
Lay counselors  
Frequency of visits 1-2 monthly 1-2 monthly 2-4 monthly 
Frequency of clinical consultations 1-2 monthly (every visit)  1-2 monthly (every visit) 12-monthly 
Emphasis of patient contacts Detecting clinical complications  Detecting clinical complications Treatment adherence, patient wellness  
Services offered to mothers ART adherence counselling  
ART dispensed 
Breastfeeding and infant feeding advice 
Family planning (contraception) 
ART adherence counselling  
ART dispensed 
Breastfeeding and infant feeding advice 
Family planning (contraception) 
ART adherence counselling  
ART dispensed 
Peer support 
Services offered to infants Infant weighing 











Infants must attend separate well-baby clinic 
(as with Site B) 
Peer-based support No emphasis No emphasis Strong emphasis 
Patient self-management Minimal emphasis Minimal emphasis Strong emphasis 
Frequency of laboratory monitoring 













Up-referral to PHC 
 
ART packing and dispensing 
 
Packed at the clinic pharmacy, dispensed 
from pharmacy or during consultations. 
Patients collect ART themselves. 
Packed at the clinic pharmacy, dispensed 
during consultations. Patients collect ART 
themselves. 
Pre-packed by central dispensing unit, 
dispensed at CAC visit. ART can be collected by 
a treatment “buddy” 
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Site A Site B Site C Site D Site E Site F Site G 
Predominant model of care Model I Model II Model II Model II Model II Model II Model III 
 Midwife Obstetric 
Unit - MOU 
(Provincial) 







Clinic 2  
(City of Cape 
Town)  
Clinic 3  
(City of Cape 
Town) 
Clinic 4  
(City of Cape 
Town) 
Clinic 5 




Club - CAC) 




     
PACER study ✓ 
 
     ✓ 
 

















perspective postpartum phase non-





    ✓ 
 





























Example of staff complement directly 




nurses (including a 






















1 professional nurse, 4 
counselors, 1 
coordinator, 3 data clerks 
* Those involved directly in postpartum services who complete timesheets for the study.  These staff members spend more than 0% and less than 100% of their 
time on postpartum services. This list excludes support staff who did not fill in timesheets, but whose time was accounted for through allocation. 
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4.2.4.2 Cost measures 
 
Capital (buildings, furniture and equipment) and recurrent (personnel, overheads and 
maintenance) costs were estimated separately and summed to give the total cost at the 
health facility. The total costs were then apportioned using the total number of 
postnatal visits divided by the total clinic headcount for each input to value the total 
postpartum phase cost under each model. For the postpartum phase, the unit cost was 
defined as the ‘cost per visit per mother-infant pair’ from delivery to cessation of 
breastfeeding or 12 months postpartum. We multiplied the average number of visits 
made by mothers by the unit ‘cost per visit’ to calculate a ‘cost per woman’, with 
average medication and diagnostic costs added subsequently.  The postpartum unit 
costs used the mother-infant pair to calculate an annual ‘cost per mother-infant pair’, 
with other per person costs of the average medication (for mothers and infants), 
diagnostic (for mothers and infants) and infant immunisation being added 
subsequently.  
 
Postnatally the PCR for early infant diagnosis, was done at birth, 10 and 18 weeks and 9 
months was added together and divided by 12 months. For postpartum diagnostic costs 
under Model I and II, initial CD4, haemoglobin and creatinine, and viral load testing at 3, 
6, 9 and 12 months were added together and divided by 12 months. Under Model III, 
once yearly haemoglobin, creatinine and viral load testing were added and divided by 
12. 
 
Medication included ART for mothers (tenofovir/emtricitabine/efavirenz) and 
nevirapine syrup for infants. The daily unit cost for medication was multiplied by 30 
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days to get the per month cost for mother and infants separately. Immunisations as per 
the National Department of Health’s Expanded Programme on Immunisation – EPI (SA) 
Revised Childhood Immunisation Schedule, included the prices of Bacillus Calmette-
Guérin (BCG); oral polio vaccine (OPV); rotavirus vaccine (RV); diphtheria, tetanus, 
acellular pertussis, inactivated polio vaccine, haemophilus influenzae type B and 
hepatitis B combined (DTaP-IPV-Hib-HBV); pneumococcal conjugated vaccine (PCV); 
and the measles vaccine according to the schedule (up to 12 months), added together 
and divided by 12 months. 
 
4.2.4.3 Cost data collection 
 
As part of this undertaking, the sites were mapped and measured (in metres squared), 
and an inventory of furniture and equipment was made. All the staff that provided 
services during the postpartum phase under the three models completed timesheets to 
ascertain the percentage of their time dedicated to the various tasks for women in the 
postpartum phase, as well as for infants. For instance, these tasks included consulting, 
adherence training and educating, dispensing medication, management of services, 
record keeping and administration. 
 
Salary information, patient utilisation and overhead costs, were provided by Site G, City 
of Cape Town and Western Cape Government Health administrators. The prices of 
equipment and furniture were sought from local medical equipment and furniture 
suppliers. Some utilisation data was sourced through the project records. The Council 
for Scientific and Industrial Research (CSIR) supplied building replacement costs. 
Diagnostic cost data was furnished by the South African National Health Laboratory 
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Services, while immunisation and medication costs were provided by Pharmacy 
Services in Western Cape Government Health (171, 172). 
 
4.2.4.4 Patient costs 
 
Patient level data was collected in terms of direct costs, which relate to the transport 
costs incurred by the patients. In addition, indirect costs were collected which cover lost 
productivity time and transport time. These costs were collected during the MCH-ART 
and PACER Studies through questionnaires administered at 6 months postpartum. The 
questionnaires provided information that could be separated easily into the three 
models of care as the control arm of MCH-ART represented postpartum mother-infant 
pairs in Model I, the intervention arm represented postpartum mother-infant pairs in 
Model II and the intervention arm of PACER represented postpartum mother-infant 
pairs in Model III.  A convenience sample of 355 consecutive women had additional 
information collected using a time-in-motion tool. The time-and-motion tool was used 
to document the time that patients spent at the seven sites in terms of productive time 
lost. These time-in-motion studies followed three separate postpartum mother-infant 
pairs, i.e. postpartum mother-infant pairs in Model I, II and III respectively. A minimum 
wage of US $1.52 per hour (for 2018) was used to calculate the cost of transport and 
productive time lost (173). Income information was collected through the resource 
questionnaires, however the information received was very sparse and may have biased 
the valuation of productivity losses and so the choice was made to use minimum wage. 
 
Sensitivity analyses assessed the change in cost if the number of visits was equalised 
between the models of care, using the scenario where mother-infant pairs attended 
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sites on a monthly basis for the year (i.e. 12 times) during the postpartum phase. In 
addition, we assumed that the cost for infants seen in well-baby clinics was the same 
whether a mother was seen in Model I or III.  
 
4.3 Results 
4.3.1 Costs for postpartum phase 
 
During the postpartum phase the mother-infant pair received care in either Model I, II 
or III. The unit cost of a visit for a mother-infant pair from a provider perspective was 
US $13, US $10 and US $7 in Models I, II and III, respectively. The average annual total 
costs for visits for the mother-infant pair from a provider perspective were US $222, US 
$335, US $249 when medication, diagnostic tests (for infants and mothers) and infant 
immunisations were included for Models I, II and III respectively or US $54, US $75 and 
US $48 for the mother-infant visit only (indicated in the yellow bars of Figure 3). Visit 
costs accounted for 24% (average of 4.5 visits), 22% (average of 6.9 visits) and 19% 
(average of 6.7 visits) of the average annual postpartum care costs per mother-infant 
pair in each model (see Figure 4). Unit costs per visit from the patient perspective (to 
and from their residence) were US $7 for Model I, US $4 for Model II and US $5 for 
Model III respectively (see Table 9 - For the direct and indirect cost of transport time, 
there were 462 responses). Annually this amounted to between US $29-54, US $23-44, 






Table 7: Impact Inventory (adapted from the Second Panel on Cost Effectiveness in 
Health and Medicine(174))  
 
Sector Type of impact Perspective 
 
Notes 
  Provider Patient   
 Formal healthcare sector   
Health Medical costs    
 Paid for by healthcare sector Costs of visits 









quantities as well 
as prices 
Not collected Timesheets were used to 
quantify healthcare 
provider time spent on 
tasks 
 Informal healthcare sector   
Health Patient time costs N/A Patient time for waiting 
was collected through 
time-in-motion 
 
 Unpaid caregiver time costs N/A Not collected  
 Transport costs N/A Direct transport costs 
collected through 
questionnaires 
Indirect transport costs 
linked to time traveling 
to and from the clinic 
was also included 
 
 Non-healthcare sectors   
Productivity Labour market earnings lost N/A Attempt to collect via a 
questionnaire however 
very sparsely completed 
 
 Cost of unpaid lost 
productivity due to illness/ 
inability to work 
N/A Calculated using the 
minimum wage (US 
$1.52 per hour) (173) 
This method has the draw-
back in that the women 
attending are likely to earn 
less income on average 
than the minimum wage, 
however their time is 
important for other 
reasons and so it can be 
argued that this monetary 
evaluation of time does 
not do the valuation 
justice 
 Cost of uncompensated 
household production 
N/A Not collected  
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care cost  
Model I –  
Routine Care 
US $13 US $1 US $9 US $9 US $10 238 238 4.49a US $12 808 US $222 
 
US $52 940 
Model II –  
Integrated Care 
US $10 US $1 US $9 US $9 US $10 233 233 6.94b US $17 396 US $335  
 
US $78 124 
Model III – 
Community Care 
US $7 US $1 US $9 US $10 US $10 84 84 6.73c US $4 019 US $249 
 
US $20 933 
a Women were retained for an average of 1.04 visits in Site A, before being transferred to Model I where they attended 3.45 visits on average 
b Women attended an average of 5.5 visits in Model II, once they ceased breastfeeding, they were transferred to Routine Care (Model I) for an average of 1.44 visits  
c Women were retained for an average of 1.04 visits in Site A, before being transferred to Model III where they attended 5.69 visits on average 
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4.3.2 Sensitivity analysis  
 
In order to look at the impact of different visit loads, we assessed what the cost would 
be if the mother-infant pair received the same number of visits (12 visits) under each of 
the models (holding the initial number of visits constant (1.44 Routine Care visits after 
transferring out for Model II; 1.04 visits in Site A for Model I and III; see Table 10 and 
Figure 3 (light blue dotted bars)).  The percentage increase for Model I would be 180% 
from the provider’s perspective, making it the most costly model of care when assessing 
annual postpartum care visit costs per mother-infant pair (increasing from US $54 to US 
$151).  
 
4.3.3 Patient time  
 
Patient time at the facility/community centre from arriving to exiting across the three 
models (n=355 patients) was 3 hours on average (standard deviation 1 hour 34 
minutes). For Model I (n= 250) the average time at the facility was 3 hours 33 minutes 
(standard deviation (SD) 1 hour and 28 minutes); the average time for Model II (n=52) 
was 1 hour 27 minutes (SD 60 minutes); the average time for Model III (n=53) was 2 
hours 1 minute (SD 53 minutes). 
 
4.3.4 Input proportions 
 
The two main recurrent inputs in visit costs were personnel and overheads (including 
maintenance). Personnel made up the largest proportion of visit costs for all three 
models: Model I - 80%; Model II - 69%; and Model III - 78%. Overheads and 
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maintenance accounted for: I - 18%; II- 27%; and III - 20%.  While the capital inputs for 
buildings accounted for less than 4% (I - 2%; II - 4%; and III - 2%,) across the three 




Understanding the costs of care for postpartum WLH and their children is critical for 
program planning and optimization of ART services during the postnatal period. We 
took the approach of considering the costs for the mother-infant pair with the trialled 
models of care specifically assessing maternal (and infant) outcomes.  In the PACER and 
MCH-ART studies Model III was found to be the most effective in terms of retention of 
mother-infant pairs and maternal viral suppression at 12 months postpartum with 84% 
of mother-infant pairs meeting this criteria (2, 4, 156, 157); Model I had a 56% and 
Model II had a 77% proportion (2, 156, 157). As the population of adults living with HIV 
is not homogeneous, there is a need to consider having a combination of different 
models depending on the characteristics of the population or individual’s phase of life.  
 
A large proportion of HIV care costs are attributable to service delivery. As ART services 
expand to achieve population-level coverage, building costs are unlikely to substantially 
increase, unless they reach capacity. However, healthcare provider time costs may go up 
significantly as larger numbers of patients receive care in the clinic or community. 
Initially there are economies of scale at play, where staff can care for more patients with 
the same resources, however when the capacity of the healthcare workers is reached 
additional staff (and other resources) will be needed (87). As the costs of ART 
medications continue to come down, the relative contribution of service delivery 
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related costs (e.g., provider time, clinic building costs/overheads, etc.) increase. With 
costs driven by service delivery elements, detailed costing data such as provided in this 
study are key to understanding the costs of different models of care.  
 
Mother-infant pairs may have different needs in terms of the care they require. The 
clinical presentation of mothers may be that they are well or not well; this could be the 
first time that they are starting ART or they could have experience in taking ART (175). 
Prior ART experience could mean that mothers access to care was previously negatively 
impacted, for instance that they were lost to follow up at some point in the treatment 
cascade or defaulted. Further to this different patient needs can be addressed by the 
distinctive models, a crucial underpinning of the idea of differentiated care (37, 68). For 
instance, not all patients will be eligible for CACs and may be better suited to care under 
Model I or II. CAC inclusion criteria being that patients should be adults, who have been 
on ART for 6-12 months, be stable with a suppressed viral load, not be pregnant and 
should not require frequent clinical management for adherence issues or comorbidities 
(4). For those eligible and attending a CAC, the less frequent visit requirement of CACs 
(see Table 5) and ability to send a treatment ‘buddy’ to collect ART may aid WLH who 
are working or who would be unable to come to the clinic as regularly (176). This 
flexibility is appreciated by those in CACs (149, 176). Integrated Care has the benefit of 
prolonging the time that the mother-infant pair are kept together which may limit (at 
least initially) the loss to follow up during transfer to another model (177). Postpartum 
WLH were also found to breastfeed for a longer time in Model II, which in turn could 
positively impact their infant’s health (2).  Further evolution of these models may 
include combining ideas such as integrating peer support into facility-based models 
such as Mother to Mothers (M2M) which has been done elsewhere in South Africa and 
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extending ART refill times decreasing the visit frequency limiting face-to-face 
interaction especially in a time of COVID-19 (37, 70). 
 
In assessing these three models of care, we were interested in considering whether 
community-based care can be a desirable alternative to facility-based care from a cost 
perspective, given the potential increase in patient numbers with expanded ART 
services. The provider’s perspective annual costs are the highest for Model II - 
Integrated Care (women and infants continue to receive care through an integrated 
maternal and child care approach during the postpartum breastfeeding period), then 
Model III - Community Care (referral of women directly to CACs and Model I - Routine 
Care (local standard of care of referral of women to general ART services and infants to 
well-baby clinics). Both the costs from the provider and patient’s perspectives are 
affected by the structure of the services provided. The important differences from a 
costing standpoint between the models are that: under Model II mother-infant pairs are 
seen together during the breastfeeding period (before transferring out to routine care 
(as per Model I); under Model I, mothers and infants are seen separately, but depending 
on the facility this may be within the same site or even in the same consultation as we 
observed in four facilities; and for Model III, mothers and infants are seen separately at 
separate sites. This has impact particularly on the patient costs, because one integrated 
visit as opposed to two visits reduces the productive time lost, time spent on transport 
and the direct transport costs. In Model II we saw a positive impact on travel costs, with 
the lowest mother-infant pair patient visit cost (see Figure 3) as only one visit is 
required for the pair.  The observed waiting time for patients in Model III is relatively 
long as patients still arrive well before their medication is dispensed (or even before the 
community centre is opened), first listening to wellness talks given by the counsellors. 
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This is counter to the rationale of a CAC which aims to minimise the time spent by 
patients collecting medication (157). 
 
 
Figure 3: Annual provider and patient visit costs (including costs from the sensitivity 
analysis) per mother-infant pair in the postpartum phase in 2018 US $ 
 
The x-axis in the figure is the cost in 2018 US $, while the y-axis shows the the three models. The yellow 
bars show the annual provider cost for a mother-infant pair for visits only.  A range is provided for Model 
I and II, where the lower amount, is shown in grey bars and the upper amount is shown in dark blue 
dotted bars. The grey bar, shows the annual patient cost for a mother-infant pair visit under the scenario 
of combined routine care for mothers and infants (both mother and infant in the same consultation). The 
dark blue dotted bars display the annual patient cost for a mother-infant pair for visits only, where 
routine care is provided under the scenario of mother and infants being seen in separate consultations i.e. 
not at the same site or on separate days. The costs from the sensitivity analysis for the annual provider 
for a mother-infant pair visit, shown here in light blue dotted bars are described in more detail in Table 
10 – they show the cost of equalising the number of visits between models for the annum.  
 
Immunisations costs per infant and diagnostic cost per mother-infant pair are the 
highest drivers of cost for Model III. However, the proportion of the annual cost for 
Model III specifically for mother’s diagnostic testing accounts for only 3%, whereas it 
represents 17% and 18% in Model I and II. These higher proportions in Model I and II 
can be attributed to the extra monitoring performed in these models, specifically more 
frequent viral load testing. For Models I and II diagnostic cost per mother-infant pair is 
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Model III - Community Care
Model II - Integrated Care
Model I - Routine Care
Annual health service mother-infant pair visit cost
Annual mother-infant pair patient visit cost (scenario of combined mother-infant routine care)
Annual mother-infant pair patient visit cost (scenario of separate mother/ infant routine care)
Annual health service mother-infant pair visit cost using sensitivity analysis
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time of healthcare professionals were the major cost driver in the visit costs for each of 
the three models, more so in Model I (19% of the annual cost) and less so in Model II 
and III (15% of the annual cost in each model respectively). Care in Model I, is delivered 
by a mix of professional nurses, nursing assistants and counsellors; Model II is mainly 
delivered by a focal nurse in conjunction with counsellors; while Model III is delivered 
primarily by a counsellor. The profession of the staff and by implication the salary level, 
as well as the time staff spent on postpartum care tasks all influence the personnel cost. 
In addition, there may be other value added such as in information exchange between 
counsellors and patients as this cadre of staff may help to de-medicalise information 
and reduce use of jargon (Model III), and more holistic care of the mother-infant pair 
when treated together (Model II). In the PACER study 78% of WLH who chose to stay in 
the control arm, reported a preference for attending a health facility (4). Zerbe et al. 
2020, also note a movement of WLH from CACs back into health facilities with these 
WLH showing poorer outcomes (4). Hence there are nuances to the three models of 






Figure 4: Proportion of average annual cost for postpartum care per mother-infant pair by category (medication, diagnostics, 




















Model I Model II Model III
Medication cost per mother-infant pair Diagnostic tests cost per mother-infant pair Visit cost per mother-infant pair Immunisations cost per infant
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Table 9: Direct and indirect patient costs for the three models of care in 2018 US $ 
 
  Indirect patient cost Non-medical 
indirect patient cost  
Non-medical direct 
patient cost  
Total per patient visit 
cost 
Total per patient visit 
cost  
  Mean waiting time/ 
lost productivity cost 
using time-in-motion 
Cost of transport 
time/ time to clinic (at 
6 months)  
Out of pocket 
payment for transport 
to the clinic (at 6 
months)  
Total indirect and 
direct (including 
transport to the 
clinic) 
Total indirect and 
direct (including 
transport to and from 
the clinic) 
Model I – 
Routine 
Care 
Number of observations n=250 n=175 n=175   
Mean (SD) US $5.41 (2.23) US $0.49 (0.35) US $0.40 (0.29) US $6.3 US $7.19 
Model II –  
Integrated 
Care 
Number of observations n=52  n=178   n=178    




Number of observations n=53 n=109 n=109   
Mean (SD) US $3.07 (1.34) US $0.50 (0.35) US $0.54 (1.05) US $3.11 US $5.15 
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In an evaluation of CAC costs (comparable to those used in the Model III) in a similar 
setting in South Africa, Bango et al. (152) (costs have been inflated from 2011 to 2018 
US$ for comparison using US $ Consumer Price Index (178)) found higher annual costs 
of US $418 for standard of care (compared to Model I - US $114 for mothers’ care only) 
and US $335 for the CACs (compared to Model III - US $90 for mothers’ care only). One 
of the factors that has affected the difference in values in the current study compared to 
the study by Bango et al. (152) is the reduction in ART medication cost by 
approximately one third. Another is the utilisation rate, which is higher in the study by 
Bango et al. (152) than for Model I in this work (10.3 versus 4.5 visits per year in the 
current study). The average number of clinic visits is an integral part of the annual cost 
and varies between the three models in this paper from 4.6 and 6.9.  
 
Although these three models have been presented separately, there is a level of 
interdependence between the models and need for thought as to how patients flow 
through these models in order to ensure mothers and infants are retained in suitable 
care. For instance, as the models currently function, all mother-infant pairs continue to 
receive care in Site A for approximately one visit (or while breastfeeding in Model II) 
before either moving to routine clinic-based ART care or community-based care in the 
form of a CAC, where infants transfer to being cared for in well-baby clinics. To this end, 
we do not suggest that one model is superior to another. We also found that in reality 
four of the five clinics in Model I were consulting with mothers and infants in the same 
visit and in two of the facilities were also dispensing medication during that 
consultation.  The total unit costs are also affected by assessing only the mother in 




Table 10: Sensitivity analysis, normalising the number of visits between models of care 













Model I: 12 visits  
Mean of 1.04 visits at Site A (in Model II - Integrated Care) 
remains constant; Model I visits increased to 10.96 
US $54 US $151                                                                                                                                             180%
Model II: 12 visits  
Model II visits increased to 10.56; mean of 1.44 visits in the 
general ART clinic for routine care (as per Model I) after 
referral out from Model II - Integrated Care, stays the same 
US $75 US $127                                                                                            70%
Model III: 12 visits  
Mean of 1.04 visits at Site A (in Model II - Integrated Care) 
remains constant; Model III visits increased to 10.96* 
US $48 US $82 
                                                                                                                                            
72% 
*An important part of CACs service delivery is that stable patients in the CACs can collect medication less 
frequently than in a standard of care setting, so in reality we would not want to increase the number of 
visits; however this is being done to be able to compare cost equally across the three model 
 
The unit costs from this study could be generalised to the wider population in South 
Africa, taking note of the specific peri-urban setting and way the services are offered. 
Further work is needed to look into the outcomes and cost-effectiveness of the different 
models of care to make judgments on which model of care or mix of models of care are 
best suited to the healthcare system and to inform what these models would cost at 
scale. In low- and middle-income countries where unit cost estimates are not available 




One limitation of this study could be the comparison of Model III, as the CAC is intended 
only for women who are already stable on ART, whereas Models I and II have no 
requirements for inclusion. In the case of the PACER study, all women enrolled had the 
prerequisite of having started ART during pregnancy, currently breastfeeding their 
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infant, with evidence of viral suppression after three months of ART (VL< 1000 copies/ 
mL) and no comorbidities that require frequent clinical review (4). As one of the goals 
of CACs service delivery model is that visits are less frequent for stable patients, we are 
not suggesting that the number of visits be increased as we have done in our sensitivity 
analysis, but rather are looking at the effect on cost when we equalise the number of 
visits. This is particularly relevant in light of the World Health Organization’s 
recommendation to extend refills for clinically stable patients to between three and six 
months (21). An ongoing South African clinical trial is aiming to assess the impact of 
less frequent refills within the CAC setting which will aid policy going forward (179).  It 
is important to note that these costs are most applicable to the population of women 
who started ART in pregnancy and may differ for those who have been stable on ART 
prior to conception. Another limitation is that the cost of care may vary from clinic to 
clinic, though our sample is representative and we present average unit costs. Also for 
Site A we used the average number of visits in the study per woman to inform the 
number of visits for postnatal care as the facility did not have utilisation data for this. 
The largest number of time-and-motion studies were completed for Model I across 





Novel data on unit costs to provide ART to mother-infant pairs during the postpartum 
phase and insight into the cost drivers has been provided through this comparative 
analysis of three models of care. The unit costs of the two new models of care, using 
Integrated Care (Model II) and Community Care approaches (Model III) respectively, 
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are more expensive, however they are also more effective in terms of retention of 
mother-infant pairs and viral suppression at 12 months postpartum as shown by the 
MCH-ART and PACER studies . These costs may be used to help make decisions around 
integrated services models and differentiated service delivery for postpartum WLH and 
their children. Importantly these costs will be useful for informing budgeting for 
postpartum care and have already fed into a cost-effectiveness analysis comparing 
Integrated Care (Model II) to Routine Care (Model I).  This work will feed into another 
cost-effectiveness analysis comparing all three models of care and a budget impact 
analysis for the South African setting.  
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4.6 Pregnancy costs unpublished supplementary information 
 
There are widespread concerns about the ability of existing health services to retain 
pregnant women living with HIV (WLH) in care and maintain the high levels of 
treatment adherence required to maximise the benefits of ART for maternal and child 
health (145).  
 
All pregnant WLH received integrated antenatal care, HIV care and antiretroviral 
treatment (ART) (including prevention of mother-to-child transmission of HIV 
(PMTCT)) services within a Midwife Obstetric Unit (MOU) (Site A). We aimed to 
estimate the costs of the pregnancy phase for women, combined across all three models, 
from health service perspective.  
 
4.7 Methods 
4.7.1 Parent study 
 
The MCH-ART study was a multiphase longitudinal cohort study where women were 
enrolled within Site A (2). This is a single, large primary care antenatal care and 
obstetric service, located in a community with a high prevalence of HIV within Cape 
Town, South Africa. During the observational component (Phase 2) approximately 600 
women seeking antenatal care services (from Phase 1), who were at least 18 years of 
age and were eligible for ART initiation, were studied from their second antenatal clinic 
visit until their first postpartum clinic visit and this data was used for the costing of the 
pregnancy phase (2, 156).  
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Pregnant women known or testing HIV positive but not on ART were started on ART on 
the day of testing (or at a maximum within one week). Antenatal care included 
palpation, blood pressure testing, weighing, education about pregnancy, breastfeeding 
and infant care. Routine blood work was done at the first antenatal care visit, as well as 
pre-test counselling for HIV testing and a rapid HIV test was performed. For these 
pregnant WLH, PMTCT services, including distributing ART, adherence counselling and 
pill counts were also provided within Site A during antenatal care visits. Routine infant 
deliveries were performed at Site A, and more complicated deliveries took place at a 
secondary level referral hospital. 
 
4.7.2 Study setting  
 
All study activities took place in a low socioeconomic community in Cape Town with 
high levels if HIV and poverty (8). All women received antenatal care at the same large 




Data regarding the mean number of visits was drawn from the study data, through 




4.7.4 Cost analysis 
4.7.4.1 Cost data 
 
Health service costs comprised an estimation of total and unit costs based on collection 
of capital and recurrent costs for pregnant WLH (Table 11). Costs are presented in 2018 
United States dollars (US $) and were inflated where necessary using the South African 
Consumer Price Index (167). Capital costs were annuitized using a standard discount 
rate of 3% (83, 87) and an expected number of years of useful life of 30 years for 
buildings and 10 years for equipment (168).  
 
4.7.4.2 Cost measures 
 
For the pregnancy phase in Site A, capital (buildings, furniture and equipment) and 
recurrent (personnel, overheads and maintenance) costs were estimated separately and 
summed to give the total cost at the health facility. The total costs were then 
apportioned using the total number of antenatal visits divided by the total clinic 
headcount for each input to value the total pregnancy phase cost. 
 
We defined the pregnancy phase unit cost as the ‘cost per visit’ from the start of 
antenatal care through to just prior to delivery. We divided the total cost of providing 
services during the pregnancy phase by the number of visits made in the same period to 
get the unit ‘cost per visit’. We multiplied the average number of visits made by mothers 
by the unit ‘cost per visit’ to calculate a ‘cost per woman’, with average medication and 
diagnostic costs added subsequently.   
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Antenatal diagnostic tests included initial Pima™ CD4 and rapid HIV test done at point 
of care; haemoglobin, alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), and creatinine, as well as HIV viral load testing at 3, 6 and 9 months, performed 
at the South African National Health Laboratory Services (NHLS). These test costs were 
added together and divided by 6 months to give the per month value.  
 
Medication included ART for mothers (tenofovir/emtricitabine/efavirenz) The daily 
cost per medication was multiplied by 30 days to get the per month cost.  
 
4.7.4.3 Cost data collection 
 
As part of this undertaking, the sites were mapped and measured (in metres squared), 
and an inventory of furniture and equipment was made. All the staff that provided 
services during the pregnancy phase completed timesheets to ascertain the percentage 
of their time dedicated to the various tasks for women in the pregnancy phase. For 
instance, these tasks included consulting, adherence training and educating, dispensing 
medication, management of services, record keeping and administration. 
 
Salary information, patient utilisation and overhead costs, were provided by Western 
Cape Government Health administrators. The prices of equipment and furniture were 
sought from local medical equipment and furniture suppliers. Some utilisation data was 
sourced through the project records. The Council for Scientific and Industrial Research 
(CSIR) supplied building replacement costs. Diagnostic cost data was furnished by the 
South African National Health Laboratory Services, while medication costs were 
provided by Pharmacy Services in Western Cape Government Health (171, 172). 
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Table 11: Impact Inventory (adapted from the Second Panel on Cost Effectiveness in Health and Medicine(174))  
 
Sector Type of impact Perspective 
 
Notes 
  Health service Patient   
 Formal healthcare sector   
Health Medical costs    
 Paid for by healthcare sector Costs of visits were collected as 
well as diagnostic and 
medication costs. This was done 
through collection of utilisation 
data/ quantities as well as 
prices 
Not collected Timesheets were used to quantify 
healthcare provider time spent on 
tasks 
 
Table 12: Unit and total costs for pregnancy phase in 2018 US $ 
 
Cost of a visit 











visits in Site A 




care cost per 
woman 
Total cost for 6-month 
pregnancy care cost 
for the cohort of 471 
women 
US $12 US $9 US $15 471 3 US $17 090 US $109* 
 
US $51 240 
*25% medication; 41% diagnostic tests; 33% pregnancy visit cost
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4.8 Results 
4.8.1 Costs for pregnancy phase 
 
We present here a set of unit and total costs for the pregnancy phase from a health 
service perspective. The pregnancy cost was the same for all women as they received 
the same pregnancy care (regardless of which of the three postpartum models they 
entered). The unit cost per visit at Site A during the pregnancy phase was US $12 (Table 
12) from a health service perspective. The cost per woman during the pregnancy phase 
was US $36 from a health service perspective, considering that there are on average 3 
visits made (based on medical record abstraction). If one includes the health service 
costs of both medication and diagnostic test costs, the average cost per woman during 
pregnancy was US $109 (25% medication; 41% diagnostic tests; 33% pregnancy visit 
cost).  
 
4.8.2 Input proportions 
 
The two main recurrent inputs in visit costs were personnel and overheads (including 
maintenance). Personnel made up the largest proportion of costs, 74%. Overheads and 
maintenance accounted for 23% of the pregnancy phase costs, while the capital inputs 




Understanding the costs of care for pregnant WLH is critical for program planning and 
optimization of ART services during the pregnancy period.  
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A large proportion of HIV care costs are attributable to service delivery. As ART services 
expand to achieve population-level coverage, building costs are unlikely to substantially 
increase, unless they reach capacity. However, healthcare provider time costs may go up 
significantly as larger numbers of patients receive care in the clinic or community. As 
the costs of ART medications continue to come down, the relative contribution of 
service delivery related costs (e.g., provider time, clinic building costs/overheads, etc.) 
increase. With costs driven by service delivery elements, detailed costing data such as 





This cost analysis provides insight into the costs to provide ART to pregnant women 
living with HIV. 
5 Chapter Five: Cost-effectiveness analysis of three postpartum 
models of care for women living with HIV in Cape Town, South 
Africa 
 
This manuscript was prepared with the journal BMC Cost Effectiveness and Resource 
Allocation in mind to fulfil Objective 3.) To compare the costs and effects of three 
models of care for mother-infant pairs during the postpartum phase (12 months 
postpartum) from a provider and patient’s perspective in a cost-effectiveness analysis; 
and will be submitted later in 2020.  Lucy Cunnama is the first author and has had input 





Great strides have been made to prevent mother-to-child transmission of HIV (PMTCT). 
Focus is now being placed on how best to serve women during the sensitive postpartum 
phase so as to optimise maternal and child healthcare. The purpose of this study was to 
establish the cost-effectiveness of two models of care (Model II and III) relative to Model 
I – Routine Care where women are seen in general antiretroviral therapy (ART) services 
and infants in well-baby clinics. The two novel models of care were: Model II – 
Integrated Care where women and infants are retained in an integrated maternal and 
childcare approach during the postpartum breastfeeding period; and Model III – 
Community Care where women directly referred to community adherence clubs with 





The annual cost per mother-infant pair for each model of care in 2019 US $ and the 
effectiveness in terms of mother-infant pairs retained and mothers virally suppressed at 
12 months postpartum were collected during two studies in Cape Town, South Africa, 
namely Strategies to Optimize ART Services for Maternal and Child Health (MCH-ART) 
Study and Postpartum Community Adherence Clubs to Enhance Support (PACER) 
Study. The incremental costs and effects of Models II and III were compared to that of 
Model I and plotted on a cost-effectiveness plane. A sensitivity analysis in the form of a 
univariate analysis using a tornado diagramme was performed to assess the robustness 
of the results. 
 
Results 
Model III is dominant to Model II with incremental cost-effectiveness ratios (ICERs) of 
US $97 and US $548 respectively, which fall below a revealed willingness to pay 
threshold of US $929 per life year saved for HIV investment in South Africa, however 
this threshold cannot be used for meaningful comparison given the difference in 
outcome measures among other reasons.  A sensitivity analysis demonstrated that the 
results were robust to changes in the costs and effects. 
 
Conclusions 
The two innovative models of care have been shown to be cost-effective in comparison 
to Model I given the threshold ‘indicators’ for the setting. The implications are that there 
is evidence that can be used to provide an approach of different types of care dependant 
on the preference of women living with HIV in the postpartum period which may in turn 
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enhance outcomes for the mother-infant pair. Further research is needed to assess the 




With the roll out of lifelong triple antiretroviral therapy (ART) initiated during 
pregnancy, huge strides have been made in terms of the reduction of mother to child 
transmission of human immunodeficiency virus (HIV) and improving maternal and 
child health (180). For those women starting ART before conception with an 
undetectable viral load, it has been proven in a cohort of thousands that transmission 
rates are negligible rising to 0.9% in the third trimester (180, 181) which emphasises 
the need to screen and start treatment as early as possible. However screening and 
uptake of services is more complex than it seems with potential fallout of the treatment 
cascade at every step (180). In Sub-Saharan Africa, there are an estimated one million 
women a year who are pregnant and living with HIV, which accounts for nearly all cases 
globally. Between 2010 and 2019, the percentage of women living with HIV who access 
ART has risen from 71% to 97% in South Africa (182). Which in turn impacted on the 
vertical transmission decreasing the overall transmission from 16% to 3% in the same 
time period (182).  
 
For those women living with HIV whose ART started during pregnancy, the transition 
from antenatal to postpartum care is an important yet precarious time.  ART should 
continue for maternal health as well as during breastfeeding to reduce the chance of 
transmission to the newborn (180, 181, 183, 184). Therefore, different models of care 
that are context specific and locally tailored should be evaluated in order to increase or 
maintain coverage and effectiveness, decrease or maintain cost, and improve the quality 
of care (185). Four main alterations to create models of care have been identified by 
Bulstra et al. 2019 (185): an integrated model combining health services; a modified 
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model where, for instance, there is task shifting of health care professionals; a simplified 
model such as one where steps are removed and ART treatment is administered less 
frequently; and a change in the place of delivery such as from the health sector into the 
community. These can be compared to the standard of care (i.e. an unaltered model). 
Bulstra et al. 2019 (185) recommend piloting models of care to assess their impact.  
 
This study is a cost-effectiveness analysis which assessed different models of care in an 
attempt to keep women retained in care and virally suppressed during the postpartum 
breastfeeding period. The data were collected during two studies conducted in a 
subdistrict of Cape Town, Strategies to Optimize ART Services for Maternal and Child 
Health (MCH-ART) and Postpartum Community Adherence Clubs to Enhance Support 
(PACER).  MCH-ART was a randomised controlled trial that evaluated two approaches 
to postpartum care for women initiating ART antenatally and their breastfed children: 
standard care of referral of women to general ART services and infants to well-baby 
clinics (Model I - Routine Care) or retaining women and infants in care during the 
postpartum breastfeeding period under an integrated maternal and child care approach 
(Model II - Integrated Care) (2, 156).  PACER, a supplementary study to MCH-ART, 
offered postpartum breastfeeding women living with HIV the choice between Model I - 
Routine Care (as described above) or referral of women directly to a community-based 
adherence club (CAC) and infants to well-baby clinics (Model III - Community Care) 
(157). 
 
We aimed to assess the cost-effectiveness of the three models of care in terms of cost 
per mother retained and virally suppressed at 12 months postpartum. In doing so we 
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intend to contribute a comparative assessment of these models of care to inform 
postpartum care going forward.  
 
5.2 Methods 
5.2.1 Study aim 
 
The aim of this study was to assess the cost-effectiveness of three novel postpartum 
models of care for mother-infant pairs. 
 
5.2.2 Study design 
 
A cost-effectiveness analysis was undertaken using costs and natural units for the 
outcome measures to calculate the incremental cost required to improve patient 
outcomes for mother-infant pairs. Empirical economic costs from a patient and 
provider’s perspective had already been collected through the two projects MCH-ART 
and PACER (186) between 2013 and 2017. The annual cost per mother-infant pair for 
each of the three models of care were inflated and are presented in 2019 US $ (187). 
The effectiveness measures, also collected during the two studies, related to retention in 
care at 12 months postpartum combined with viral suppression, which was defined as 
HIV ribonucleic acid (RNA) <50 copies/mL (2, 156, 157).   
 
5.2.3 Data analysis 
 
A cost-effectiveness analysis was performed in a purpose built Microsoft Excel 
spreadsheet. 
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To assess the cost-effectiveness of the three models of care, the annual cost 
per mother-infant pair were ranked from low to high (least to most costly). Then the 
incremental costs were calculated for the second most costly model in comparison to 
the model with the lowest annual cost, and the most costly in comparison to the model 
with the lowest annual cost. The costs and effects were plotted in a cost-effectiveness 
plane with R software (R Project, Vienna, Austria) using the user interface of RStudio. 
 
5.2.4 Sensitivity analysis 
 
A sensitivity analysis was performed to assess uncertainties in both the costs and 
outcomes. The annual costs for Model II and III were altered by 5%, 10%, 15% and 20% 
above and below the figures established in the cost analysis (186) to determine the 
impact on incremental cost-effectiveness ratio (ICER). The same was done for the 
effectiveness measure.  Maternal retention and viral suppression at 12 months 
postpartum, was also altered by 5%, 10%, 15% and 20% above and below the figures 
established in the effectiveness studies PACER (4, 157) and MCH-ART (2, 156), to 
determine the impact on ICER. Plausible ranges in which to vary the parameters were 






Figure 5: Cost-effectiveness plane with incremental cost per retained and virally 




Figure 6: Cost-effectiveness plane with incremental cost per retained and virally 
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Model III – Community Care dominated Model II – Integrated Care in terms of cost-
effectiveness. Model III cost slightly more, but was more effective in comparison to 
Model I – Routine Care (Tables 1 and 2). When plotted on a cost-effectiveness plane, 
both Model II and III are found in the North-East quadrant whether the costs utilised 
are from a provider’s or patient and provider’s perspective (Figure 5 and 6). The ICER 
for Model III was US $97 (Figure 5).  
 
Table 13: Annual and incremental costs per mother-infant pair from a provider’s 











Per mother-infant pair 
patient and provider’s and 
perspective 
Incremental cost 
(Per mother-infant pair 
patient and provider’s 
perspective) 
Model I - 
Routine Care 
US $226  - US $261 - 
Model III - 
Community 
Care 
US $254  US $27  US $330 US $69 
Model II - 
Integrated 
Care 






Table 14: Effectiveness and incremental effectiveness, in terms of proportion of 
mothers retained in care and viral suppressed at 12 months postpartum, for each model 
of care 
  
Effectiveness:  maternal retention in 
care and viral suppression (%) 
Incremental effectiveness 
Model I - Routine Care 56% - 
Model III - Community 
Care 
84% 28%* 





The tornado diagramme visually displays which of the input variables, namely clinical 
effect and annual cost, have the biggest impact on the ICER (which is the output). They 
are displayed in decreasing importance where clinical effect altered by 20% has the 
most impact on ICER for Model II (Figure 7) and the annual cost being changed by 20% 




Cost-effectiveness aims to assess the opportunity cost of implementing a new 
programme in place. Some countries, such as the United Kingdom, have a threshold for 
cost-effectiveness analysis (CEA), and if an ICER for a programme falls below that 
threshold then it is considered good value (188). In South Africa, we do not have a cost-
effectiveness threshold, but instead assess each CEA relative to those previously done as 
well as looking at the relative cost-effectiveness of programmes. Leech et al. 2018 (189) 
analysed the CEAs (using a disability adjusted life year (DALY) as an output so 
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technically a cost utility analysis (CUA) in our definition) performed between 2010 and 
2015 in low- and middle- income countries to assess practice going forward. They found 
that the majority that report the use of a threshold used a now unsupported technique 
of comparison to gross domestic product per capita (188, 189). Their advice from the 
analysis was that, where possible, locally developed thresholds should be utilised. A 
study by Edoka and colleagues (190) estimated the value of a DALY averted in South 
Africa to be US $3 250 (inflated to 2019 US $) (190-192).  
 
 
Figure 7: Tornado diagramme of univariate sensitivity analysis for Model II, base value 
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Figure 8: Tornado diagramme of univariate sensitivity analysis for Model III, base value 
ICER US $97 
 
The purple and blue vertical ‘threshold lines’ in Figure 7 are US $929 (193) and US $1 
289 (133) below which an intervention could be considered cost-effective (inflated to 
2019 US $)) (187). The lower threshold of US $929 per life year saved (the purple line in 
the tornado diagramme, Figure 7) is the revealed willingness to pay threshold for South 
Africa which was established as part of the HIV investment case (193) however as the 
outcomes are different (retention and viral suppression versus life years saved) this 
does not lead to meaningful comparison and is not recommended as an indication of 
cost-effectiveness by the authors. The ‘opportunity-cost-based’ cost-effectiveness 
threshold of US $1 289 (133) is the recommended lower bound (US $5 173 is the upper 
bound) for South Africa as indicated by Woods et al. 2016. Using all of these threshold 
‘indicators’, both Model II and Model III can be considered cost effective in the South 
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As Bulstra et al. (185) appropriately state, a mix of models of delivery may be the most 
acceptable to the population that is being served and may indeed reach the goals of 
maintaining cost, effectiveness, quality and coverage or better still decreasing cost, 
increasing effectiveness, improving quality and increasing coverage.  Fox et al. assessed 
retention in adherence clubs and standard of care for individuals with HIV, not 
specifically postpartum women, and found there to be a benefit to adherence clubs in 
terms of retention (194). 
 
Dugdale et al. performed a similar cost-effectiveness analysis limited to a comparison 
between Model I and II for postpartum care, utilising the visit unit costs and 
effectiveness from the MCH-ART Study and the Cost-Effectiveness of Preventing AIDS 
Complications (CEPAC)-International and CEPAC-Pediatrics Models which are 
components of a long established complex HIV simulation model. They found Model II 
to be cost-effective in comparison to Model I with an ICER of US $599 per year of life 
saved with the threshold being an ICER below US $903 per year of life saved (158). The 
finding of this study was that Model II had an ICER of US $548 per mother-infant pair 
retained and virally suppressed at 12 months postpartum which is expectedly in line 
with the results of the model simulation by Dugdale et al. considering that the cost and 
effectiveness data was generated from the same study (158), despite the differencing 
effectiveness measures.. The main differences between this work and the work by 
Dugdale et al. are that we have added the comparison of a third model of care which 
was also empirically costed and effectiveness measures were captured through a 
parallel substudy which maintained the same measures; and unlike the work by 
Dugdale et al. this work comprised a focus on the comprehensive empirical costing of 
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these three models using simple methods without complex modelling and the implicit 
assumptions of a complex model. 
 
In a the province of Yunnan in China, another modelling study found that Option B+ was 
cost-effective in their setting with the high ICER of US $5 485 per life year gained in 
mothers in comparison to Option B and the very low ICER of US $35 per quality 
adjusted life year (QALY) gained in infants (when inflated to 2019 US $) (187, 195).  A 
recent systematic review located 15 economic evaluation studies for prevention of 
mother-to-child transmission of HIV (PMTCT) specifically in the Sub-Saharan African 
region with reference years between 2009-2016 (42). The revealed median values from 
these studies were US $1 447 per HIV infection averted and US $194 per DALY averted 
or QALY gained (when inflated to 2019 US $), noting that PMTCT in the region can be 
considered very cost-effective (42, 187). Our findings are similar in that both Models II 
and III can be considered cost-effective relative to Model I. The sensitivity analysis 
demonstrates the changes in ICER when either the effects or costs are altered. Apart 
from changes larger than 10% for the effectiveness of Model II (Figure 7), the ICER for 
both Models II and III (Figure 6) remain below the threshold indicators. 
 
This study findings are generalisable to the rest of South Africa as well as other low- and 
middle-income settings with similarities to South Africa. However, it should be noted 
that for this study the setting was peri-urban and there may be factors, such as 
champion healthcare workers (in particular for the integrated approach of Model II) 
and well established and numerous CACs, which may have impacted the findings.  
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The main limitation of this study is that the outcomes are expressed in natural units 
making it difficult to make comparisons with other healthcare programmes. However, 
these measures are useful as they express important measures of HIV care, specifically 
retention in care - an important aspect of treatment allowing for a viral suppression 
which is a good indication of adherence to treatment and the model working to achieve 
its aims of maternal and child health.  It is encouraging to see models of care that are 
locally relevant and which can be considered cost-effective relative to these threshold 
‘indicators’. Further research is needed to establish the affordability of scaling up these 




Model III – Community Care, which involved postpartum care for mothers at CACs and 
infants at well-baby clinics, is the most cost-effective model relative to the other models 
of care, whether costs were utilised from a provider’s perspective or patient and 
providers’ perspective.  Model II - Integrated Care approach for mother-infant pairs was 
also found to be cost-effective relative to the threshold ‘indictors’ for the country. These 
findings are particularly notable for policy going forward as they could allow for a mix 
of models of care that are cost-effective, acceptable to mother-infant pairs, provide 
highly effective care in terms of retention and viral suppression, and have known costs 







6 Chapter Six: Scaling-up postpartum models of care for mother-
infant pairs in South Africa: A budget impact analysis 
 
This manuscript was prepared with the journal BMC Cost Effectiveness and Resource 
Allocation in mind to fulfil Objective 4.) To estimate the budget impact of nationally 
scaling-up models of care for the postpartum period; and will be submitted later in 
2020.  Lucy Cunnama is the first author and has had input from co-authors Edina 





In the age of universal antiretroviral therapy (ART), three postpartum models of care 
for mother-infant pairs in the Western Cape, South Africa, were assessed in terms of 
their relative cost-effectiveness. The three models were Routine Care (Model I) with 
women being cared for in general ART services and infants in well-baby clinics; an 
integrated maternal and child approach (Integrated Care - Model II) with women and 
infants being retained together during the postpartum breastfeeding period; and 
Community Care (Model III) where women are directly referred to community 
adherence clubs, with their infants receiving care at well-baby clinics.  The purpose of 
this study was to assess the budget impact of nationally scaling up a more cost-effective 
postpartum model of care than current routine care.  
 
Methods 
The annual cost per mother-infant pair of the three models of care which were 
empirically collected, were inflated to 2019 US $. The target population of women living 
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with HIV in the reproductive age group of 15-49 years, who had delivered a baby in the 
last year in the public sector, was estimated through a series of steps using publicly 
available data. The cost of implementing the most cost-effective model of care (Model 
III) was compared to the cost of routine care at scale (Model I). In order to assess the 
robustness of results, four additional scenario analyses were performed (Alternate 
Scenarios A-D). This was compared to the National Healthcare Budget for South Africa 
for, the National Strategic Plan (NSP) summary of the anticipated budget for HIV, TB 
and STIS and the HIV and AIDS Component of the HIV, TB, Malaria and Community 
Outreach Grant, all for the period 2020/21. 
 
Results 
Implementing a relatively more cost-effective model of care, Model III at scale (100% 
coverage), resulted in an increased budget requirement of US $5 720 096, in 
comparison to Model I at scale. The total budget requirement of US $52 751 995 for 
Model III, represents an additional 0.2% of the total health budget, 0.3% of the NSP 
anticipated budget and an additional 0.5% of the HIV and AIDS Component of the 
Community Outreach Grant for 2020/21. In the scenario analyses a coverage of 12%, 
23%, 65% for the three models respectively, Alternate Scenario A, an additional US $9 
303 763 (in comparison to Model I) is required. If an equal weighting (Alternate 
Scenario B) between the three models of care is used (i.e. 33.3% of the target population 
is covered under each) then an additional US $9 886 016 is required (in comparison to 
Model I). Alternate Scenario C found the extra budgetary need for Model II at 100% 
scale was US $23 939 660, which is a 51% increase compared to Model I at scale. The 
fourth scenario, Alternative Scenario D, would only require an additional US $3 260 455 
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to implement Model III (in place of Model I), but would only cover 57% of those in need 
of care.   
 
Conclusions 
The net budget impact to introduce a more cost-effective model than the current 
standard of care represents an increase of 0.9 - 2.2% of the national healthcare budget. 
However as the different models are designed to suit different women’s preferences, for 
instance facility based care (Models I and II) or non-facility based care (Model III) one of 
the alternate scenarios providing differentiated care although more expensive may be 
more acceptable to mothers. The potential implications are that more cost-effective 
novel options for postpartum maternal and child health have been established in the 
Western Cape which if scaled up countrywide could have particular impact on the 




Prevention of mother-to-child transmission (PMTCT) of the human immunodeficiency 
virus (HIV) has been a global success, however at every point in the HIV treatment 
cascade, there is a risk that mothers will disengage from care (144). There is hope for 
the complete elimination of transmission of HIV from mother-to child which seemed 
impossible in the past (144, 180) and this aim is supported by the Sustainable 
Development Goals which states that progress in combating HIV/AIDS needs to be 
increased (196). In the eastern and southern region of Africa, 60% of new infections are 
in females of reproductive age 15-49 (182). In South Africa, pregnant women living with 
HIV are often diagnosed and initiate treatment during the pregnancy phase, and 
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continue to receive care and antiretroviral therapy (ART) in combination with their 
antenatal care (144, 197). As they transition to the postpartum period there is a chance 
that women will be lost to follow up (LTFU). In some cases the lost to follow up rate has 
been found to be as high 49% in the first 6 months (164) however in another study 37% 
of women who were considered LTFU were found to be seeking HIV care in another 
facility sometimes in a different province (198). In order to retain women in care, 
different models of care are needed according to patient preference, for instance at 
different locations: facility-based or community-based; drug collection at differing 
intervals: monthly or multi-monthly; individual or peer group adherence counselling; 
and fast tracking or making use of a ‘buddy’ system for picking up medication (199). 
 
Prior research assessed the costs and effectiveness of two models of postpartum care 
compared to the standard of care.  A detailed costing study with a bottom-up 
methodology was undertaken (186) and then subsequently a cost-effectiveness analysis 
(CEA) was performed utilising ‘the cost per mother-infant pair virally suppressed and 
retained in care’ as the outcome measure for each model of care (159). The first of the 
two studies was Strategies to Optimize ART Services for Maternal and Child Health (MCH-
ART) a randomised controlled trial conducted in a subdistrict of Cape Town that 
evaluated two approaches to postpartum care for women initiating ART antenatally and 
their breastfed children: standard care of referral of women to general ART services and 
infants to well-baby clinics (Model I - Routine Care) or retaining women and infants in 
care during the postpartum breastfeeding period under an integrated maternal and 
child care approach (Model II - Integrated Care) (2, 156). And the second study was 
Postpartum Community Adherence Clubs to Enhance Support (PACER) a supplementary 
study to MCH-ART where postpartum breastfeeding women living with HIV were 
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offered the choice between Model I - Routine Care (as described above) or referral of 
women directly to a community-based adherence club (CAC) and infants to well-baby 
clinics (Model III - Community Care) (157). The purpose of this analysis is to assess the 
budgetary impact of scaling up these complementary models of care nationally 
 
Budget impact analysis (BIA) can provide evidence for decision making as it looks at the 
cost of scaling up a programme and estimates the funding needed to implement the 
programme.  Which importantly is an assessment of the economic impact and hence 
uses information including economic costs (110, 200). When a programme is scaled up, 
then we need to assess what it will displace in term of cost within the budget and what 
the resultant opportunity cost will be.  BIA considers the scale of the displacement 
within a budget or the amount that the budget will need to be adjusted so that all 
programmes can be funded (110). Whereas a CEA considers the relative costs and 
effects of a programme in combination, a BIA evaluates the budgetary need of a 
programme.  
 
We identified the need for a BIA to be able to adequately judge the affordability of 
implementing postpartum models of care at scale. In light of estimating the budget 
needed, the national budget for healthcare in South Africa for 2020/21 is R56.7 billion 
or US $3.2 billion, while the Medium Term Expenditure Framework for the HIV and 
AIDS Component of the ‘HIV, TB, Malaria and Community Outreach Grant’ for the same 
financial year (2020/2021) is R22.2 billion or US $1.3 billion (114-116). In total the 
National Strategic Plan details that the anticipated budget for HIV, TB and STI is R37.5 
billion or US $2.1 billion for the 2020/21 period which includes funding from the South 
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African Government, PEPFAR and USAID, Global Fund and estimated private sector ART 
funding (17).    
 
This BIA aimed to assess how the introduction of novel postpartum models of care, in 
particular how the scale up of integrated care and community care would affect the 
healthcare budget for South Africa and the opportunity cost of implementation in terms 
of its impact on the HIV component of the conditional grant. Importantly the 
preferences and needs of women lead us to explore differing mixed strategies as well as 
the impact of coverage levels. The contribution that this BIA will add is in terms of data 
which can then be used for informed decision making with regard to the national scale 
up of postpartum models of care. 
 
6.2 Methods 
6.2.1 Study aim 
 
The aim of this study was to assess the budget impact of national scale-up in terms of 
implementing these new postpartum models of care (Models II and III) in South Africa. 
 
6.2.2 Study design 
 
A BIA which assesses the net budget impact when adding a new approach or 
combination of approaches was utilised for this work. The economic unit costs of the 
three models of care were estimated from a provider perspective and have been 
discussed elsewhere (186). The costs for the three models of care were inflated and are 
presented in 2019 US $ (201) (see Table 15). These costs comprise apportioned capital 
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(building costs, furniture) and recurrent costs (healthcare worker costs, overheads, 
immunisations for infants, medication, diagnostic costs) for postpartum care annually, 
per mother-infant pair.  
 
Table 15: Annual unit cost per mother-infant pair for each of the three models of care in 
2019 US $ 
 
Model of care Annual unit cost per mother-infant pair in US $ 
Model I – Routine Care 226 
Model II – Integrated Care 341 
Model III – Community Care 254 
 
These unit cost estimates were combined with the effectiveness measures (retention in 
care at 12 months postpartum combined with viral suppression, HIV ribonucleic acid 
(RNA) <50 copies/mL) to assess the cost-effectiveness of the three models of care 
(159). These unit cost estimates were then used in this study to analyse the budget 
impact of nationally scaling up (to 100%) the most cost-effective model of care , Model 
III - Community Care, relative to the other two models, Model I - Routine Care and 
Model II – Integrated Care. The scaling up of Model III to 100%, to replace Model I, is the 
base case scenario where the resulting displacement of funds and budget requirements 
are calculated. 
 
6.2.3 Data analysis 
 
We have utilized the National Institute for Health and Care Excellence (NICE) Budget 
Impact Template in Microsoft Excel which provides a framework for estimating the BIA, 
in order to standardize the BIA process (202). It is a generic tool which can be adapted 
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to any country (202).The first step was to adapt the population by entering the South 
African national population of 58.8 million for 2019 (203). The national target 
population for this BIA, of the number of women living with HIV for reproductive ages 
(15-49), who had a baby in last year (2019) was then estimated and the cost of scaling 
up the base case scenario, Model III at 100% scale (in comparison to Model I at 100% 
scale), using the annual unit costs (Table 15) was calculated. In terms of effects, Model 
III, 84% of women were virally suppressed and retained at 12 months postpartum in 
the PACER study (4). Model III was also found to be the dominantly cost-effective model 
of care (159).  
 
6.2.4 Sensitivity analysis 
 
Sensitivity analysis took the form of scenario analysis to look at the structural 
uncertainty, where four alternate scenarios were modelled in addition to the base case 
of 100% coverage of Model III nationally. The first scenario (Alternate Scenario A), 
makes use of the preference of women in the PACER study, in which 65% chose Model 
III – Community Care, rather than Model I - Routine Care. The remaining proportion of 
the women (35%) were divided in a ratio of 1:2 to Model I (12%) and Model II (23%), 
with the rationale that Model II has a higher effectiveness (in terms of viral suppression 
and retention in care (77% of women were virally suppressed and retained at 12 
months postpartum in Model II in the MCH-ART study)) than Model I (where 56% were 
virally suppressed and retained), but also a higher annual cost per mother-infant pair 
(2). The second scenario (Alternate Scenario B) uses equal weighting between the three 
models of care (Model I, II and III each accounting 33.33% coverage) acknowledging 
that there are merits to each of the models and potentially different characteristics that 
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would work for some mother-infant pairs and not for others. The third scenario 
(Alternate Scenario C), assesses Model II at scale, displacing Model I.  The fourth 
scenario (Alternate Scenario D) is where Model III replaces Model I, but only at 57% 
coverage (for both Models I and II), which relates to the reported 118 608 antenatal 
clients initiated on ART in the 2017/8 financial year (115). In addition we used the 
Thembisa Model (a large mathematical model for HIV in South Africa) to consider the 
differences in estimated numbers of women living with HIV for reproductive ages (15-




We have assumed that the reproductive ages for women in South Africa are between 
15-49 years, and that all reported births come from this age group. We have subtracted 
the infant deaths from the nationally reported birth figure based on the infant mortality 
rate for 2019 of 22.1 per 1000 live births. This assumes that the reported birth figure 
does not account for infant mortality. We have also assumed that the number of women 
that would be in the postpartum phase are equal to the number of live births (which 
does not take into account the birth of multiples but factors in infant mortality as 
described above). Models I-III, were specifically designed for the postpartum period 
where mothers started ART in pregnancy, this BIA however uses National HIV 
prevalence so treatment may already be well established in these women living with 
HIV. The proportion used to calculate the number of (births) postpartum women in the 




6.3.1 Estimating the target population 
 
We estimated the eligible population in a series of steps shown in Table 16. Almost one 
in every four women of reproductive age is HIV positive. Essentially the target 
population, of 208 084 mother-infant pairs, for the BIA was calculated using the number 




Table 16: Steps to estimate the target population  
 
Step 1 Total population of South Africa (male and female)  58 800 000 Source: (203)  58 075 532 Source: Thembisa Model Version 4.4 
(206) 
Step 2 National numbers of women for reproductive ages (15-49)  15 850 574 Source: (203) Table 6 15 757 455 Source: (206) 
Step 3 % HIV prevalence for women for reproductive ages (15-49) 23% Source: (203) Figure 5 20% Source: (206) 
Step 4 Number of women for reproductive ages (15-49) living with HIV 3 599 665 Calculation:  
15 850 574*23%  
3 091 565 
 
Calculation:  
15 757 455*20% 
Step 5 All recorded births nationally 1 171 219 Source: (203) Table 4 1 171 219 Source: (203) Table 4 
Step 6 All recorded births nationally minus infant deaths (infant 
mortality 22.1 per 1000 live births) 
1 145 335 Calculation:  
1 171 219 - (1 171 219*2%) 
1 145 335 Calculation:  
1 171 219 - (1 171 219*2%) 
Step 7 All live births in public health sector 916 268 Calculation:  
1 145 335*80%  
Source: (205) 
916 268 Calculation:  
1 145 335*80%  
Source: (205) 
Step 8 Number of women living with HIV for reproductive ages (15-49), 
who had a baby in last year (2019) 






6.3.2 Scaling up  
 
Model III – Community Care was found to be the most cost-effective model relative to 
Models I and II (159). It was found that if Model III was implemented at 100% coverage 
in South Africa, it would cost US $52 751 995 (see Table 17). Model I – Routine Care, 
which is the current practice, nationally has a budget requirement of US $47 031 899 
when at 100% coverage. This means that the net budget impact or addition to the 
budget for Model III at scale is US $5 720 096 for the annum, a 12% increase from 
Model I, at scale. 
 
As a proportion of the HIV, TB, Malaria and Community Outreach Grant, Model I 
currently consumes approximately 1.5%, while a change to 100% care on Model III, 
which was relatively the most cost-effective model, would require an additional 0.2% of 
this grant.  
 
6.3.3 Sensitivity analysis 
 
One can visually see the Alternate Scenarios A-D in Figure 9 below. An additional US $9 
303 763 is required for Alternate Scenario A, an additional US $9 886 016 for Alternate 
Scenario B and an additional US $23 939 660 for Alternate Scenario C, all in comparison 
to Model I at scale.  Alternate Scenario D, uses a more modest coverage level of 57% 
which results in an increased budget need of only US $3 260 455 in comparison to 
Model I (also at 57% coverage). When using the prevalence as portrayed in the 
Thembisa Model one can see that the difference between the two estimates for the 
number of women living with HIV for reproductive ages (15-49), who had a baby in last 




Figure 9: Budget impact for Base and Alternate Scenarios with percentage of the Healthcare Budget (2020/21) required displayed on 












































Budget for Standard of Care at scale (100%) Additional budgetary requirement
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Table 17: Budget impact and scenario analysis (all in 2019 US $) 
 
Scenario Eligible population  Total budget at scale Net budget impact 
(relative to Model I 




Percentage of NSP 
anticipated funding 
for HIV, TB and STIS 
2020/21 
Percentage of HIV 
and AIDS 
Component*  
Standard of Care:  
Model I - Routine Care at scale 
- 100% 




Base Scenario:  
Model III – Community Care 
at scale – 100% 
208 084 US $52 751 995 
 




0.3% (2.5%) 0.5% (4.2%) 
 
Alternate Scenario A: 
Model I – 12% coverage  
Model II – 23% coverage 
Model III – 65% coverage 
208 084 
Model I: 24 276 
Model II: 48 553  
Model III: 135 255 
US $56 335 662 
 




0.4% (2.6%) 0.7% (4.5%) 
 
Alternate Scenario B: 




Model I: 69 361 
US $56 917 915 
 




0.5% (2.7%) 0.8% (4.5%) 
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Model I – 33.3% coverage  
Model II – 33.3% coverage 
Model III – 33.3% coverage 
Model II: 69 361  
Model III: 69 361 
 
Alternate Scenario C: 
Model II – Integrated Care at 
scale – 100% 
208 084 US $70 971 560 
 
US $23 939 660 
 
0.7% (2.2%) 1.1% (3.3%) 1.9% (5.6%) 
Alternate Scenario D: 
 
Eligible population  Total budget at 57% 
implementation 
Net budget impact 






Percentage of NSP 
anticipated funding 
for HIV, TB and STIS 
2020/21 
Percentage of HIV 
and AIDS 
Component * 
Standard of Care:  
Model I - Routine Care at scale 
- 57% 






Alternate Scenario D: 
Model III – Community Care 
at scale – 57% 
118 608 US $30 068 637 
 
US $3 260 455 
 
0.1% (0.9%) 0.2% (1.4%) 0.3% (2.4%) 





The annual cost of scaling up these postpartum models of care countrywide were 
between US $3 260 455 and US $23 939 660. One aspect mentioned in the National 
Strategic Plan on HIV, TB and STIs, is the need to continue care for the mother-infant 
pair through breastfeeding with the aim of sustaining mothers’ adherence to medication 
and keeping mother-to-child transmission risk low (17). The hope is that through 
addressing adherence and retention, mother-to-child transmission can be eliminated as 
transmission is linked to maternal replication of the virus (180). However different 
models of care suited to mother-infant pairs are needed to enhance adherence and 
retention and achieve this aim. 
 
Dugdale et al. 2019 (158) assessed the budget impact of implementing Model II in place 
of Model I using an estimated 250 000 women in need of HIV care during the 
postpartum phase which is similar but slightly higher (17%) than the estimate used in 
this BIA. The amount quoted for Model I in this BIA is almost a quarter (23%) of what 
was estimated (when inflated from 2016 to 2019 US $) in the Dugdale et al. study (158), 
and 34% of the amount estimated for Model II at scale (Alternative Scenario C) due to a 
much higher annual mother-infant pair cost under both models (US $550 and US $570 
respectively) used in the Cost-Effectiveness of Preventing AIDS Complications (CEPAC) 
model utilised by Dugdale et al (158, 201).  As the Dugdale et al. study (158) used the 
same unit cost for visits, the difference in cost can be attributed to differences in the 
medication, immunisation, diagnostic costs and frequency of visits. 
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In the 2017/8 financial year 118 608 antenatal clients were initiated on ART (115) 
which is 57% coverage when using the target population of 208 084. If we use this 
number as a proxy for mother-infant pairs currently in postpartum care as we have 
done in the Alternate Scenario D, then we see that the increased budget needed to 
change to a more cost-effective model of care only requires 0.9% of the National 
Healthcare Budget.  
 
Model II - Integrated Care, was particularly successful in the MCH-ART study due to a 
champion professional nurse who provided services which would often be delivered by 
a whole team of individuals namely: the services of a midwife, specifically antenatal and 
postnatal care, as well as ART and HIV care and paediatric services. The implementation 
of Model II would need adequately trained staff who are able to deliver these services as 
an individual or multidisciplinary team in an integrated manor. Model III could be easily 
‘scaled up’ for postpartum women within the Western Cape where there are already in 
the region of 1300 CACs and approximately a quarter of all ART patients are attended to 
through this community-based approach (207, 208). Women in the postpartum phase 
are already attending CACs as standard adult clients.  
 
Published work by MacGregor and colleagues (209) assessing the scaling-up of CACs 
cautions that once adherence clubs reached the critical point where more than one 
meeting was provided per day (over 40 clubs) in the Western Cape, a system failure was 
noted which then impacted on the quality delivered by the clubs provided prior to this 
point. This was due to capacity and logistical reasons such as provision of large 
quantities of medication (209). This is a crucial finding which in part guides our 
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recommendation that although Model III was the most cost-effective of the three 
models assessed in this dissertation, we do not recommend its exclusive use.   
 
The main limitation of this study is that we are unsure what the particular mother-
infant pair preference would be nationally in terms of models of care. Therefore we 
suggest that a discrete choice experiment would be beneficial further research. In 
addition in the current climate of a pandemic (COVID-19), healthcare budgets will be 
under huge pressure and expansion for current services, whether cost-effective or not 
may not be seen as a priority and may not be affordable. Modelling efforts suggest that 
due to COVID-19, we may see negative effects such as an estimated 10% increase in 
deaths for those living with HIV in high burden settings such as South Africa, over the 
next five years (36). The suggestion for keeping HIV programmes impactful is by 
ensuring continued access to ART during this time of increased strain on health systems 
(36). It is important to note that these costs are most applicable to the population of 
women who started ART in pregnancy and may differ for those who have been stable on 
ART prior to conception. In this work we have not evaluated the impact of scale on unit 
costs as it was difficult given the scope of the work, however we recommend that future 
research assesses this important aspect.  
 
In order to cater for individual’s preferences we have provided Alternate Scenario 
analyses with varying combinations. For instance CACs have been found to be 
welcomed by patients for their flexibility (176). The essential message from this BIA 
however is that in order to have a more cost-effective model in place whether at 100% 
or in combination with other cost-effective models of care, there will be increased 
budgetary needs ranging from 12% to 51%. This BIA relates to affordability of scaling 
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up more cost-effective models and displacing the standard of care which should be 
decided by policy-makers. If an increase of 0.9-2.2% can be accommodated in the 
current healthcare budget then more cost-effective models can be put in place or 
alternatively additional funds can be raised to facilitate the inclusion of more cost-
effective models of care. 
 
Model II and III have been shown to be effective in terms of maternal retention and viral 
suppression (2, 4). If mother-infant pairs are retained and virally suppressed then 
potentially there may be upstream effects that are also mitigated, such as reduced LTFU, 
decreased transmission and fewer opportunistic infections. These long term savings 
from the implementation of cost-effective interventions for HIV, promote the increased 
need for spending by the South African government now (210). 
 
The findings of this BIA, namely the evidence for scale up, are directly applicable to 
South Africa and could be generalised to other Sub-Saharan African settings or similar 
low- and middle-income settings. These models would be most beneficial and relevant 
to settings where there is a need for differentiated care and improved retention and 
viral suppression in mothers. In order to secure the necessary budget there will have to 
be opportunity costs in other less pressing areas of the health budget (i.e. budget cuts) 
or preferably an injection of funding committed by the South African Government 
perhaps through the minimisation of administration costs or additional funding secured 
through international donors. This is especially important given the goal of ending AIDS 
by 2030 linked to the Sustainable Development Goals (27) as well as HIV/AIDS being a 





Evidence of the amount of funding needed to scale up innovative models of care for 
South Africa has been provided. Tangible figures have been presented for different 
structures of provision and differing levels of scale up to better protect and support the 
postpartum phase for women living with HIV going forward. The net budget impact to 
introduce a more cost-effective model than the standard of care represents an increase 
of 0.9 - 2.2% of the national healthcare budget and 2.4 - 5.6% of the committed HIV and 
AIDS Component of the ‘Community Outreach Grant’. Differentiated care is needed to 
suit different women’s preferences, for instance facility based care (Models I and II) or 
non-facility based care (Model III) and therefore one of the alternate scenarios 
providing differentiated care although more expensive may be more acceptable to 
mothers.  
 
The HIV burden among pregnant women is large with almost a quarter of women of 
reproductive age being HIV positive (23%). The potential implications of this BIA are 
that more cost-effective novel options for postpartum maternal and child health have 
been established in the Western Cape which if scaled up countrywide could have 








7 Chapter Seven: Discussion and conclusion 
 
This chapter brings together the contents of the four results chapters summarizing the 
key messages for policy makers in South Africa, Eswatini and similar settings. This 
chapter also highlights the unique contributions of this thesis to the literature generally. 
Costs in this section have been inflated to 2019 US $ using CPI for comparability (201) 
 
7.1 Summary of thesis findings 
7.1.1 Aim of the research 
 
 
As described in Chapter One, the overall aim of this work was to evaluate the cost and 
cost-effectiveness of different models of PMTCT for women living with HIV and their 
infants, in order to estimate the national budget for large scale implementation, taking 
into consideration the change to the lifelong ART (Option B+) approach. 
 
7.1.2 Specific objectives were 
 
1. To compare the costs and effects of the Option B+ approach to the Option A 
approach to PMTCT from a provider’s perspective in a cost-effectiveness analysis 
 
2. To estimate the costs of three models of care for mother-infant pairs during the 
postpartum phase (at 12 months postpartum) from a provider and patient’s 
perspective and b.) to estimate the costs of the pregnancy phase for mothers 
from a provider’s perspective 
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3.  To compare the costs and effects of three models of care for mother-infant pairs 
during the postpartum phase (12 months postpartum) from a provider and 
patient’s perspective in a cost-effectiveness analysis 
 
4. To estimate the budget impact of nationally scaling-up models of care for the 
postpartum period  
 
We accomplished this aim and these objectives through three parent studies, SG, MCH-
ART and PACER. This dissertation assessed the cost and cost-effectiveness of Option A 
in comparison to the Option B+ approach to PMTCT in Eswatini as well as the cost of 
transitioning, using a step wedge design in the SG implementation science study. The 
costs and cost-effectiveness of three models of care for postpartum WLH, as well as the 
costs of the preceding pregnancy phase, were assessed through another 
implementation science project MCH-ART where women were randomised into two 
models of care, Model I – Routine Care (mothers in general ART clinics and infants in 
well-baby clinics) and Model II – Integrated Care (mothers-infant pairs seen together in 
integrated care in the MOU (Site A)); and PACER a supplementary study to MCH-ART in 
the same geographical area without randomisation, but rather determined by the choice 
of the postpartum WLH in the study, allowing for the evaluation of an additional model 
of care, Model III – Community Care (mothers in CACs and infants in well-baby clinics) 
in comparison to Model I – Routine Care (as provided in MCH-ART).  
 
7.1.3 Summary of chapter contents 
 




Chapter Three - Cost and cost-effectiveness of transitioning to universal initiation 
of lifelong antiretroviral therapy for all HIV-positive pregnant and breastfeeding 
women in Swaziland includes a paper which was published in Tropical Medicine and 
International Health in 2018 (117).  This chapter found that universal/ lifelong ART 
(Option B+) can be considered cost-effective in Eswatini using the intermediate 
outcome of retention with an incremental cost effectiveness ratio (ICER) of US $984 per 
mother retained to six months postpartum (inflated to 2019 US $) in comparison to ART 
initiation based on CD4 cell count and WHO clinical staging (Option A). The total cost of 
PMTCT was US $936 724 for universal ART and US $734 027 for ART initiation based on 
CD4 cell count and clinical staging. Under universal ART the cost per woman treated per 
month was US $197 while the weighted average cost per woman treated was US $891 in 
2019 US $ (201). The main cost drivers were the start-up costs, additional training 
provided, and staff time spent on PMTCT tasks. 
 
Chapter Four - Provider- and patient-level costs associated with providing 
antiretroviral therapy during the postpartum phase to women living with HIV in 
South Africa: A cost comparison of three postpartum models of care includes a 
paper which has been accepted for publication in Tropical Medicine and International 
Health in 2020, which is available online ahead of print (143). When inflated to 2019 US 
$ (201), Routine Care (Model I) cost US $226 per mother-infant pair per annum; 
Integrated Care cost US $341 (Model II); and Community Care cost US $254 (Model III). 
Annual patient costs for Models I-III, were US $30-55, US $23-45 and US $76 per 
mother-infant pair respectively (in 2019 US $). Average visit frequencies were 4.5, 6.9 
and 6.7 visits postpartum for Models I, II and III respectively. 
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From a health service perspective, the unit cost per visit during the pregnancy phase 
was US $12 in 2019 US $ (201), of which personnel was the biggest cost driver, 
accounting for 74% of the costs. Through medical record abstraction we were able to 
establish that there are on average three visits made during the pregnancy phase 
resulting in a cost per woman of US $37 from a health service perspective. If one 
includes the health service costs of both medication and diagnostic test costs, the 
average cost per woman during pregnancy was US $111 (25% medication; 41% 
diagnostic tests; 33% pregnancy visit cost).  
 
Chapter Five - Cost-effectiveness analysis of three postpartum models of care for 
women living with HIV in Cape Town, South Africa includes a paper which has been 
prepared for submission later in 2020. Comparatively Community Care (Model III) was 
found to be the most cost-effective model with an ICER of US $97 per mother-infant pair 
retained and virally suppressed which was defined as HIV RNA <50 copies/mL at 12 
months postpartum (in 2019 US $). The ICER falls below a revealed willingness to pay 
threshold of US $872 for HIV investment in South Africa indicating that Community 
Care (Model III) can be considered cost-effective in comparison to the other two 
evaluated models of care (193). 
 
Chapter Six: Scaling-up postpartum models of care for mother-infant pairs in 
South Africa: A budget impact analysis includes a paper which has been prepared for 
submission later in 2020. Scaling-up Community Care (Model III) nationally in South 
Africa to 100% coverage would require US $5 720 096 more than Routine Care (Model 
I) at scale, which would comprise 0.2% of the total health budget for 2020/21 or an 
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additional 0.5% of the HIV and AIDS Component of the HIV, TB, Malaria and Community 
Outreach Grant for 2020/21. Using a scenario analyses, Alternate Scenario A, where 
Routine Care (Model I) is at a coverage of 12%, Integrated Care (Model II) is 23%, and 
Community Care (Model III) is at 65% coverage, an additional US $9 303 763 (in 
comparison to Routine Care only, at scale (100% coverage)) is required. Alternate 
Scenario B demonstrated that if an equal weighting between the three models of care is 
used (i.e. 33.3% of the target population is covered under each) then an additional US 
$9 886 016 is required (in comparison to Routine Care only, at scale (100% coverage)). 
 
7.2 Generalisability 
Broadly speaking the results of this dissertation will be useful for informing HIV budget 
formation and planning the prioritisation of model implementation in South Africa, 
Eswatini and similar LMIC settings especially in Sub-Saharan Africa. In Chapter Three, 
the data was collected specifically in the context of Eswatini transitioning from the 
Option A approach to lifelong ART (Option B+), which may limit the generalisability of 
the results due to the small size of Swaziland as a country, the high level of donor 
partnerships in health and the MoH’s strong participation in healthcare programmes. To 
aid generalisability we have presented average unit costs, have included a mix of urban 
and rural facilities of differing sizes and have presented economic costs including 
volunteered time and donated goods. In settings such as South Africa, where there was 
no empirical evidence regarding cost-effectiveness of Option B+, this study may have 
helped inform decision making for expanding lifelong ART (Option B+) countrywide, 
which has been the recommendation since 2015, and may assist as universal ART 
becomes the standard of care for PLWHA. It may also serve neighbouring countries with 
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similar settings, where costs for PMTCT programmes are lacking and will provide a 
reliable comparison for LMICs when countries assess the costs of lifelong ART starting 
in pregnancy in literature.  
 
The study findings from Chapters Four to Six are generalisable to the rest of South 
Africa as well as other LMIC settings with similarities to South Africa in particular 
landlocked Eswatini. However, it should be noted that for this study the setting was 
peri-urban with well-established and numerous CACs. There may be factors which 
could have impacted the findings, such urbanicity of placement of clinics and CACs, and 
champion healthcare workers, which make this work hard to generalise to rural areas 
or settings with staff that are less trained or motivated. However with these factors in 
mind one could utilise these costs to inform budgetary processes and planning for HIV 
in particular for PMTCT programmes. 
 
This dissertation generated evidence that is directly applicable to South Africa, 
regarding the affordable scale up of models of care which could be generalised to other 
Sub-Saharan African settings or similar LMIC settings. These models would be most 
beneficial and relevant to settings where there is a need for differentiated care and 




There are several study limitations within this dissertation. As is always a concern, 
there may have been a Hawthorne effect, where personnel observed and involved in 
discussion may behaved differently due to the nature of being involved in a study, which 
may impact on both the costs and the effectiveness of the interventions, either 
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positively or negatively. In order to minimise this, the researcher observed over several 
sessions, and verified information with the facility managers, other staff and research 
staff. Another limitation is that the costs and effectiveness were not estimated over a 
period of more than 18 months and so the long-term cost-effectiveness has not been 
established in this work. We opted not to model longer than the duration of retention in 
care, nor did we make use of a multidimensional outcome measure (QALY or DALY) in 
the cost-effectiveness analyses. The rationale being that the focus was on empirical data 
collection and analysis of this data, which is where a substantial data gap was identified 
in the literature. The use of natural units does of course limit comparability with other 
studies, but are useful as they express important measures of HIV care in the treatment 
cascade, specifically retention in care. 
 
In SG, there were some challenges in tracing infants which meant that MTCT (measured 
through a positive infant PCR result) was not included as an effectiveness measure or in 
the cost-effectiveness outcome. CACs are intended only for women who are already 
stable on ART, however Routine and Integrated Care (Models I and II) do not have this 
limiting factor. 
 
It is important to note that these costs are most applicable to the population of women 
who started ART in pregnancy and may differ for those who have been stable on ART 
prior to conception. Another limitation is that the cost of care may vary from clinic to 
clinic, though our samples are small (but relatively normal for costing work) it is 
representative of different sized facilities and we present average unit costs which 
should mitigate this concern. 
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One of main limitations of the BIA is that we are unsure what the particular mother-
infant pair preference would be nationally in terms of models of care or what the 
capacity would be for hosting multiple models of care in different provinces. In addition 
COVID-19 is placing healthcare budgets under huge pressure and expansion for current 
services, whether cost-effective or not may not be seen as a priority and may not be 
affordable. 
 
7.4 Summary of thesis contributions 
 
The findings of this dissertation have the following implications. During the Safe 
Generations study, the Eswatini MoH made the decision to implement lifelong ART in 
PMTCT programmes nationwide based on interim results and discussion with research 
staff. Costs from this work on lifelong/ universal ART could also be used for budgeting 
and planning for decision makers in Eswatini and similar settings.  In Uganda the 
change to Option B+ for mother-infant pairs (when inflated to 2019 US $) cost US $239 
per annum with ART for mothers being the biggest cost driver at 63% of the cost (54, 
201). Similarly, in Ethiopia the cost of ART for PMTCT for mother-infant pairs 
comprised the largest proportion of the annual cost. The range of unit cost per mother-
infant pairs per year was US $355-1 224 (when inflated to 2019 US $) (55, 201). 
Although this dissertation did not find ART to be the biggest cost driver, the overall 
annual costs for the studies in Uganda and Ethiopia were similar to our findings. 
 
Community care (Model III), which involved postpartum care for mothers at CACs and 
infants at well-baby clinics, was found to be the most cost-effective model of care 
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relative to the other models assessed, whether costs were utilised from a provider’s 
perspective or patient and providers’ perspective. However, we recommend that a 
mixture of the three models of care would be most ideal, given the needs and 
expectations of the mother-infant pairs (211).  Published work by MacGregor and 
colleagues (209) assessing the scaling-up of CACs cautions that once adherence clubs 
reached the critical point where more than one meeting was provided per day (over 40 
clubs) in the Western Cape, a system failure was noted which then impacted on the 
quality delivered by the clubs provided prior to this point. This was due to capacity and 
logistical reasons such as provision of large quantities of medication (209). This is a 
crucial finding which in part guided our recommendation that although Model III was 
the most cost-effective of the three models assessed in this dissertation, we do not 
recommend its exclusive use.   
 
In a systematic review investigating the literature on the cost-effectiveness of 
preventative interventions in Sub-Saharan Africa, PMTCT had the lowest median cost-
effectiveness rations of US $1 144 per HIV infection averted and US $191 per DALY 
averted. This provides evidence that most PMTCT interventions that have been 
assessed are cost-effective in the African setting (42). Although we have not used a 
multidimensional outcome unit such DALYs averted, our findings that Option B+ and 
Community Care are cost-effective are in line with current literature which showed 
these interventions to be cost-effective.  
 
The HIV burden among pregnant women in South Africa is large with almost a quarter 
of women of reproductive age being HIV positive (23%). The potential implications of 
this dissertation are that more cost-effective novel options for postpartum maternal and 
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child health have been established in the Western Cape which if scaled up countrywide 
could have particular impact on the health of the mothers of our country as well as the 
next generation. 
 
It has been made evident in this work that innovative models of care may be affordable 
in the South African context as decided by budgeters and policy makers. Evidence of the 
amount of funding needed to scale up these models has been provided. Tangible figures 
have been presented for different structures of provision and differing levels of scale up 
to better protect and support the postpartum phase for women living with HIV going 
forward. The data generated in this study can be used for informed decision making in 
South Africa, Eswatini as well as other similar LMIC settings. 
 
7.5 Key messages for policy makers: 
 
• Lifelong ART was found to be cost-effective in the Eswatini setting with an ICER 
of US $984 (2019 US $) for every additional mother retained in care through six 
months postpartum 
 
• Community Care, provided through community adherence clubs was found to be 
cost-effective in the South African setting, with an ICER of US $97 per mother-
infant pair retained and virally suppressed which was defined as HIV RNA <50 
copies/mL at 12 months postpartum (in 2019 US $), below the revealed 
willingness to pay threshold of US $872 for HIV investment in South Africa  
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• The financial requirement to implemented Community Care at scale (100% 
coverage) may be considered affordable depending on the decisions made by 
budgeters and decision-makers, entailing US $5 720 096 more than Routine Care 
at scale, which would comprise 0.2% of the total health budget for 2020/21 or an 
additional 0.5% of the HIV and AIDS Component of the HIV, TB, Malaria and 
Community Outreach Grant for 2020/21. However we recommend the utilisation 
of one of our scenario analyses as a combination of care is strongly suggested to 
cater for mother-infant pair preferences and needs 
 
• Implementation science studies (such as Safe Generations) are able to assess 
changes as they happen, allowing for careful evaluation and involvement of 
stakeholders such as MoH and Departments of Health 
 
• Now in the era of universal ART, a mix of care in the postpartum period may be 
more acceptable for mother-infant pairs, and be more apt and feasible for 
sustainable management, not overloading the healthcare system or the 
exceeding capacity of models of care 
 
7.6 Future directions 
 
As donors continue to withdraw funding generally and from HIV/AIDS in particular, it 
becomes even more crucial that HIV programmes are well and efficiently run, with 
thought as to what patients need from models of care (185). Differentiated care should 
take into consideration the context such as urbanicity and HIV burden; the specific 
population in need for example postpartum WLH; and clinical characteristics namely 
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are the individuals stable or unstable on their ART which can inform the level of 
healthcare provider involvement in their care (68).  The findings of this dissertation 
have provided evidence for three models of care in a high HIV burden peri-urban 
context for postpartum WLH who are both stable and unstable on treatment as well as 
providing several different combinations for how these models could be scaled-up in 
South Africa. However, to establish the preferences of the mother-infant pairs in terms 
of the model of care that best suits their needs a discrete choice experiment would be 
beneficial further research. Additional work on quality of care of scaled-up models of 
care will be needed particularly to assess if further investment and resources are 
required to prevent capacity being surpassed leading to system failure. Also 
understanding the differential pattern of service needs or preferences across different 
regions and areas should be added to the future research agenda. 
 
Models of care which improve access and adherence of ART allow for better outcomes, 
but in turn changes the focus to providing more support for non-communicable 
diseases which are more prominent as people live longer (185). This points to further 
integration of programmes for instance of postpartum HIV care with non-
communicable diseases such as through CACs. Hence in the South African setting 
additional work is needed to tailor new models of care that integrate HIV and non-
communicable diseases. And broadly further research is required to assess ways of 
retaining mothers in care, ensuring adherence, and reaching the goal of eliminating 
paediatric HIV is necessary in the southern African context. 
 
In terms of strengthening the health system work should be done to ensure that medical 
file numbers and other linkages are maintained, so that infants are not lost to follow up, 
 151 
which would also assist future studies. The assessment of the economic impact of loss to 
follow up would be of interest going forward. As HIV regimens and models change, 
updated estimates of cost and cost-effectiveness will be needed.  And in terms of HIV 
prevention for pregnant women, as encouraging work emerges on the safety of pre-
exposure prophylaxis (PrEP) for women during pregnancy and postpartum while 
breastfeeding (212, 213) more research will be needed to assess the acceptability, 
affordability, outcomes and ability of the health system to provide PrEP for this 




The findings from this dissertation are particularly notable for policy going forward as 
they could allow for a mix of postpartum models of care as part of universal/ lifelong 
ART, that are cost-effective, acceptable to mother-infant pairs, provide highly effective 
care in terms of retention and viral suppression, and have known costs for planning and 
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9 Appendices  
 
9.1 Appendix 1: Supplemental information linked to Chapter Three 
Supplementary appendix from Cost and cost-effectiveness of transitioning to 
universal initiation of lifelong antiretroviral therapy for all HIV-positive 
pregnant and breastfeeding women in Swaziland 
 
A secondary aim of this research is to estimate the cost of transitioning to Option B+ 
from Option A in Swaziland, as is described below.  
 
9.1.1 Additional methodological details  
Swaziland is a LMIC, with a population of 1.2 million and an HIV prevalence of 31% (for 
individuals aged between 18 and 49 years) (214). Globally, it has the most severe 
countrywide HIV epidemic (215). 
 
The transition from Option A to B+ under SG resulted in a more than two-fold increase 
in the number of women initiating ART and a decrease in median days from first ANC 
visit to ART initiation of 40 to 0 days. An advantage of the study design was that study 
staff did not alter clinical care, providing a true snapshot of services and health worker 
time unlike many other economic evaluations relying on studies where participants are 
enrolled and studied. Very few of the retained infants tested PCR positive and reported 




9.1.2 Patient management process  
9.1.2.1 Option A 
 
Pregnant women, under Option A, who received positive rapid HIV test results, in the 
antenatal care departments of the clinics, were given a series of tests (CD4, 
haemoglobin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), 
creatinine) during their first antenatal visit. These women were differentiated by CD4 
count into receiving either lifelong ART (TDF+3TC+EFV) if their CD4 count was below 
350 cells/μl or prophylactic AZT. Women spent time with providers during 
consultations, going through adherence training and education, and receiving 
medication. 
 
9.1.2.2 Option B+ 
 
Pregnant women, under Option B+, in the antenatal care departments of the clinics, 
were given the same series of tests (CD4, haemoglobin, alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), creatinine) during their first antenatal visit if their 
rapid HIV test was positive. These women started lifelong ART (TDF+3TC+EFV) on the 
same day as HIV testing occurred. A desktop flipchart, aided the staff when educating 
the patients about how to take their medication correctly. As with women under Option 
A, under Option B+ women spent time with a variety of providers during consultations, 
going through adherence training and education, and 
having medication dispensed to them. 
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9.1.3 Study design 
 
The economic costs include capital as well as recurrent costs such as the time of the 
study staff involved in training, mentoring and facilitating clinical work. The costing 
uses real world costs (except for diagnostic tests (CD4, point of care PIMA CD4, 
haemoglobin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), 
creatinine and rapid HIV tests) which are costed per guideline) and estimates the costs 
incurred. 
 
All costs were estimated using bottom-up methods, except the category of overheads, 
which was estimated using top-down methods (165). Above service level costs (such as 
running costs within the MoH, NGO and FBO, information technology and human 
resources support) were excluded. 
 
The prices of performing diagnostic tests were obtained from the National Health 
Laboratory Services South Africa rather than from Swaziland, as only the actual test 
prices were available in Swaziland, and not the cost of performing the tests (for instance 
the inclusion of personnel time, equipment use, running and building costs). Further 
work is needed in Swaziland to cost the diagnostic tests performed at the Swaziland 
Health Laboratory Service. Using South African prices is a limitation given the two 
countries’ differing GDPs and the percentage allocated to healthcare expenditure. 
Additionally, the higher numbers of individuals seeking care in South Africa means that 
economies of scale come into play. 
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The five purposively chosen clinics were a mix of three urban and two rural sites, 
variably sized ranging from total clinic headcount of ~3,800-48,000 per year and had 
different funding structures: three MoH, a NGO and a FBO (see Supplementary Table 1).  
 
9.1.3.1 Recurrent costs 
 
The overhead costs of running the clinics include use of electricity, water, sewage, 
cleaning, laundry, security, phone, internet and stationery (subscriptions, photocopying 
and printing, packaging if any). In addition, maintenance costs of the buildings and 
equipment were included at an annual rate of 7% of the total cost (216).  
 
9.1.3.2 Cost allocation  
 
The capital items were apportioned to PMTCT services using the percentage of the 
PMTCT visits out of total clinic visits in a year, as were the recurrent components of 
overheads and personnel at the clinics who were not directly involved in PMTCT 
services. Initial training on PMTCT under Option A, start-up costs under Option B+, 
medication and diagnostics costs were directly allocated to the PMTCT services. 
Staff involved in providing PMTCT services filled out timesheets to provide a sample of 
the usual tasks performed in one week during the three study visits (to minimise recall 
bias). This was done together with a health economist to assess distribution of time for 
the various PMTCT and non-PMTCT tasks. Salary costs were then allocated using the 
ratio of the time spent on different PMTCT activities divided by the total time spent 
working in the week.  
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9.1.3.3 Transitioning costs 
 
The transitioning costs involved in moving from the Option A to Option B+ approach 
were estimated by incorporating the additional costs of the resources needed to 
implement the Option B+ approach. These costs are presented separately, but 
incorporate elements of the start-up costs of Option B+. These costs include more staff 
being involved in services (SG nurse site coordinator, data clerk, adherence and 
psychosocial counselling officer), the toolkit (mentioned above under start-up costs), 
training and additional equipment (a new filing cabinet and adult weighing scale for 
each clinic). 
 
The annualised cost of transitioning from Option A to Option B+ including additional 
human resources, equipment, training related to the study, toolkit development and 
reproduction as well as Option B+ training was US $21 425. The main cost related to 
staff time (92%), with the toolkit (4%), study specific training (2%) and Option B+ 




Supplementary Table 1: Description of selected clinics by characteristics of rural or 
urban placement, region, total clinic headcount and funding  
 
 
Supplementary Table 2: Medication and diagnostic tests for Option A and Option B+ as 
costing in Swaziland 
 
  
and non-PMTCT tasks. Salary costs were then allocated using the ratio of the time spent on 
different PMTCT activities divided by the total time spent working in the week.  
Transitioning costs 
The transitioning costs involved in moving from the Option A to Option B+ approach were 
estimated by incorporating the additional costs of the resources needed to implement the Option 
B+ approach.  These costs are presented separately, but incorporate elements of the start-up costs 
of Option B+. These costs include more staff being involved in services (SG nurse site co-
ordinator, data clerk, adherence and psychosocial counselling officer), the toolkit (mentioned 
above under start-up costs), training and additional equipment (a new filing cabinet and adult 
weighing scale for each clinic). 
The annualised cost of transitioning from Option A to Option B+ including additional human 
resources, equipment, training related to the study, toolkit development and reproduction as well 
as Option B+ training was US $21,425. The main cost related to staff time (92%), with the 
toolkit (4%), study specific training (2%) and Option B+ training (2%) making up the remainder 
of the cost. 
 
Supplementary Table 1: Description of selected clinics by characteristics of rural or urban 
placement, region, total clinic headcount and funding  
Clinic  Rural/ urban placement, region Total clinic headcount 2013 Total clinic headcount 2014 Funding 
Clinic 1 Urban/semi-urban in Manzini 
Matshapa corridor 
47988 39319 Government 
supported 
Clinic 2 Urban/semi-urban in Manzini 
Matshapa corridor 
3926 3864 Non-governmental 
organization 
supported 
Clinic 3 Urban/semi-urban in Manzini 
Matshapa corridor 
10823 11511 Faith based 
organization 
Clinic 4 Rural clinic, South-west of 
Manzini 
37208 34081 Government 
supported 
Clinic 5 Rural clinic, South-west of 
Manzini 




Supplementary Table 2: Medication and diagnostic tests for Option A and Option B+ as 
costed in Swaziland 
 Treatment (eligible if CD4 
count below or equal to 350 
cells/μl) 
Prophylaxis 
(ineligible if CD4 count 
above 350 cells/μl) 
Diagnostic tests  
Antepartum 
Option A  
Lifelong ART 
(TDF+3TC+EFV) and CTX 
 
Zidovudine (AZT) and 
CTX 
CD4, Haemoglobin, alanine 
aminotransferase (ALT), aspartate 
aminotransferase (AST), 






Lifelong ART (TDF+3TC+EFV) and CTX regardless of 
CD4 count 
CD4, Haemoglobin, alanine 
aminotransferase (ALT), aspartate 
aminotransferase (AST), 
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9.2 Appendix 2: Supplemental information linked to Chapter Four 
Supplemental appendix from ‘Provider- and patient-level costs associated with 
providing antiretroviral therapy during the postpartum phase to women 
living with HIV in South Africa: A cost comparison of three postpartum 
models of care’ 
 
9.2.1 Parent studies 
 
The MCH-ART study was a multiphase longitudinal cohort study where women were 
enrolled within Site A in order to evaluate a novel platform of integrated postpartum 
care in South Africa (2). For the observational component women were enrolled when 
they booked for antenatal care, prior to ART initiation (eligible for ART), and were 
followed through until shortly after delivery of their infants. Those women who 
continued to breastfeed when seen within a month of delivery, were enrolled into a 
randomised trial of two different ART delivery models. 
 
The current standard of care was compared to the MCH-ART intervention of integrating 
concurrent and co-located maternal ART and paediatric care into the MCH clinic 
through the end of breastfeeding. The MCH-ART intervention increased the primary 
endpoint of combined maternal retention and virologic suppression (HIV RNA <50 
copies/mL) at 12 months postpartum and extended breastfeeding duration (2).  
 
In Phase 1, approximately 1600 women who were infected with HIV, seeking antenatal 
care were part of a cross-sectional evaluation. During Phase 2 approximately 600 
women from Phase 1, who were eligible for ART initiation, were studied from their 
second antenatal clinic visit until their first postpartum clinic visit. 
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In Phase 3, approximately 440 postpartum breastfeeding WLH were randomised into 
receiving ART in two different ways, either in Model I or II. Model I entailed referral to 
their nearest general adult ART services between 4-8 weeks postpartum and infants to 
their local well-baby clinic for early infant diagnosis (using (PCR testing) as well as 
nevirapine refills, immunisations and other services. Model II entails continued ART 
receipt and care for mothers in the antenatal clinic, where mothers were only referred 
to general adult ART services at the end of breastfeeding and once the final infant HIV 
status was determined. The infants in Model II also continued to receive the same care 
they would in the well-baby clinic (such as early infant diagnosis (using PCR testing) as 
well as nevirapine refills, immunisations and other services) in Site A. The medications 
used as well as the routine monitoring was standard for Model I and II. 
 
The third postpartum model of care, Model III – Community Care, was assessed under 
the PACER study. There is a concern that patients spend large amounts of time waiting 
in the clinic in order to receive medication (217). CACs were designed to unload the 
clinic as well as provide care to people living with HIV/AIDS (PLWHA), which is less 
time intensive for patients. CAC members attend counselling in a group of peers (15-30 
individuals) facilitated by a community healthcare worker and collect medication 
(which is pre-packed) every eight weeks outside of the clinic setting (218). They are 
assessed annually by a nurse and can be referred back to the clinic if necessary. The 
outcomes of the CACs have been assessed in terms of loss to follow-up and have been 
found to show a reduced loss to follow-up rate in comparison to the community health 
centre (169). For PLWHA, such as mothers in the PACER study, medication is just one 
aspect of their lives, and by reducing the need to access clinics as frequently, individuals 
are able to focus on other areas of their lives.  
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ICP ICAP - 823100X
Mailman School of Public Health/ICAP
722 West 168th Street
MSPH
Protocol Number: IRB-AAAL0661





On July 10, 2013, a modification to the above-mentioned protocol was reviewed and approved under an expedited review procedure by 
the Chair or Designee of Columbia University Medical Center Institutional Review Board (IRB) Exp. You may now implement the 
following.
Modification:
- Addition of the MOH waiver of consent letter dated June 11, 2013
- Revised Protocol version 3.0 dated 6/25/2013
- Locator form and questionnaires updated to correctly reflect the names of the study sites.
- Decrease of interviews from 3 to 2.
- Interviews to now occur at 1 month after women initiate PMTCT services and at approximately 3-6 months postpartum.
- Revised PP PMTCT Client Acceptability Questionnaire- updated 14May2013; attached 7/1/2013
- Revised PCR Consent Form_6.25.2013; attached 7/1/2013
- Revised HCW Consent Form, 06.25.2013; attached 6/25/2013
- Revised PMTCT Client Accept Consent, 06.25.2013; attached 6/26/2013
- Revised SG Locator Form, 05.14.2013; attached 6/25/2013
- Revised HCW Accept. F/U Questionnaire, 05.14.2013; attached 6/25/2013
- Revised HCW Baseline Questionnaire, 05.14.2013; attached 6/25/2013
- Revised ANC PMTCT Client Accept. Questionnaire, 05.14.2013; attached 6/25/2013
Reminders:
- Please be reminded that approval from University of Cape Town Ethics committee must be obtained and submitted to the CUMC IRB 
prior to the initiation of procedures at that site. Please include documentation of Uni versity of Cape Town Ethics Committee approval 
with your next submission to the IRB.
- Please archive/remove the obsolete/inactive documents associated with your project when preparing your ne xt submission to the IRB. If 
you need assistance removing the documents please contact the RASCAL help team at (212) 851.0213
During the approval period, all subjects enrolled not only must provide voluntary informed consent to participate in the study, but also 
must sign a copy of the appropriate stamped consent document(s). A copy of the consent document(s) must be given to the subjects for 
their record.
The requirement to obtain informed consent from the subjects will be w aived by the IRB in accordance with 45 C.F.R. § 46.116(d) for the 
PMTCT Options Evaluation.
The following study-related materials were approved:
- Protocol version 3.0 dated June 25, 2013, attached 06/26/2013
- MOH Waiver of Consent Letter, attached 06/25/2013
- SG Locator Form, 05.14.2013, clean, attached 06/25/2013






























MCH-ART: Time motion tool version 2.0 
08 May 2015 
 
 
Weekly Timesheet: MCH-ART Study – MOU Antenatal and Focused care 
Name of clinic:   _____________________________ 
Position/post:   _____________________________ 
Date:     _____________________________ 
Shift (times)   _____________________________ 
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8:00 – 16:00 
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8:00 – 16:00 
            
 
Thursday 
8:00 – 16:00 
            
 
Friday 
8:00 – 16:00 






     for use until: 10/28/2015







MCH-ART: Time motion tool version 2.0 
08 May 2015 
 
 
Weekly Timesheet: MCH-ART Study – General ART 
Name of clinic:   _____________________________ 
Position/post:   _____________________________ 
Date:     _____________________________ 
Shift (times)   _____________________________ 
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MCH-ART: Time motion tool version 2.0 
08 May 2015 
 
 
Weekly Timesheet: MCH-ART Study – Infants  
Name of clinic:   _____________________________ 
Position/post:   _____________________________ 
Date:     _____________________________ 
Shift (times)   _____________________________ 
 





































































































8:00 – 16:00 
            
 
Tuesday 
8:00 – 16:00 
            
 
Wednesday 
8:00 – 16:00 
            
 
Thursday 
8:00 – 16:00 
            
 
Friday 
8:00 – 16:00 







     for use until: 10/28/2015
IRB Approval Date: 05/19/2015
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MCH-ART: Time motion tool version 2.0 
08 May 2015 
 
MCH-ART: TIME MOTION TOOL 
Facility:  MOU/Hannan Crusaid/NY1/  
Other: ____________ 
Fieldworker initials: ____________   (e.g. LS) 
Date: ___/___/_____   (DD/MM/YYYY) 
Patient folder number: ____________ 
Time of arrival at facility: ____________   (e.g. 06:22) 
Time folder drawn: ____________   (e.g. 08:22) 
Time of exiting facility: ____________   (e.g. 08:37) 
 
MCH-ART: TIME MOTION TOOL 
Facility:  MOU/Hannan Crusaid/NY1/  
Other: ____________ 
Fieldworker initials: ____________   (e.g. LS) 
Date: ___/___/_____   (DD/MM/YYYY) 
Patient folder number: ____________ 
Time of arrival at facility: ____________   (e.g. 06:22) 
Time folder drawn: ____________   (e.g. 08:22) 
Time of exiting facility: ____________   (e.g. 08:37) 
 
MCH-ART: TIME MOTION TOOL 
Facility:  MOU/Hannan Crusaid/NY1/  
Other: ____________ 
Fieldworker initials: ____________   (e.g. LS) 
Date: ___/___/_____   (DD/MM/YYYY) 
Patient folder number: ____________ 
Time of arrival at facility: ____________   (e.g. 06:22) 
Time folder drawn: ____________   (e.g. 08:22) 
Time of exiting facility: ____________   (e.g. 08:37) 
 
MCH-ART: TIME MOTION TOOL 
Facility:  MOU/Hannan Crusaid/NY1/  
Other: ____________ 
Fieldworker initials: ____________   (e.g. LS) 
Date: ___/___/_____   (DD/MM/YYYY) 
Patient folder number: ____________ 
Time of arrival at facility: ____________   (e.g. 06:22) 
Time folder drawn: ____________   (e.g. 08:22) 





     for use until: 10/28/2015
IRB Approval Date: 05/19/2015
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MCH-ART: Demographics & Medical History, Phase 3 12mo pp PID: 3 - __ __ __ __ - __ __ 
Xhosa-English Version 3.3, 29 September2013 
Visit Date: __ __/__ __ __/__ __ __ __ 
Sokubeleka sicela ukujonga ukuba  zisemi ngendlela  owawusinike yona iinkcukacha zakho: 
Please can we update your locator information: 
1. 
Usahlala  okanye ufudukile kula ndlu ubukade uhlala 
kuyo ukugqibela sithetha? 
Have you moved to a different home since we last spoke to you? 
Hayi/No =0   
Ewe/Yes =1 
If YES, updated LOCATOR 
FORM. 
2. 
Uzitshintshile inombolo zakho zomnxeba ukugqibela 
kwethuukuthetha? 
Have you changed your cell phone number(s) since we last spoke to 
you? 
Hayi/No =0   
Ewe/Yes =1 
If YES, updated LOCATOR 
FORM. 
3. 
Ukhona omnye umntu esinoqhakamishelana naye xa 
kukho imfuneko? 
Is there anyone else that we can contact if we are looking for you in 
the event of an emergency? 
Hayi/No =0   
Ewe/Yes =1 
If YES, updated LOCATOR 
FORM. 
Siza kubuza imibuzo embalwa: 
We are now going to ask you a few questions: 
4. 
Uze njani ekliniki namhlanje? 
How did you get to the clinic today? 
Uqeshe imoto = 1 
Hired car 
Uze ngemoto yakho=2 








Other, specify  
5. 
Uthathe ixesha elingakanani ukuza ekliniki namhlanje?       




Uhlawule malini ngesithuthi?       
How much did you pay for transport? 
Rand: __________________ 
7. 
Uthathe ixesha emsebenzini ukuza apha? 
Did you take time off of work to come here? 
Hayi/No =0   
Ewe/Yes =1 
8. 
Kuye kwafuneka wenze isivumelwano nabantu 
bajonge umntwana/abantwana? 
Did you have to make special arrangements for people to watch your 
child/children? 
Hayi No = 0  Gqithela ku Q10 
 SKIP to Q10 
Ewe Yes = 1 
Andinabantwana = 2  Gqithela ku Q10 
Don’t have any children         SKIP to Q10 
9. 
Kuye kwafuneka uhlawule umntu oza kujonga usana 
ngelixesha uze ekliniki? 
Did you pay someone to watch your child so you could come to the 
clinic? 
Hayi/No =0   
Ewe/Yes =1 
10. 
Ukugqibela kwethu ukuthethanawe uye wathunyelwa 
kwesinye isibhedlele ngenxayokugula(Jooste,Groote 
Schuur) 
Since we last spoke to you, have you been referred to any other 
health facility for other medical care (eg, GF Jooste or Groote 
Schuur)?  
Hayi No = 0  Gqithela ku Q11 
 SKIP to Q11 
Ewe Yes = 1 
a. 
Ubuthunyelwe phi? 
Where were you referred? 
Igama lendawo: _________________ 
Location 
b. 
Wawusithini umhla wokuthunyelwa kwakho? 
What was the date of the referral?  
Umhla:____ Inyanga:_______ Unyaka:______ 
Day                  Month                      Year 
Page 1 of 5 Initials of counsellor: ________ 
IRB-AAAK8059
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MCH-ART: Demographics & Medical History, Phase 3 12mo pp PID: 3 - __ __ __ __ - __ __ 
Xhosa-English Version 3.3, 29 September2013 
c. 
Yintoni isizathu sokuthunyelwa kwakho? 




Ingaba wafumana unyango olutsha/ amayeza? 
Did you receive any new treatment or medications as a result of this 
referral? 
Hayi/No =0   
Ewe/Yes =1 
Ukuba nguEwe, cacisa:_______________________ 
If Yes, specify 
11. 
Oku ulubelekile usana lwakho, selukhe lwathunyelwa 
kwamanye amacandeo empilo kuba lugula zizifo 
zabantwana? 
Since delivery, has your new baby been referred to any other health 
facility for infant-related care? 
Hayi No = 0  Gqithela ku Q12 
 SKIP to Q12 
Ewe Yes = 1 
a. 
Ubuthunyelwe phi? 
Where were you referred? 
Igama lendawo: _________________ 
Location 
b. 
Wawusithini umhla wokuthunyelwa kwakho? 
What was the date of the referral?  
Umhla:____ Inyanga:_______ Unyaka:______ 
Day                  Month                      Year 
c. 
Yintoni isizathu sokuthunyelwa kwakho? 




Ingaba wafumana unyango olutsha/ amayeza? 
Did you receive any new treatment or medications as a result of this 
referral? 
Hayi/No =0   
Ewe/Yes =1 
Ukuba nguEwe, cacisa:_______________________ 
If Yes, specify 
12. 
Ukugqibela kwethu ukuthetha ugqira okanye unesi 
bakhe bathi une-TB? 
Since we last spoke to you, has a doctor or nurse told you that you 
have TB? 
Hayi No = 0  Gqithela ku Q17 
 SKIP to Q17 
Ewe Yes = 1 
13. 
Uxelelwe nini ngoku kugula? 
When did you receive this diagnosis? 
Umhla:____ Inyanga:_______ Unyaka:______ 
Day                  Month                      Year 
14. 
Uxelelwe phi ngoku kugula? 
Where did you receive this diagnosis? 
Igama lekliniki : ________________ 
Name of clinic 
15. 
Iphi emzimbeni wakho le TB? 
Where in your body was the TB (eg, lungs, other location)? 
Indawo emzimbeni : _________________________ 
Place in body 
16. 
Uye wafumana unyango lwayo? 
Did you receive treatment for TB? 
Hayi/No =0   
Ewe/Yes =1 
17. 
Ukugqibela kwethu ukuthetha nawe ukhona omnye 
umntu osele umxelele  ukuba uphila nentshologwae 
ongakhange umxelele kuqala? 
Since we last spoke to you have you told anyone about your HIV-
status who you had not told before? 
Hayi No = 0  Gqithela ku Q20 
 SKIP to Q20 
Ewe Yes = 1 
18. 
Nceda phendula lombuzo 
ngelungu ngalinye losapho 
oludweliswe ngezantsi. 
Please answer this question for 
each of the family members listed 
below.  
i. Bahlala nawe ?
Do they live with you?
If NA selected, do not answer 
i and ii for that person 
ii. Bayazi uphila
nentsholongwane ?
Do they know you are HIV
positive?
iii. Bayazi utya iART?




Hayi/No = 0      
Ewe/Yes = 1 
N/A = 9 
Hayi/No = 0      
Ewe/Yes = 1 
Hayi/No = 0      
Ewe/Yes = 1 
b. Umama 
Mother 
Hayi/No = 0      
Ewe/Yes = 1 
N/A = 9 
Hayi/No = 0      
Ewe/Yes = 1 
Hayi/No = 0      
Ewe/Yes = 1 
Page 2 of 5 Initials of counsellor: ________ 
IRB-AAAK8059
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MCH-ART: Demographics & Medical History, Phase 3 12mo pp PID: 3 - __ __ __ __ - __ __ 
Xhosa-English Version 3.3, 29 September2013 
c. Utata 
Father 
Hayi/No = 0      
Ewe/Yes = 1 
N/A = 9 
Hayi/No = 0      
Ewe/Yes = 1 
Hayi/No = 0      
Ewe/Yes = 1 
d. Udade 
Sister 
Hayi/No = 0      
Ewe/Yes = 1 
N/A = 9 
Hayi/No = 0      
Ewe/Yes = 1 
Hayi/No = 0      
Ewe/Yes = 1 
e. Umtakwenu 
Brother 
Hayi/No = 0      
Ewe/Yes = 1 
N/A = 9 
Hayi/No = 0      
Ewe/Yes = 1 
Hayi/No = 0      
Ewe/Yes = 1 
f. Intombi 
Daughter 
Hayi/No = 0      
Ewe/Yes = 1 
N/A = 9 
Hayi/No = 0      
Ewe/Yes = 1 
Hayi/No = 0      
Ewe/Yes = 1 
g. Unyana 
Son 
Hayi/No = 0      
Ewe/Yes = 1 
N/A = 9 
Hayi/No = 0      
Ewe/Yes = 1 
Hayi/No = 0      
Ewe/Yes = 1 
h. Umalume 
Uncle 
Hayi/No = 0      
Ewe/Yes = 1 
N/A = 9 
Hayi/No = 0      
Ewe/Yes = 1 
Hayi/No = 0      
Ewe/Yes = 1 
i. U-anti 
Aunt 
Hayi/No = 0      
Ewe/Yes = 1 
N/A = 9 
Hayi/No = 0      
Ewe/Yes = 1 
Hayi/No = 0      
Ewe/Yes = 1 
j. Umzala wesikhomo 
Male cousin 
Hayi/No = 0      
Ewe/Yes = 1 
N/A = 9 
Hayi/No = 0      
Ewe/Yes = 1 
Hayi/No = 0      
Ewe/Yes = 1 
k. Umzala wesikhomokazi   
Female cousin 
Hayi/No = 0      
Ewe/Yes = 1 
N/A = 9 
Hayi/No = 0      
Ewe/Yes = 1 
Hayi/No = 0      
Ewe/Yes = 1 
l. 
Enye indoda yalapha 
efemelini 
Other male family member 
Hayi/No = 0      
Ewe/Yes = 1 
N/A = 9 
Hayi/No = 0      
Ewe/Yes = 1 
Hayi/No = 0      
Ewe/Yes = 1 
m. 
Esinye isikhomokazi  se 
femeli 
Other female family member 
Hayi/No = 0      
Ewe/Yes = 1 
N/A = 9 
Hayi/No = 0  
Ewe/Yes = 1 
Hayi/No = 0      
Ewe/Yes = 1 
19. 
Ngaphandle kwabantu bakho bekhaya abasentla 
,ngubani omnye umntu omxelele ngokuphila 
nentsholongwane ongazange umxelele ngaphambili? 
Aside from family members listed above, who else have you told 
about your HIV status who you had not told before? (read and 
answer for all) 
i. Bayazi uphila
nentsholongwane?
Do they know you are HIV
positive?
ii. Bayazi utya iART?
Do they know if you are
taking ART?
a. Amanesi/ogqira  
Health professionals 
Hayi/No = 0      
Ewe/Yes = 1 
Hayi/No = 0      
Ewe/Yes = 1 
b. Iqumru lenxaso labantu abaphila nentsholongwane 
Support group 
Hayi/No = 0      
Ewe/Yes = 1 
Hayi/No = 0      
Ewe/Yes = 1 
c. Umntu owabelana naye ngesondo ongahlali naye 
A sexual partner who does not live with you 
Hayi/No = 0      
Ewe/Yes = 1 
Hayi/No = 0      
Ewe/Yes = 1 
d. Isihlobo 
Friends 
Hayi/No = 0      
Ewe/Yes = 1 
Hayi/No = 0      
Ewe/Yes = 1 
e. Inkokheli ngokwa kwamoya 
Spiritual leader 
Hayi/No = 0      
Ewe/Yes = 1 
Hayi/No = 0      
Ewe/Yes = 1 
f. Umntu okuqashileyo/wayekuqashile 
Current or former employer 
Hayi/No = 0      
Ewe/Yes = 1 
Hayi/No = 0      
Ewe/Yes = 1 
g. Ukuchaza esidlangalaleni 
Public disclosure/ community 
Hayi/No = 0      
Ewe/Yes = 1 
Hayi/No = 0      
Ewe/Yes = 1 
h. Abanye, chaza: _______________
Other, specify 
Hayi/No = 0      
Ewe/Yes = 1 
Hayi/No = 0      
Ewe/Yes = 1 
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20. 
Ukugqibela kwethu ukuthetha kuye kwakho utshintsho  
phakathi kwakho nomyeni/iqabane? 
Since we last spoke to you, have there been any changes in your 
relationship with your husband or partner? 
Hayi No = 0  Gqithela ku Q26 
 SKIP to Q26 
Ewe Yes = 1 
21. 
Ukuba nguEwe, yintoni ethe yatshintsha kokuthandana
If Yes, what has changed in your relationship since we last spoke? 
If participant reports that there have been changes in relationship, complete the following questions (Q22-25) with updated information. 
22. 
Unomntu omtsha othandana naye?
Are you currently in a new relationship? 
Hayi/No = 0   Gqithela ku Q26 
 SKIP to Q26
Ewe/Yes = 1 
23. 
Loo mntu umtsha uthandana naye uhlala nawe
Is your new partner living with you? 
Hayi/No = 0      
Ewe/Yes = 1 
24. 
Uyathandana /wabelana ngesondo nabanye abantu  
ngaphandle kwalo mntu mtsha?
Do you have relationships/sexual partners with people other than this 
new partner? 
Hayi/No = 0   Gqithela ku Q26 
 SKIP to Q26
Ewe/Yes = 1 
25. 
Sinjani isimo sobunye ubuhlobo bakho? 
What is the nature of your other relationship(s)? 
Rhangqa konke okungqamene nawe. 










Loluphi usuku ukugqibela kwakho ukutya iART? 
When was the last day you took ART? 
Umhla:____ Inyanga:_______ Unyaka:______ 
Day                  Month                      Year 
a. 
Ukhe wawatya iART akho kwezi ntsuku zi-7 
zidlulileyo? 
Have you taken ART at all in the last 7days? 
Hayi/No = 0  
Ewe/Yes = 1  Gqithela ku Q27 
 SKIP to Q27         
b. 
Ukuba hayi, kutheni? 




Ekugqibeleni kwethu ukuthetha,ubukhe wathetha 
nekhawunsela ekliniki ngokutya iART? 
Regardless of whether or not you have taken ART: 
Since we last spoke to you have you spoken to a counsellor at the 
clinic/ hospital about taking ART?  
Hayi/No = 0 
Ewe/Yes = 1 
a. 
Ukuba ewe,uye phi? 
If Yes, where did you go? 
Igama lekliniki: ________________ 
Clinic name 
b. 
Emva kokuba sithethile nawe,ukhawunselwe 
kangaphi? 
Since we last spoke to you how many times have you been 
counselled? 
Amaxesha: ____________  
# of times  
c. 
Uye wathetha nabani  ngoku ubukhawunselwa? 
Who did you speak to during this counselling? 
d. 
Ngoku ubukhanselwa niye nathetha ngantono? 
What did you talk about during this counselling? 
28. 
Ugqibele nini ukuya exesheni? 
When was your last menstrual period? 
Umhla:____ Inyanga:_______ Unyaka:______ 
Day                  Month                      Year 
Andiqinisekanga/Unsure = 9 
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29. 
Ukhulelwa ngoku? 
Are you pregnant at the moment? 
Hayi/No = 0 Phela apha/END 
Ewe/Yes = 1 
Not sure = 2 
30. 
Ingaba oku kukhelelwa kuqinisekisiwe? 
Has the pregnancy been confirmed? 
Hayi/No = 0 DO PREGNANCY TEST NOW 
Ewe/Yes = 1 
Date completed: __ __ /__ __ __ / __ __ __ __     Signed counsellor completing CRF: _________________ 
Date of QC: __ __ /__ __ __ / __ __ __ __         Signed measurement nurse: _________________ 
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MCH-ART Resource Interview  







 __ __/__ __ __/__ __ __ __ 
IMIGAQO: Gqibezela olu dliwano-ndlebe nomthathi nxaxheba wophando uze ufake iimpendulo 
zomthathi nxaxheba zombuzo ngamnye. Umbuzo ngamnye mawuphendulwe ngumthathi 
nxaxheba, Hayi umbuzi-mibuzo. Bhala kuphela iimpendulo zomthathi nxaxheba wophando 
ngokurhangqa inani elililo nkgqo. Nceda khetha impendulo ibenye qha kumbuzo ngamnye. 
 
INSTRUCTIONS: Complete this interview with the study participant and enter the participant’s response for 
each question. Each question is to be answered by the participant, not the interviewer. Record only the 
participant’s response by circling the appropriate number. Please choose only one answer for each question. 
 
NOTE: All these questions are referring to routine health care services and NOT study 
measurement visits. 
A) Maternal Interview 
Nceda ucinge ngobom bakho kwezinyanga zintathu zidlulileyo. Kangangoko ukhumbula, phendula 
le mibuzo ilandelayo malunga nendlela ezahlukeneyo enokuthi impilo yakho ibe ibuchapazele 
ubom bakho kwezinyanga zintathu zidlulileyo. 
Please think about your life over the past 3 months. As well as you can remember, answer the following 
questions about the different ways your health may have affected your life during these past 3 months. 
 NONE 
0 




1. KWINYANGA EZINTATHU 
EZIDLULILEYO, zintsuku ezingaphi uhleli 
ebhedini ubuninzi bemini kuba 
ubungaziva mnandi? 
DURING THE PAST 3 MONTHS, HOW MANY DAYS 
did you stay in bed most of the day because you were 
not feeling well? 
0 1 2 3 4 5 :________ 
2. KWINYANGA EZINTATHU 
EZIDLULILEYO, zintsuku ezingaphi 
ucutha imisebenzi yakho yesiqhelo, nje 
ngomsebenzi wakho, umsebenzi 
wasendlini, okanye isikolo kuba 
ubungaziva mnandi? 
DURING THE PAST 3 MONTHS, HOW MANY DAYS 
did you reduce your usual daily activities, such as your 
work, housework, or school because you were not 
feeling well? 
0 1 2 3 4 5 :________ 
3. KWINYANGA EZINTATHU 
EZIDLULILEYO, zintsuku ezingaphi 
kusiza omnye umntu endlini/ekhayeni 
lakho ukuza kunceda kuba ubungaziva 
mnandi? 
DURING THE PAST 3 MONTHS, HOW MANY DAYS 
did someone come to your home/household to help 
you because you were not feeling well? 
0 1 2 3 4 5 :________ 
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4. KWINYANGA EZINTATHU 
EZIDLULILEYO, zintsuku ezingaphi 
uchithe ubusuku esibhedlele, ekliniki 
okanye iwadi lehospisi ngenxa yempilo 
yakho? 
DURING THE PAST 3 MONTHS, HOW MANY 
NIGHTS did you stay in a hospital ward, clinic, or 
hospice ward for your own health?  
0 1 2 3 4 5 :________ 
5. KWINYANGA EZINTATHU 
EZIDLULILEYO, utyelele kangaphi 
ekliniki okanye kwi-wadi labagula 
behamba (ingozi okanye indawo yezimo 
eziphuthumayo) ngenxa yempilo yakho? 
DURING THE PAST 3 MONTHS, HOW MANY VISITS 
did you make to a health clinic or casualty ward 
(accident or emergency facility) for your own health? 
0 1 2 3 4 5 :________ 
6. KWINYANGA EZINTATHU 
EZIDLULILEYO, utyelele kangaphi 
kugqirha wesintu ngenxa yempilo yakho? 
DURING THE PAST 3 MONTHS, HOW MANY VISITS 
did you make to a traditional healer for your own 
health? 
0 1 2 3 4 5 :________ 
7. KWINYANGA EZINTATHU 
EZIDLULILEYO, ukhe wamkela umvuzo 
ngenxa yohlobo oluthile lomsebenzi 
okanye ingqesho? 
DURING THE PAST 3 MONTHS, did you earn any 
income through some kind of work or occupation? 
No=0  SKIP to 
Section B 
Yes=1 continue to 7a) 
7a) UKUBA EWE, xa ubusenza 
lomsebenzi/ingqesho, ingaba ubukhulu 
becala ubusebenza isigxina okanye 
manqapha-nqapha? 
If yes, when you did this work/occupation, did you 
mostly work full time or part time? 
Isigxina/ Full time = 0 
manqapha-nqapha/ Part 
time =1 
B) Infant Interview 
Nceda ucinge ngempilo yosana lwakho kwezi nyanga zinthathu zidlulileyo. Kangangoko unako 
ukukhumbula, phendula le mibuzo ilandelayo ngendlela ezahlukeneyo ezichaphazela ngayo impilo 
kwezinyanga zinthathu zidlulileyo. 
Please think about your child’s life over the past 3 months. As well as you can remember, answer the 
following questions about the different ways your child’s health may have affected their life during these past 
3 months. 
 
NOTE: These questions pertain to your youngest child, the one that you had most recently. 
 NONE 
0 




8. KWEZINYANGA ZINTHATHU 
ZIDLULILEYO, zintsuku ezingaphi 
umntwana engadlali ngesiqhelo, 
njengokutya, ukulala kuba engaziva 
mnandi? 
DURING THE PAST 3 MONTHS, HOW 
MANY DAYS did your child reduce their 
usual daily activities, such as eat, sleep, 
because they were not feeling well? 
0 1 2 3 4 5 :________ 
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9. KWEZINYANGA ZINTHATHU 
ZIDLULILEYO, zintsuku ezingaphi  
umntwana achithe ubusuku esibhedlele 
ngenxa yempilo yakhe? 
DURING THE PAST 3 MONTHS, HOW 
MANY NIGHTS did your child stay overnight 
in a hospital for their own health?  
0 1 2 3 4 5 :________ 
10. KWEZINYANGA ZINTHATHU 
ZIDLULILEYO, utyelele kangaphi 
umntwana wakho ekliniki, okanye 
kwincandelo le trauma (ingozi, unyango 
olukhawulezileyo) ngenxa yempilo 
yakhe, kodwa akalaliswa? 
DURING THE PAST 3 MONTHS, HOW 
MANY VISITS did your child make to a 
health clinic or trauma unit (accident or 
emergency facility) for their own health but 
did not stay overnight? 
0 1 2 3 4 5 :________ 
11. KWEZINYANGA ZINTHATHU 
ZIDLULILEYO, kubekangaphi umntwana 
wakho etyelela kugqirha wesintu? 
DURING THE PAST 3 MONTHS, HOW 
MANY VISITS did your child make to a 
traditional healer for their own health? 
0 1 2 3 4 5 :________ 
C) Health clinic visits 
Le mibuzo ilandelayo inxulumene namava akho ngokuya eklinik (ekuhlukuhleni, kumaziko 
amachiza okuthomalalisa intsholongwane kagawulayo) malunga nempilo yakho 
The following questions are related to your experiences going to a health clinic (ANC, ART) for your own 
health.  
QAPHELA: le mibuzo ayinxulumenanga nokuza kutyelelo lophando 
NOTE: These questions are not related to attending study visits. 
Ukusuka kumbuzo 16-24- cinga into oqhele ukuyenza xa kufuneka uye eklinik ukuya 
kufumana ukhathalelo lwempilo. 
For Questions 16-24- Think of what you typically do when you have had to go to the health 
clinic to receive medical care . 
 
12. Uye njani eklinik? 
How did you get to the clinic?  
 
Imoto eqeshiweyo/Hired Car=1 
Imoto yam/My own car = 2 
Itaxi/Taxi = 3 
Ibhasi/Bus = 4 
Ngenyawo/Walk = 5 
Enye/Other = 6, Chaza/specify: ________________ 
13. Kuthatha ixesha elingakanani ukuza 
kufika eklinik? 





Iiyure/ Hours: ___________________ 
 
14. Uhlawula malini kwisithuthi ukuya 
eklinik? 
How much did you pay for transport to the 
clinic? 
Rand: ____________________ 
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15. Kuye kwafuneka ungapha ngeli ukuze 
uze kutyelelo ekliniki? 
Did you have to take time off of work to 
attend clinic visits? 
Hayi/ No = 0 
Ewe/ Yes = 1 
16. Ukuba kunjalo, ingaba uphulukene 
nomvuzo kuba uze kutyelelo eklinik? 
If yes, did you miss income because of 
having to attend these clinic visits? 
Hayi/ No = 0 
Ewe/ Yes = 1 
Khange ndithathe xesha emsebenzini, ndiphinde 
ndaya emsebenzini/Did not have to take time off/sick 
leave = 3 
Ngale mini yotyelelo lwam eklinik/I still went to work 
on the day of my clinic visit =4 
17. Ukuba kunjalo, qikelela ixabiso lomvuzo 
ophulukene? 
If yes, estimate amount of missed wages. 
Rand: ____________________ 
18. Ingaba kuye kwafuneka wenze 
amalungiselelo akhethekileyo nabantu 
ukujonua umntwana/abantwana ukuze 
ukwazi ukuza? 
Did you have to make special arrangements 
for people to watch your child/children so 
that you can attend these clinic visits? 
Hayi/ No = 0 
Ewe/ Yes = 1 
Andina bantwana/Don’t have any children = 2 
19. Kuye kwafuneka uhlawule umntu 
ozakugcinela umntwana ukuze eze 
eklinik? 
Did you have to pay someone to watch your 
child so that you could attend these clinic 
visits? 
Hayi/ No = 0 
Ewe/ Yes = 1 
Andina bantwana/Don’t have any children = 2 
20. Ukuba kunjalo, umhlawule malini?  
If yes, how much did you pay? 
Rand: ____________________ 
Andina bantwana/ Don’t have any children = 0 
Bekungeyomfu-neko yomgcini mntwana/ Didn’t need 
childcare = 1 
D) Infant Feeding 
21. Oko wazalwa umntwana wakho wakhe 
wamthengela ubisi olungumgubo 
lwabantwana? 
Since your child’s birth have you purchased 
any formula milk for your infant? 
Hayi/ No = 0 
Ewe/ Yes = 1 
22. Ukuba kunjalo, uchitha malini ukuthenga 
ubisi elingumgubo wabantwana? 
If yes, how much did you spend per week on 
formula? 
Rand: ____________________ 




Date completed: __ __ /__ __ __ / __ __ __ __          Signed counsellor completing CRF: _____________ 
 
Date of QC: __ __ /__ __ __ / __ __ __ __              Signed measurement nurse: __________________ 
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